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It is now well established that tumor growth, progression and metastasis is not just 
determined by malignant cells themselves, but also require the tumor 
microenvironment. The latter includes extra-cellular matrix (ECM) components, 
hypoxia and stromal cells, either resident or recruited from the circulation, represented 




Fig. 1.Tumor as complex tissue. Cancer is not single cell disease and tumor initiation and progression is 
highly influenced by tumor stroma that includes fibroblasts, immune cells and endothelial cells. 
 
Tumor stroma is similar to that observed during wound healing and it is commonly 
referred to as "reactive stroma", which is associated with an increased number of 
fibroblasts, enhanced capillary density and collagen and fibrin deposition (Kalluri and 
Zeisberg, 2006). Cancer cells create a complex and continuative “cross-talk” with 
surrounding, non-malignant cells and/or with the extracellular architecture, made of 
direct cell-to-cell contacts and paracrine/exocrine signals. Tumor-stroma interactions at 
both the primary and secondary tumor sites allow and support tumor survival and 
outgrowth, organ homing and invasion. The role of tumor support played by stromal 
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cells spans from growing of new vessels, with the recruitment of endothelial progenitors 
and their activation to form functional vessels, to secretion of a large amount of 
cytokines and soluble factors affecting cancer cell behavior (Taddei et al., 2013). 
Neoplastic cells and stromal cells around them change progressively during the 
multistep transformation of normal tissues into high-grade malignancies and tumor-
stroma interactions evolve along with tumor progression. Incipient neoplasia begin the 
interplay by recruiting and activating stromal cell types that assemble into an initial 
preneoplastic stroma, which in turn responds reciprocally by enhancing the neoplastic 
phenotypes of the nearby cancer cells. The cancer cells, which may further evolve 
genetically, again feed signals back to the stroma, continuing the reprogramming of 
normal stromal cells to serve the budding neoplasm; ultimately signals originating in the 
tumor stroma enable cancer cells to invade normal adjacent tissues and disseminate 
(Hanahan and Weinberg, 2011). In this context, several evidences have identified 
fibroblasts as key mediators in promoting tumor progression. 
 
 
Fibroblasts and Cancer Associated Fibroblasts 
Fibroblasts are elongated cells, characterized by extensive cellular processes, with 
fusiform and tapered shape (Tarin and Croft, 1969). They can be easily isolated from 
tissues and cultured in vitro. Their fusiform morphology makes them identifiable and, 
despite the paucity of specific markers, some molecules can be related to a fibroblastic 
phenotype, although none of these is exclusive of fibroblasts and/or expressed in all 
fibroblasts. Among these markers, the fibroblasts specific protein-1 (FSP-1) seems to 
provide the best specificity for the identifications of fibroblasts in vivo, but other 
markers can be considered site-specific, like desmin, a specific marker for skin 
fibroblasts. 
The important functions of fibroblasts include the deposition of ECM, regulation of 
epithelial differentiation, regulation of inflammation and involvement in wound healing 
(Kalluri and Zeisberg, 2006). Fibroblasts synthesize many of the constituents of ECM, 
such as type I, III and V collagen and fibonectin. They also contribute to the formation 
of basement membranes by secreting type IV collagen and laminin. Fibroblasts are also 
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an important source of ECM-degrading proteases such as matrix metalloproteinases 
(MMPs), which highlights their crucial role in maintaining an ECM homeostasis by 
regulating ECM turnover. In addition, fibroblasts are important in maintaining the 
homeostasis of adjacent epithelia through the secretion of growth factors and direct 
mesenchymal-epithelial cell interactions (Kalluri and Zeisberg, 2006). 
As well as their function in healthy organs, fibroblasts have a prominent role in wound 
repair. They invade lesions, generate ECM to serve as a scaffold for other cells, and 
possess cytoskeletal elements that facilitate contractions of healing wounds (Kalluri and 
Zeisberg, 2006). When tissue injury occurs, fibroblasts undergo an activate state named 
"myofibroblast", characterized by the de novo expression of α-SMA protein, the actin 
isoform typical of smooth muscle cells, and the ability to synthesize increased levels of 
ECM components and ECM-degrading proteases such as matrix metalloproteinase-2 
(MMP-2), MMP-3 and MMP-9, thus facilitating increased ECM turnover and altering 
ECM composition (Rodemann H.P. and Muller G.A., 1991) (Fig.2). Activated 
fibroblasts often secrete increased amounts of growth factors such as Hepatocyte 
Growth Factor (HGF), Insulin-like Growth Factor (IGF), Nerve Growth Factor (NGF), 
WNT1, Epidermal Growth Factor (EGF) and Fibroblast Growth Factor-2 (FGF2), 
which can induce proliferative signals within adjacent epithelial cells (Bhowmick et al., 
2004). Activated fibroblasts also have an important role as modulators of the immune 
response following tissue injury, through the secretion of cytokines such as interleukin-
1 and chemokines such as monocyte chemotactic protein 1 (MCP1) (Strieter et al., 
1989; Rollins et al., 1989). Activated fibroblasts are found in healing wounds and 
sclerosing tissues, and are also associated with tumors. Different stimuli induce this 
activation, including growth factors such as Transforming Growth Factor-β (TGF-β), 
EGF, Platelet-Derived Growth Factor (PDGF) and FGF2, which are released from 
injured epithelial cells and infiltrating mononuclear cells such as monocytes and 
macrophages. In addition, fibroblasts are activated by direct cell-cell communication 
and contacts with leukocytes through adhesion molecules such as Intercellular-
Adhesion Molecule-1 (ICAM1) or Vascular-Cell Adhesion Molecule-1 (VCAM1) 
(Clayton et al., 1998). Fibroblast activation can also be achieved through reactive 
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Fig.2. Fibroblasts activation. Fibroblasts can acquire an activated phenotype, which is associated with 
an increased proliferative activity and enhanced secretion of ECM. Phenotypically, activated fibroblasts 
are often characterized as expressing α-smooth-muscle actin. 
 
Most of knowledge about tumor stromal cells stem from the studies of carcinomas. In 
the early growth of tumors, cancer cells form a neoplastic lesion that is embedded in the 
microenvironment of a given tissue (Hanahan and Weinberg, 2000) but separated from 
the surrounding tissue and contained within the boundary of a basement membrane. 
This is called the carcinoma in situ (CIS). CIS is associated with "reactive stroma", 
similar to that observed during wound healing. Vascular Endothelial Growth Factor 
(VEGF), produced mainly by fibroblasts and inflammatory cells, represents a key 
molecule for the development of the stroma (Brown et al., 1999). VEGF induces 
microvascular permeability, thus allowing the extravasation of plasma proteins such as 
fibrin, which attracts fibroblasts, endothelial cells and inflammatory cells (Senger et al. 
1983; Dvorak et al., 1984; Brown et al., 1999). These cells produce ECM that is rich in 
fibronectin and type I collagen, both implicated in the development of tumour 
angiogenesis (Leung et al., 1989; Brown et al., 1999; Feng et al., 2000). During tumor 
progression from carcinoma in situ to invasive carcinoma, tumor cells invade the 
reactive stroma (Dvorak et al., 2011; Ronnov-Jessen et al. 1996). Basement membrane 
and stroma are degraded, and myofibroblast come into direct contact with the tumor 
cells. Invasive cancer is usually associated with the expansion of tumor stroma and to an 
increase of the deposition of ECM, (Shekhar et al. 2003; Ronnov-Jessen et al. 1996; 
Van Kempen et al. 2003). This phenomenon appears to be very similar to the changes 
that take place during fibrosis, but while fibrosis is associated with a decrease of 
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Activated fibroblasts associated with reactive stroma are called Cancer Associated 
Fibroblasts (CAFs) and they are characterized by contractile and secretory features 
(Cirri and Chiarugi, 2012; Kalluri and Zeisberg, 2006) (Fig.3). CAFs become activated 
in response to tumor-delivered factors through a mesenchymal-mesenchymal transition 
(MMT). They were first identified by immunocytochemistry using a combination of 
different markers such as α-SMA (α-smooth-muscle-actin), vimentin, desmin and 
Fibroblast Activation Protein (FAP), a serine protease located on the cell surface of 
tumor stromal fiboblasts (Garin-Chesa et al., 1990; Lazard et al., 1993; Mueller and 
Fusenig, 2004). Unlike what happens for myofibroblasts, CAF activation is not reversed 
once the activating stimulus is attenuated, so their presence persists in tumor stroma 
(Tomasek et al., 2002; Hinz et al., 2001). Indeed, CAFs represent the most prominent 
cell type within the reactive stroma of many cancers, such as breast, prostate and 
pancreatic carcinoma (Pietras and Ostman, 2010; Kalluri and Zeisberg, 2006). CAFs are 
associated with cancer cells at all stages of cancer progression by promoting tumor 
growth, angiogenesis and the metastatic process (Tlsty and Coussens, 2006; Kalluri and 
Zeisberg, 2006; Orimo et al., 2005). 
 
 
Fig. 3. Cross-talk between CAFs and different types of cells of tumor microenvironment. 
 
CAFs originate through different ways. In primis, CAFs derive from resident fibroblast 
activated by cancer-derived growth factors such as TGF-β, PDGF and FGF2 (Elenbaas 
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and Weinberg, 2001). TGF-β is associated with an increase of fibrotic tissue, tumor 
progression and fibroblasts recruitment (Siegel and Massague, 2003). In addition, TGF-
β is the most important factor of the tumor microenvironment promoting Epithelial-
Mesenchymal Transition (EMT) in tumor cells and leading fibroblasts to a CAF 
phenotype expressing α-SMA in vitro (Siegel and Massague 2003). EMT is an 
epigenetic program that leads epithelial cells to lose their cell–cell and cell-ECM 
interactions to undergo cytoskeleton reorganization and to gain morphological and 
functional characteristics of mesenchymal cells, thus generating an invasive cell, able to 
secrete proteases, to deeply change the surrounding ECM and to move away from the 
site of the primary tumor (Friedl, 2004; Kalluri and Weinberg, 2009; Nieto and Cano, 
2012). 
Several data indicate that CAFs activation is a redox dependent process (Cirri and 
Chiarugi, 2011); indeed, stimulation of CAFs with TGF-β elicits a burst of reactive 
oxygen species (ROS) which causes the achievement of the activated phenotype, the 
down regulation of gap junctions as well as their tumor promoting activity in skin tumor 
(Cat et al., 2006; Stuhlmann et al., 2004). In addition, the importance of oxidative stress 
in CAFs activation has been highlighted by Toullec et al.; in particular, ROS promote 
conversion of fibroblasts into highly migrating myofibroblasts through accumulation of 
the hypoxia-inducible factor (HIF)-1α transcription factor and the CXCL12 chemokine 
(Toullec et al., 2010) (Fig.4). 
 
 
Fig.4. In carcinoma, chronic oxidative stress promotes the conversion of fibroblasts into myofibroblasts. 
 
Recent studies conducted in our laboratory have shown that IL-6, secreted by prostate 
carcinoma PC3 cells isolated from a bone metastasis of prostate carcinoma (PCa) cells, 
promotes a particular phenotype named PCa-activated fibroblast (PCa-AF). In contrast 
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to the TGF-β-dependent phenotype, these cells do not express α-SMA, but their 
activated state is confirmed by the expression of the FAP protein and production of 
ECM. The PCa-AFs strongly activate the process of EMT and therefore PC3 cells 
invasiveness (Giannoni et al., 2010) (Fig. 5). According to our observations, production 
of IL-6 by tumor cells has been correlated to higher carcinomas aggressiveness 
(Royuela et al., 2004; Chung et al., 2005; Niu et al., 2009). 
A second source of CAFs are represented by bone marrow-derived mesenchymal stem 
cells (MSCs) which are recruited at tumor site by cytokines and growth factors 
produced by tumor cells (Dwyer et al., 2007; Spaeth et al., 2008; Feng and Chen, 2009). 
Moreover, emerging evidence indicates that also EMT involving normal epithelial cells 
flanking to the tumor, is a source of activated fibroblasts in both fibrosis and cancer 
(Selman and Pardo, 2006). In addition, CAFs may originate directly from carcinoma 
cells through EMT (Kalluri and Zeisberg, 2006; Radisky et al., 2007), allowing cancer 
cells to adopt a mesenchymal cell phenotype, with increased migratory and invasive 
capacities (Kalluri and Weinberg, 2009). Indeed, mainly in breast cancers, it has been 
reported CAF somatic mutations in p53 and PTEN, as well as gene copy number 
alteration at other loci in tumor stroma (Kurose et al., 2002; Moinfar et al., 2000). 
Finally, CAFs may derive from proliferating endothelial cells via endothelial to 
mesenchymal transition (EndMT) under TGF-β stimulation (Zeisberg et al., 2007). 
 
 
Role of CAFs in tumor progression 
Cancer cells and CAFs establish a close cross-talk based on mutual stimulation: 
carcinoma cells elicits a reactive response in the stroma and ,conversely, the activated 
fibroblasts located in the microenvironment affect cancer cell responses, thus 
influencing tumor progression. 
Several findings underline the role of CAF in tumor growth. It has long been known 
that only human prostatic CAFs co-cultured with initiated human prostatic epithelial 
cells strongly stimulate growth and altere histology of the epithelial population, while 
normal prostatic fibroblasts are unable to elicit this effect (Olumi et al., 1999). 
Accordingly, it has been demonstrated that only tumor prostate fibroblasts, but not 
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normal prostatic fibroblasts, stimulate proliferation and malignant transformation of 
epithelial cells derived from SV40-T antigen immortalized benign prostate hyperplasia 
(Hayward et al., 2001). Beside, a direct involvement of resident fibroblasts in the 
initiation of cancer has been elucidated: in a mouse model, the overexpression of TGF-β 
and/or HGF in fibroblasts induces the initiation of breast cancer within the normal 
epithelium (Kuperwasser et al., 2004). 
Alongside the role of CAFs in the initiation of neoplasia, CAFs play a mandatory role in 
progression of tumors towards malignancy by the regulation of motility and invasion of 
cancer cells, thus positively affecting their metastatic spread towards distant organs 
(Joyce et al., 2009) (Fig. 5). The contribution of CAFs to the invasive process of cancer 
cells is mainly due to the induction of EMT (Brahimi-Horn et al., 2011; Pani et al., 
2010). This feature is primarily dependent on CAFs’ ability to remodel the ECM. 
Indeed, in addition to secreting growth factors that directly affect cell motility, CAFs 
are sources of ECM degrading proteases as MMPs, which allow cancer cells to escape 
the primary tumor site (Kalluri and Zeisberg, 2006). It has been demonstrated that 
treatment of mammary epithelial cells with MMP3, which is highly expressed in 
fibroblasts, results in cleavage of E-cadherin and EMT induction, thus sustaining a 
progressive phenotypic conversion from normal mammary epithelial cells to an invasive 
mesenchymal phenotype (Lochter et al., 1997). In addition, EMT has been correlated 
with the induction of a cancer stem phenotype both in breast and in prostate cancer 
(Giannoni et al., 2010; Mani et al., 2008; Blick et al., 2010). This ability confers to 
cancer cells the self renewal capability that is crucial for clonal expansion during 
metastatic dissemination (Polyak and Weinberg, 2009). In particular, recent studies 
conducted by our research group showed that CAFs exposure promotes EMT of 
prostate carcinoma cells associated with enhanced expression of stem cell markers, 
ability to form prostaspheres and to self-renew, leading to an increase of aggressiveness 
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Fig. 5 Reciprocal interplay between stromal fibroblasts and PCa cells through secretion of IL-6 (efferent 
pathway) and MMP-dependent EMT in PCa cells (afferent pathway). 
 
Moreover, in pancreatic cancer it has been highlighted a key role of the 
microenvironment in the induction of stemness: indeed, co-cultures of tumor and 
pancreatic stellate cells, the major profibrogenic cell type in the pancreas, enhance the 
cancer stem cell-like phenotypes of tumor cells (Hamada et al., 2012). Beside, the 
chemokine (C-C motif) ligand 2 (CCL2) secreted by CAFs, stimulates sphere formation 
and cancer stem cells self-renewal in breast cancer cells (Tsuyada et al., 2012). Finally, 
myofibroblasts, through hepatocyte growth factor secretion, activate β-catenin-
dependent transcription and subsequently colon cancer cells clonogenicity (Vermeulen 
et al., 2010). 
MicroRNAs are emerging as potential regulators of the relationship between EMT and 
stemness. Indeed, breast cancer stem cells show a miRNA expression profile very 
similar with respect to breast cancer cells undergoing EMT (i.e., high levels of miR-155 
and low levels of miR-200 family) (Blick et al., 2010; Shimono et al., 2009). In 
agreement, manipulation of miRNAs able to revert the EMT phenotype, suppresses 
cancer stem cell properties, as demonstrated by the lower tumorigenic potential of miR-
200c-expressing CD44high/CD24low cells. Furthermore, the achievement of EMT 
correlates to an increase in the resistance to apoptosis, allowing cells to survive along 
their route from the primary tumor to the site of dissemination (Gal et al., 2008). 
Recent evidences suggests that EMT is a redox-dependent phenomenon. In mammary 
epithelial cells, exposure to MMP3 induces EMT, through a Rac1b-mediated release of 
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mitochondrial ROS (Radisky et al., 2008). Accordingly, CAFs promote EMT of cancer 
cells by exploiting the intrinsic or extrinsic oxidative stress and producing cytokines and 
proteases (Cirri and Chiarugi, 2011). In keeping, our research group demonstrated that 
prostate CAFs release cytokines and MMP2 and MMP9, which in turn activate the 
small GTPase Rac1, cyclooxygenase-2 (COX-2) and a consequent COX-2-mediated 
ROS production (Giannoni et al., 2011). The establishment of a pro-oxidant 
environment in prostate cancer cells is also necessary for the redox dependent 
stabilization of HIF-1α and NF-kB (Comito et al., 2011; Gloire and Piette, 2009; 
Hamanaka and Chandel, 2009). These factors sustain then the activation of the 
transcription factors Snail and Twist, promoting the EMT program in prostate 
carcinoma cells (Fig. 5). 
Furthermore, it is useful to mention that even senescent fibroblasts are able to induce 
EMT in nearby epithelial cells, thus influencing tumor progression (Laberge et al., 
2012). Indeed, cellular senescence is associated with an increased oxidative stress and 
secretion of several pro-inflammatory cytokines which collectively generate the so-
called SASP (Senescence Activated Secretory Pathway) phenotype (Bavik et al., 2006). 
Induction of EMT by SASP has been reported for breast cancer where the SASP 
component factors IL-6 and IL-8 enhance the invasiveness of a panel of cancer cell lines 
in culture (Badache and Hynes, 2001; Coppe et al., 2008; Yuan et al., 2005). 
CAFs have a primary role in the guidance of tumor cell movement. Indeed, it has been 
demonstrated that stromal fibroblasts co-cultured with squamous cell carcinoma 
collectively move across the ECM; in particular cancer cells use Cdc42 and MRCK 
(Myotonic Dystrophy Kinase-Related CDC42-binding protein kinases) mediated 
regulation of myosin light chain (MLC) activity, exploiting the tracks generated by 
fibroblasts (Gaggioli et al. 2007). The contractile force in stromal fibroblasts to remodel 
the ECM for the creation of tracks for the collective migration is dependent on the 
activation of the kinase JAK1 (Sanz-Moreno et al., 2011). The same pathway is also 
responsible for the actomyosin contractility of melanoma cells that migrate with an 
amoeboid motility style (Sanz-Moreno et al., 2011). 
The pro-invasive role of CAFs during tumor progression has been shown in several 
types of tumors, such as breast cancer, prostate cancer (Giannoni et al., 2010; Orimo et 
al., 2005) and head and neck squamous carcinoma (Hinsley et al., 2012). In ovarian 
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carcinoma has been underlined that CAFs play a vital role in promoting angiogenesis, 
lymphangiogenesis and cancer cell invasion with respect to normal fibroblasts 
(Giannoni et al., 2010; Orimo et al., 2005; Zhang et al., 2011). Moreover, CAFs 
expressing FAP increase the migration and invasion of colorectal cancer cells through a 
Fibroblasts Growth Factor-1/Fibroblast Growth Factor Receptor 3 (FGF1/FGFR-3) 
signaling (Henriksson et al., 2011). Finally, in a model of human pancreatic cancer, the 
overexpression of FAP in fibroblasts directly modifies the stromal ECM through its 
enzymatic activity. The authors show that FAP alters the architecture and the 
composition of the ECM promoting tumor invasion along characteristic parallel fiber 
orientation (Lee et al., 2011). 
Alongside their pro-invasive role, CAFs are able to recruit endothelial precursor cells 
(EPCs) from bone marrow, thereby inducing de novo angiogenesis (Orimo et al., 2005) 
and participate in the preparation of the metastatic site in which the secondary tumor 
will grow up. Recent data demonstrated that the metastatic cells can bring their stromal 
components from tumor primary site to the metastatic niche in the lungs. The stromal 
cells, co-traveling with metastatic cancer cells, provide them an early growth advantage 
and protect them in the bloodstream from anoikis (the apoptotic cell death due to lack or 
improper cell adhesion to ECM), thus ensuring long-term survival and proliferation in 
the metastatic sites (Duda et al., 2010). 
Beside MMPs, which remodel ECM, activated fibroblasts produce several growth 
factors and cytokines that sustain tumor progression. Indeed, CAFs produce paracrine 
diffusible signals, including TGF-β, HGF, VEGF, FGF, Stromal cell-Derived Factor-1 
(SDF-1) as well as cathepsins and plasminogen activators (Joyce and Pollard, 2009; De 
et al., 2008). In particular, it has been shown that CAFs promote the growth of breast 
carcinoma cells significantly more with respect to normal mammary fibroblasts derived 
from the same patients. These CAFs, play a central role in promoting directly the 
growth of tumor cells through their ability to secrete SDF-1 as well as in promoting 
angiogenesis through the recruitment of EPCs (Orimo et al., 2005). Moreover, 
fibroblast-derived SDF-1 enhanced the invasion of pancreatic cancer cells as well as 
their production of CXCL8. The cooperation between CXCL8 and SDF-1 enhances also 
the proliferation/invasion of human umbilical vein endothelial cells, thus sustaining 
tumor progression (Matsuo et al., 2009). Furthermore, in the same cellular model, 
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cancer cell-derived IL-1α significantly promotes HGF expression by fibroblasts. As a 
consequence, HGF enhances not only the invasiveness and proliferation of pancreatic 
cancer cells, but also enhances migration and proliferation of human umbilical vein 
endothelial cells, thus positively influencing the metastatic potential of pancreatic 
cancer cells (Xu et al., 2010). 
Anyway, the role of CAFs in tumor progression goes beyond the engagement of pro-
invasive features in cancer cells and embrace a real metabolic reprogramming of both 
cell types. This topic will be extensively described later. 
 
 
Role of other microenvironmental components in 
tumor progression 
Among components of tumor microenvironment, both hypoxia and acidity require 
adaptive response that influence cancer cells behaviors and involve metabolic pathway 
and invasive properties. 
 
HYPOXIA 
Solid tumors frequently outgrow the blood supply, resulting in nutrient and oxygen 
insufficiency. In this state, commonly referred as hypoxia, tumors can experience 
decreased oxygen pressure to 1% or below. Hypoxia is considered as an independent 
negative prognostic indicator and contributes to cancer progression affecting the 
behavior of both cancer and stromal cells (Taddei et al., 2013). Intratumoral hypoxia 
causes: 
 activation of a glycolytic metabolism to circumvent lack of oxygen; 
 acquisition of invasive features, mainly through EMT, in order to escape from 
the hostile environment; 
 activation of pathways for survival to stressful conditions; 
 secretion of soluble growth factors eliciting de novo angiogenesis allowing 
nutrient/oxygen supply. 
The ability of cells to sense and adapt to hypoxia is mainly mediated by hypoxia 
inducible factor (HIF) family of transcription factors. Targets of HIFs span from 
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glucose, glutamine and fat metabolism, oxygen homeostasis, tissue remodeling and 
motility, angiogenesis, erythropoiesis, proliferation, and survival to stress (Keith et al., 
2012). HIF1 and HIF2 complexes are the major responsible from gene expression 
changes during hypoxia. They are heterodimers composed of the constitutively 
expressed HIF-1β (or ARNT) subunit and either the HIF-1α or HIF-2α subunits. Under 
normoxic conditions, the HIF-1α subunits undergo oxygen-dependent hydroxylation by 
prolyl-hydroxylases (PHDs) on Pro402 and Pro564, which results in their recognition 
by von Hippel-Lindau tumor suppressor (VHL), an E3 ubiquitin ligase, and subsequent 
degradation (Chan et al., 2002) (Fig. 6). Of note, PHDs catalyze the hydroxylation 
reaction requiring oxygen and α-ketoglutarate as substrates, iron and ascorbate as 
cofactors. When hypoxia is occurring, HIFα are stabilized by lack of hydroxylation and 
functionally dimerizes with its partner HIF-1β to bind to the core sequence 5'-RCGTG-
3' and enhancing the transcription of target genes involved in promoting all adaptations 
to hypoxia (Fig. 7). Levels of HIF-1α are also influenced in normoxic conditions by 
genetic alterations, including mutations of VHL gene, succinate dehydrogenase and 
fumarate hydratase, or growth factors, hormones and cytokines produced by both tumor 
and stromal cells (Dery et al., 2005) (Fig. 6). 
 
 
Fig. 6. Regulation of HIF-1 stabilization. HRE: Hypoxia response element. 
 
Hypoxic cells undergo a glycolytic switch from aerobic to anaerobic metabolism 
(Wheaton et al., 2011), allowing maintenance of metabolic activities under limited 
oxygen avaibility. Other adaptive metabolic features include, engagement of pentose 
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phosphate pathway (PPP) and addiction to glutamine use. Of note, several of these 
adaptations have been acknowledged as the biochemical basis for resistance to 
chemotherapy and radiation (DeClerck and Elble, 2010; Heddleston et al., 2010; 
Rohwer and Cramer, 2011). Several genes controlling glucose uptake (e.g, glucose 
transporters GLUT1 and GLUT3), glycolysis (e.g., hexokinase-1/2, enolase, 
phosphoglycerate kinase-1, aldolase, pyruvate kinase M), lactate fermentation (lactate 
dehydronase A), inhibition of mitochondrial respiration (e.g., pyruvate dehydrogenase 
kinase) are directly targeted by HIFs (Stubbs and Griffiths, 2010) (Fig. 7). 
 
 
Fig. 7. HIF target genes. 
 
Increased glucose uptake is associated with inhibition of pyruvate kinase. Indeed, all 
tumors analyzed to date express the M2 variant of pyruvate kinase (PKM2), which is a 
redox sensitive enzyme undergoing inhibition following cysteine oxidation (Anastasiou  
et al., 2011; Bayle and Devilee, 2012; Chen et al., 2010). Hypoxia has been correlated 
with a state of oxidative stress, both due to mitochondrial or NADPH oxidase delivery 
of ROS causing ROS-mediated inhibition of PHDs through a Fenton reaction, and 
leading to HIF-1 stabilization. Hypoxic oxidative stress causes oxidation and inhibition 
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of PKM2, with the consequence of accumulation of glycolysis intermediates, rapidly 
fueling anabolism of aminoacids and proteins, as well as PPP. The latter increases the 
pool of NADPH, leads to synthesis of ribose and DNA, allowing to safely handle with 
oxidative stress and to overcome DNA damage and chemotherapy stress. In keeping 
with this, hypoxia and PPP reprogramming have been correlated with increased 
resistance to therapy in several cancer models (Anastasiou  et al., 2011; Brahimi-Horn 
et al., 2011; Gruning and Ralser, 2011). 
In hypoxia, cancer cells are unable to catabolize pyruvate into acetyl-CoA, stimulating 
lipid biosynthesis. This is mainly due to HIF-1-mediated expression of pyruvate 
dehydrogenase kinase (PDK), which totally blocks decarboxylation of pyruvate through 
pyruvate dehydrogenase (PDH) (Wheaton et al., 2011). Hypoxic cells solve this 
problem becoming addicted to glutamine uptake (Dang, 2012). Using a reductive 
carboxylation, glutamine is converted into isocitric acid by isocitric dehydrogenase-2 
(IDH-2), leading to citrate exportation from mitochondria. Citrate is converted by ATP-
citrate lyase to acetyl-CoA that is used to lipid synthesis. IDH1/IDH2 acknowledged to 
produce α-hydroxy-glutarate which is a strong inhibitor of PHDs due to its competition 
with their cofactor α-ketoglutarate, have been correlated to activation of HIF-1-
dependent transcriptional response (Chowdhury et al., 2011; Metellus et al., 2011). 
A latere with metabolic changes, during hypoxia tumor cells activate a specific escaping 
program to run away this hostile environment. In addition, the products of glycolysis 
cause acidification of the extracellular space and the resulting cellular toxicity acts as a 
further selective pressure for cells that are resistant to acidic conditions (Pani et al., 
2010). Moreover, hypoxic cells release angiogenic factors that stimulate de novo 
vascularisation, which restores O2 and nutrient supply in order to meet the growing 
metabolic demands of proliferating cells. 
To escape the hypoxic environment, the first strategy is to activate an invasive program 
and the primary driver engaged by hypoxia is the hepatocyte growth factor-MET 
receptor (Pennacchietti et al., 2003). In particular, mitochondrial ROS lead to 
stabilization of HIF-1α and expression and activation of MET, resulting in cell 
migration towards the blood or lymphatic microcirculation (Comito et al., 2011). 
Moreover, hypoxia also promotes tumor cell motility and invasion by triggering the 
EMT. Indeed, HIF-1α is a potent activator of Twist and other EMT inducers (Giannoni 
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et al., 2011; Cannito et al., 2008; Jiang et al., 2011; Yang et al., 2008). Twist1/2 cause 
downregulation of E-cadherin, that is concomitant with de novo expression of N-
cadherin, a trait leading to up-regulation of polarized motility through the small GTPase 
Rac1. Through both MMPs produced during EMT program and up-regulation of 
urokinase-type plasminogen activator receptor expression, hypoxia enhances proteolytic 
activity at the invasive front of cancer cells, stimulating motility by altering 
integrin/ECM interactions (Sullivan and Graham, 2007; Del Rosso et al., 2002). In 
addition, hypoxia induced EMT has been correlated to a supplementary adaptation, i.e. 
resistance to anoikis (Sullivan and Graham, 2007; Nieto, 2011; Gort et al., 2008; 
Whelan et al., 2010). This adaptation allows survival in the bloodstream of metastatic 
cancer cells which have experienced activation of the HIF-1 transcriptional program. 
Hypoxia-driven EMT is reinforced by a reciprocal activation between HIF-1α and NF-
kB, underscoring a further link between hypoxia and inflammation (Giannoni et al., 
2011; Rius et al., 2008). 
In order to permit successful metastases, hypoxia elicits adaptations useful to permit 
successful metastases, such as de novo angiogenesis and lymphangiogenesis (Sullivan 
and Graham, 2007). HIFs target several angiogenic factors, the masterpiece of which is 
VEGF, reportedly correlated with sprouting angiogenesis, lymphangiogenesis, as well 
as with the dynamic tumor-stromal interactions required for the subsequent stages of 
metastasis (Carmeliet and Jain, 2011). Angiogenesis and lymphangiogenesis within the 
primary tumor provide the necessary routes for dissemination, and VEGF-induced 
changes in vascular permeability promote both intravasation and extravasation. Through 
instruction of these critical pathways and adaptations, hypoxia promotes several step of 
the metastatic cascade, selecting tumor cell populations able to escape the hostile 
microenvironment of the primary tumor. In addition, HIFs transcription factors have 
been involved in the regulation of stemness, both in normal and in cancer cells, through 
up-regulation of pluripotency genes (Simon and Keith, 2008). Indeed, HIF-2 is an 
upstream regulator of Oct4, one of the mandatory transcription factors to reprogram 
differentiated cells towards stemness (the so called induced-stem cells) (Iida et al., 
2012; Li et al., 2009). Recent data have demonstrated that even HIF-1 shows a 
mandatory role in the regulation of stemness of cancer cells induced by hypoxia. 
Indeed, at least in lymphomas, the HIF-1α inhibitor echinomycin selectively kills c-
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 cancer stem cells, and the ablation of HIF-1α in these cancer stem cells 
severely impedes their self-renewing and tumor-initiating activity (Wang et al., 2011). 
 
ACIDITY 
Deregulated pH is emerging as another adaptive response of most cancers. Tumor cells 
show a ‘reversed’ pH gradient with a constitutively increased intracellular pH (pHi) that 
is higher than the extracellular pH (pHe) (Webb et al., 2011). In normal adult cells, pHi 
is generally ~7.2, while pHe is ~7.4. On the contrary, cancer cells have a higher pHi of 
>7.4 and a lower pHe of ~6.7–7.1 (Gallagher et al., 2008). 
The acid-outside pH of tumor cells is a consequence of the adaptation towards 
glycolytic metabolism induced by hypoxia; indeed, enhanced glucose uptake and his 
conversion to lactic acid, as well as the inefficient removal of lactate and CO2 as a 
consequence of a poor vasculature within the tumor mass, result in the increase of acid 
production (Brahimi-Horn and Pouyssegur, 2007; Brahimi-Horn et al., 2007a; Brahimi-
Horn et al., 2007b). 
Intracellular pH is crucial to normal cell function. Therefore, hypoxic tumor cells have 
developed key strategies to protect the cytosol from acidosis and allow cells to survive 
in hypoxia. HIF-1 regulates proton extrusion and pH homeostasis by enhancing 
expression of plasma membrane ion pumps and transporters (Brahimi-Horn and 
Pouyssegur, 2007). The most notable pHi regulatory systems of tumor cells are: 
 the Na+/H+ exchanger (NHE-1), known to play a key role in vivo in tumor 
development, in particular when highly glycolytic cells produce large amounts 
of lactate (Cardone et al., 2005; Pouyssegur et al., 2001; Shimoda et al., 2006); 
 the V-ATPase, which mainly contributes to the maintenance of an aberrant pH 
gradient between the alkaline cytosol and the acidic extracellular environment 
(Nishi and Forgac, 2002); 
 the monocarboxylate transporters (MCTs), whose increased expression confers a 
selective advantage to cancer cells owing to the high affinity of these 
transporters for lactate (Ullah et al., 2006); 
 the bicarbonate transporters that import HCO3
-





exchangers, playing an important role in cellular alkalinization, since the 
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 traps intracellular H
+
 and thus maintains a permissive pHi that 
favors cell survival (Izumi et al., 2003; Karumanchi et al., 2001). 
Another contribution to intracellular alkalinization is provided by a family of proteins, 
the carbonic anhydrases (CAs), which have extracellular catalytic domains that 




. In particular, expression 
of the membrane-associated CA IX and CA XII isoforms is substantially increased 
under hypoxic conditions in HIF-1-dependent manner (Chiche et al., 2009; Chiche et 
al., 2010; Ilie et al., 2010; Loncaster et al., 2001; Pastorekova et al., 2006; Swietach et 
al., 2009; Wykoff et al., 2000; Kaluz et al., 2009; Supuran, 2008). 
Deregulation of pH confers adaptive advantages to cancer cells, allowing the 
achievement of specific features, such as growth-factor independent proliferation, 
evasion of apoptosis, metabolic adaptation, migration and invasion and thus facilitating 
the metastatic dissemination of tumor cells (Cardone et al., 2005; Gatenby et al., 2006; 
Stock and Schwab, 2009). For example, the polarity of migrating cells, the de novo 
assembly of actin filaments and the dynamics of integrin-ECM attachments are 
processes facilitated by high pHi. Moreover, the low pH of tumor extracellular 
microenvironment may promote the degradation and remodeling of ECM through the 
activation of proteolytic enzymes, including MMPs and tissue serine proteases (Busco 
et al., 2010; Rofstad et al., 2006). Of note, the activity of MMP3, is higher at acidic pH 
(Johnson et al., 2000) and the expression and secretion of MMP9 increases at lower pHe 
and higher pHi (Bourguignon et al., 2004; Putney and Barber, 2004). In addition, there 
is strong evidence indicating a pivotal role of lysosomal-like vesicles in the degradation 
of ECM, cell invasion and cell migration (Glunde et al., 2003; Montcourrier et al., 1994; 
Montcourrier et al., 1997). For example, in breast cancer, acidic pHe causes a 
significant redistribution of lysosomes from the perinuclear region to the cell periphery 
(Glunde et al., 2003). Lysosomes displacement to the cell periphery may be a 
mechanism to facilitate increased secretion of degradative enzymes (Glunde et al., 
2003). In malignant tumor cells, vesicles containing cathepsin B also redistributed 
toward the cell periphery at acidic pHe and constitutive secretion of active cathepsin B 
allowed for the cleavage of secreted, latent MMPs into active enzymes (Giusti et al., 
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The uncontrolled cell proliferation, that represents the essence of neoplastic disease, 
involves not only deregulated control of cell growth but also corresponding adjustments 
of energy metabolism, in order to fuel anabolic pathway. One important characteristic of 
cancer cell metabolism is the consistent switch of the energy production pathway from 
oxidative phosphorylation to glycolysis (Kondoh et al., 2007) (Fig.8). 
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In 1924, Otto Warburg observed that cancer cells consume much larger quantities of 
glucose than their normal counterparts and metabolize it predominantly through 
glycolysis, thus producing high levels of lactate even in oxygen-rich conditions 
(Warburg, 1956, Warburg et al., 1924). This process is called aerobic glycolysis, or 
"Warburg effect". In general, through the glycolysis process, one molecule of glucose 
generates two molecules of pyruvate and produces two molecules of ATP. In mammals, 
pyruvate has diverse fates. In an environment with limited oxygen, pyruvate is 
converted into lactate by lactate dehydrogenase (LDH), a process which is called 
anaerobic glycolysis. In the presence of oxygen, pyruvate is oxidized into acetyl-CoA 
by the pyruvate dehydrogenase (PDH) complex (Fig. 9). 
 
 
Fig. 9. Fates of pyruvate. 
 
Acetyl-CoA is oxidized in the citric acid cycle (also known as Krebs cycle or 
trocarboxylic acid cycle) to generate electrons -in the form of NADH and FADH2- and 
CO2 in the mitochondria. The electron transport chain generates a pH gradient across 
the inner mitochondrial membrane. The force motive produced by the pH gradient 
generates ATP by ATP synthase. This process is called oxidative phosphorylation. In 
the latter, one molecule of glucose can be completed degraded into H2O and CO2 to 
produce 36 molecules of ATP. Overall, the oxidative phosphorylation process is more 
efficient in producing ATP than glycolysis. The reason why cancer cells prefer 
consuming more glucose by aerobic glycolysys to produce ATP is not well defined yet. 
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Further studies by Warburg itself hypothesized that the Warburg effect was mainly 
related to a mitochondrial deficiency developed by tumor cells, for example, through 
genetic mutations, thereby leading to a low energy delivery from mitochondrial 
respiration. Finally, aerobic glycolysis had to be the only possible metabolic mechanism 
that allowed cells to survive (Warburg, 1956). Anyway, subsequent studies 
demonstrated that mitochondrial deficiency was a rare condition in cancer cells 
(Weinhouse, 1956). Today, several authors highlight that the importance of aerobic 
glycolysis for tumor cells, as well as for proliferating cells in multicellular organisms, 
extends beyond ATP production, to allow nutrient assimilation into biosynthetic 
precursor and facilitate biomass accumulation (Lunt and Vander Heiden, 2011). 
Therefore, the main function of up-regulated glycolysis is to maintain the levels of 
glycolytic intermediates needed to support biosynthesis. Indeed, glucose provide the 
precursors for the chemical constituents (nucleotides, amino acids, lipids) that are used 
to build macromolecules essential for cell division. For example: 
 glucose-6-phosphate can be oxidized into PPP in order to produce NADPH and 
ribose-5-phosphate, which in turn are used to synthesize nucleotides for DNA 
and RNA; 
 dihydroxyacetone phosphate is the precursor to glycerol-3-phosphate, that is 
crucial for the biosynthesis of the phospholipids and triacylglycerols that serve 
as major structural lipids in cell membranes; 
 3-phosphoglycerate provides the carbons for cysteine, glycine and serine, 
whereas pyruvate provides the carbons for alanine. 
Besides aerobic glycolysis, cancer cells exhibit substantial alterations in several 
metabolic pathway including tricarboxylic acid (TCA) cycle, glutaminolysis, 
mitochondrial respiratory chain and PPP. The metabolic changes can be attributed to the 
activation and/or malfunction of oncogenes, and/or loss of tumor suppressors (Chen and 
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Fig. 10. Metabolic pathways active in proliferating and cancer cells are directly controlled by signaling 
pathways involving known oncogenes (green) and tumor suppressor genes (red). 
 
 
Regulation of cancer cell metabolism: the Warburg 
effect 
Aerobic glycolysis has been observed in a wide variety of tumors that originate from 
different cell types, but most normal cells in adult tissues from which cancer cells arise 
generally do not utilize this kind of metabolism. Thus, cancer cells revert to a metabolic 
phenotype that is characteristic of rapidly dividing cells, which suggests that aerobic 
glycolysis must provide advantages during proliferation. 
 
GLUCOSE TRANSPORTERS AND GLYCOLYTIC ENZYMES 
Glucose import into mammalian cells is facilitated primarily by five transmembrane 
transporters, GLUT1–5. Although GLUT2, GLUT4, and GLUT5 are found only in 
specific tissues, GLUT1 and GLUT3 are expressed in nearly all mammalian cells and 
have the lowest KM values (1mM) of the five, which allow them to transport glucose 
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into the cell at a nearly constant rate from serum in which the glucose concentration 
ranges from 4mM to 8mM. Tumor cells frequently overexpress GLUT1 and GLUT3 
and have an increased capacity for glucose uptake (Au et al., 1997; Suzuki et al., 1999; 
Yamamoto et al., 1990; Younes et al., 1996). Suppression of GLUT1 expression in a 
human gastric cancer cell line can decrease the number of cells in S phase and inhibit 
tumor growth (Noguchi et al., 2000). 
Once in the cell, glucose must be converted to glucose-6-phosphate by hexokinase (HK) 
to prevent its transport out of the cell and to prime it for metabolism in subsequent 
reactions (Berg et al., 2007). Four mammalian HK isoforms (HKI–IV) are known, and 
HKI is expressed in most normal cells and at particularly high levels in brain tissue 
(Wilson, 2003). HKII expression is more limited and is normally found mainly in 
skeletal muscle and adipose tissue. However, cancer cells frequently overexpress HKII 
(Mathupala et al., 2006), and at least some glioblastoma cells are specifically dependent 
on HKII over other isoforms of the enzyme (Wolf et al., 2011). Both HKI and HKII are 
associated with the voltage-dependent anion channel (VDAC) on the cytosolic side of 
the outer mitochondrial membrane. This VDAC-HK association may inhibit 
mitochondria-induced apoptosis (Majewski et al., 2004) and give HK preferential access 
to mitochondria generated ATP (Arora and Pedersen, 1988). Why mitochondria-bound 
HKII appears to be selected for in cancer cells remains unclear. 
Although HK traps glucose inside the cell, phosphofructokinase-1 (PFK1) controls its 
commitment to glycolysis and is therefore highly regulated. PFK1, which irreversibly 
converts fructose-6-phosphate to fructose-1,6-bisphosphate (FBP), is overexpressed in 
various human cancer cell lines (Vora et al., 1985). PFK1 is allosterically inhibited by 
high levels of ATP (Berg et al., 2007), and relieving this ATP inhibition is an important 
means to increase glucose metabolism in proliferating cells (Fang et al., 2010; Israelsen 
and Vander Heiden, 2010; Scholnick et al., 1973). PFK1 inhibition by ATP is 
diminished by fructose-2,6-bisphosphate, a metabolite synthesized from fructose-6-
phosphate by PFK2. Regulation of PFK2 expression or activity has been proposed as an 
important way to couple growth signals with regulation of glucose metabolism in 
proliferating cells (Christofk et al., 2008; Marsin et al., 2000; Telang et al., 2006); 
moreover, PFK2 is expressed constitutively in several human cancer cell lines and is 
found to be required for tumor cell growth (Chen and Russo, 2012). In human tissues, 
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PFK1 subunit composition, a complex mixture of homotetramers or heterotetramers 
composed of up to three different subunits, can vary depending on tissue type. Each 
subunit (C, L, M) differs in sensitivity to allosteric effectors; thus, the kinetic and 
regulatory properties of PFK1 are determined by subunit composition (Dunaway et al., 
1988). PFK1 subunits overexpressed in rat thyroid carcinomas and human gliomas are 
less sensitive to the allosteric inhibitors ATP and citrate (Meldolesi et al. 1976, Oskam 
et al. 1985, Staal et al. 1987). In addition to controlling glucose commitment to 
glycolysis, PFK1 may regulate the amounts of glucose-6-phosphate available for 
nucleotide biosynthesis (Lunt and Vander Heiden, 2011). 
 
Among glycolytic enzymes, pyruvate kinase (PK) has received particular attention 
during the last few years. Indeed, recent findings have shown that many cancer cells 
exclusively express the M2 isoform of PK (Mazurek et al., 2005), and PKM2 
expression is important for tumor growth (Christofk et al., 2008). PK catalyzes the 
reaction generating pyruvate and ATP from phosphoenolpyruvate (PEP) and ADP. Four 
isoforms of PK (L, R, M1, and M2) are present in mammals. The L and R isotypes are 
encoded by the PKLR gene. Their expression is tissue specific and is regulated by 
different promoters. The L isotype is expressed in the liver, kidney, and intestine, and 
the R isotype is expressed in red blood cells (Mazurek et al., 2005; Mazurek, 2011; 
Clower et al., 2010; Noguchi et al., 1987). PKM1 and PKM2 are encoded by the PKM 
gene and are the products of two mutually exclusive alternatively spliced exons (exon 9 
and exon 10, respectively) (Clower et al., 2010; David et al., 2010; Noguchi et al., 
1986): M1 is expressed in most adult differentiated tissues such as brain and muscle, 
whereas M2 is expressed in embryonic cells, adult stem cells, and cancer cells 
(Christofk et al., 2008, Mazurek et al., 2005; Mazurek, 2011; Bluemlein et al., 2011; 
Lee et al., 2008; Cairns et al., 2011). Splicing of PKM is controlled by the splicing 
repressors, heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and A2, as well as 
polypyrimidine tract binding protein (PTB, also known as hnRNPI), and the expression 
of those repressors is up-regulated by c-Myc (Clower et al., 2010; David et al., 2010). 
These proteins bind to exon 9 and repress PKM1 mRNA splicing, resulting in the 
inclusion of exon 10 and thereby contributing to the high levels of PKM2 expression 
(Clower et al., 2010; David et al., 2010; Chen et al., 2012) (Fig. 11). 
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Fig. 11. PKM1 and PKM2 expression after alternative splicing. 
 
A number of regulators of PKM2 expression have been reported (Clower et al., 2010; 
Mazurek, 2011; David et al., 2010; Chen et al., 2012; Luo et al., 2011; Lv et al., 2011; 
Panasyuk et al., 2012): in particular, a recent study showed that PKM2 expression is 
induced by activated mTOR (mammalian target of rapamycin), which transactivates 
HIF-1 and promotes the c-Myc-hnRNPs–mediated alternative splicing, leading to the 
aerobic glycolysis in tumor cells (Sun et al., 2011). The expression and lower glycolytic 
enzyme activity of PKM2 are necessary for the Warburg effect, which provides cancer 
cells with selective advantages, including tumor growth and suppression of ROS 
(Christofk et al., 2008; Vander Heiden and Cantley, 2009; Cairns et al., 2011; 
Anastasiou et al., 2011) for the following reasons. First is that the glycolytic pathway 
generates ATP more rapidly than the oxidative phosphorylation (Pfeiffer et al., 2011), 
allowing faster incorporation of carbon into its biomass (Vander Heiden and Cantley, 
2009; Hamanaka and Chandel, 2012). Between yield and rate of ATP production, a 
trade-off has been reported to be present in sugar degradation by glycolysis and 
mitochondrial respiration. Then, glycolysis generates ATP at a high rate but low yield 
via massive consumption of glucose (Pfeiffer et al., 2011; Vazquez et al., 2010). The 
second reason is that lower activity of PKM2 facilitates the production of glycolytic 
intermediates to enter the glycolysis branch pathways, such as glycerol synthesis, amino 
acid syntesis and the pentose phosphate pathway, which generates NADPH to suppress 
ROS production and is also involved in nucleotide synthesis (Vander Heiden and 
Introduction 
30 
Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 
Tesi di Dottorato in Scienze Biomolecolari e Biotecnologiche-Università degli Studi di Sassari 
 
Cantley, 2009; Cairns et al., 2011; Hamanaka and Chandel, 2012; Jiang et al., 2010; 
Boxer et al., 2010). In other words, the increase in glycolysis induced by the lower 
activity of PKM2 can supply cancer cells with varied resources of substrates necessary 
for their rapid proliferation (Fig 12). 
PKM2 exists as either a low-activity dimeric or high-activity tetrameric form, whereas 
PKM1 constantly exists as a high-activity tetrameric form (Mazurek, 2011; Mazurek et 
al., 2005; Dang, 2009). Cancer cells predominantly express the low-activity dimeric 
form of PKM2 (Christofk et al., 2008; Christofk et al., 2008a; Hitosugi et al., 2009). 
Christofk and colleagues (Christofk et al., 2008) and Vander Heiden and colleagues 
(Vander Heiden et al., 2010) reported that PKM1-expressing cells showed much higher 
PK activity than PKM2-expressing cells; these cells consumed more oxygen, produced 
less lactate, and were highly sensitive to the mitochondrial ATP synthesis inhibitor, 
oligomycin (Christofk et al., 2008). In addition, Hitosugi and colleagues reported that 
tyrosine phosphorylation (Tyr 105) of PKM2 disrupts the active tetrameric form of 
PKM2, leading to the suppression of its activity. Furthermore, PKM2-mutated cells, in 
which tyrosine residue 105 is replaced with a phenylalanine, had increased PK activity 
as observed in PKM1-expressing cells (Hitosugi et al., 2009). Therefore, the low 
activity of dimeric PKM2 is a very important driver for glycolysis. In contrast, the high 
activity of PKM2 and PKM1 tetramers drives the TCA cycle (Christofk et al., 2008; 
Christofk et al., 2008a; Hitosugi et al., 2009) (Fig. 11, Fig. 12). 
Various factors have been reported to control the switch between the dimeric and 
tetrameric forms of PKM2 (Fig. 11, Fig. 12). For example, fructose-1,6-bisphosphate 
binds allosterically to PKM2 and facilitates the formation of the active tetramer 
(Tamada et al., 2012). Serine is also a positive regulator of PKM2 (Mazurek, 2011; 
Ward and Thompson, 2012; Ashizawa et al., 1991; Eigenbrodt et al., 1983; Ye et al., 
2012). In contrast, tyrosine phosphorylation of PKM2 induces the release of fructose-
1,6-bisphosphate, which causes PKM2 to convert from tetrameric form to less active 
dimeric form (Christofk et al., 2008a; Hitosugi et al., 2009). In addition, oncoproteins 
such as HPV-16 E7 and activated pp60v-src kinase dissociate the tetrameric form to 
yield the dimeric form (Mazurek et al., 2002). Furthermore, recent studies show that 
oxidative stress causes dissociation of the tetramer and a subsequent reduction in PKM2 
activity (Anastasiou et al., 2011), and that acetylation of lysine residue within PKM2 
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suppresses its catalytic activity and induces the degradation by chaperone-mediated 
autophagy (Lv et al., 2011). In addition, it has been reported that mucin 1 
phosphorylated by EGF receptor (EGFR) interacts with PKM2 and suppresses its 
activity (Kosugi et al., 2011). As previously described, PKM2 activity is inhibited by 
oxidative stress as well as tyrosine phosphorylation (Anastasiou et al., 2011). Oxidative 
stress induces the oxidization of Cys358 within PKM2, which promotes glycolysis and 
PPP flux, leading to the production of glutathione (GSH) and consequent ROS depletion 
(Anastasiou et al., 2011; Gruning and Ralser, 2011; Hamanaka and Chandel, 2011). 
Thus, cancer cells have multiple mechanisms for avoiding ROS accumulation, which 
gives them a survival advantage in terms of tumor growth and therapeutic resistance 
(Anastasiou et al., 2011; Tamada et al., 2012; Ishimoto et al., 2011). 
 
 
Fig. 12. Metabolic pathway regulated by PKM2 in cancer cells. 
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Finally, an increasing number of reports document the non-glycolytic functions of 
dimeric PKM2. In particular, the role of PKM2 in transcription is attracting attention. It 
has been reported that PKM2 interacts directly with the HIF-1 subunit and promotes 
transactivation of HIF-1 target genes (Luo et al., 2011). As HIF-1 also activates the 
transcription of the genes encoding PKM2, cancer cells may have the positive feedback 
loop between PKM2 and HIF-1, which contributes to the characteristic metabolism in 
cancer cells. 
Nuclear PKM2 has been shown to activate gene transcriptions and cell proliferation 
(Lee et al., 2008; Hoshino et al., 2007; Gao et al., 2012; Luo et al., 2011; Yang et al., 
2011; Ignacak and Stachurska, 2003). Translocation of PKM2 into the nucleus induced 
by EGFR activation was reported to promote β-catenin transactivation, leading to 
expression of cyclinD1 and c-Myc (Yang et al., 2011). Given that c-Myc upregulates 
transcription of hnRNPs contributing to the high PKM2/PKM1 ratio (Clower et al., 
2010; David et al., 2010), and that c-Myc promotes glycolysis by driving the expression 
of GLUT1 and LDHA (Munoz-Pinedo et al., 2012; Dang et al., 2009), the events 
induced by the translocation of PKM2 into the nucleus may be connected with a feed-
forward loop to drive glycolysis. 
 
MOLECULAR PATHWAYS IN AEROBIC GLYCOLYSIS 
The metabolic changes induced by cell growth signals are largely conserved between 
normal and cancer cells; however, cancer cells activate signaling pathways in the 
absence of normal extracellular stimuli, thus promoting a metabolic phenotype that 
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Fig. 13. Regulation of glucose transporters and glycolysis by c-Myc, HIF-1α and p53. 
 
A major regulator of glucose metabolism is the phosphoinositide 3-kinase (PI3K) 
signaling pathway. PI3K signaling through the protein kinases AKT and mTOR can 
increase uptake of glucose by increasing expression of the glucose transporter GLUT1 
(Barthel et al., 1999; Frauwirth et al., 2002; Vander Heiden et al., 2001) and 
maintaining GLUT1 levels on the cell surface by preventing internalization (Wieman et 
al., 2007) (Fig. 13). AKT activation enhances flux through glycolysis (Elstrom et al. 
2004) in part by maintaining HK association with mitochondria (Gottlob et al., 2001) 
and PFK2 through phosphorylation, which generates the allosteric activator of PFK1 
fructose-2,6-bisphosphate (Deprez et al., 1997). In normal cells, the PI3K pathway is 
tightly controlled to increase glucose uptake and metabolism in response to growth 
signals (Cantley, 2002). However, in cancer cells, various mutations activate PI3K in 
the absence of growth signals, which suggests that inappropriate activation of this 
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Rapidly proliferating cells require close proximity to blood vessels for access to oxygen 
and nutrients. As tumors grow, cells may encounter hypoxic conditions that lead to 
induction of HIF-1 transcription factor. HIF-1 increases the expression of VEGF to 
facilitate the growth of new blood vessels. HIF-1 also increases the transcription of 
glucose transporters (GLUT1, GLUT3), many glycolytic enzymes, and LDHA 
(O’Rourke et al., 1996; Semenza et al., 1994) (Fig. 13). During periods of fast growth 
and rapid biomass synthesis, such as embryogenesis and tumorigenesis, local hypoxic 
conditions may arise and stimulate HIF-1 to enhance glycolytic gene expression. HIF-1 
is required for embryogenesis, as mice homozygous for a loss-of-function mutation in 
HIF-1α or HIF-1β die at mid gestation (Iyer et al., 1998; Maltepe et al., 1997). Loss of 
HIF-1α in cancer cells also dramatically slows their growth as xenograft tumors in nude 
mice (Jiang et al., 1997; Maxwell et al., 1997; Ryan et al., 1998). Even under normoxic 
conditions, HIF-1α can be induced by the glycolytic metabolites pyruvate and lactate 
(McFate et al., 2008), mTOR activation, NAD
+
 levels, reactive oxygen species, nitric 
oxide, many TCA cycle metabolites (Semenza, 2010b), and oncogene gain of function 
or tumor suppressor gene loss of function (Semenza, 2010a). Of note, recent findings 
have highlighted the role of mitochondrial NAD-dependent deacetylase SIRT3 in 
destabilizing HIF-1α. Indeed, SIRT3-loss increases ROS production, leading to HIF-1α 
stabilization. SIRT3 expression is reduced in human breast cancers and several other 
malignancies and its loss correlates with the up-regulation of HIF-1α target genes. Loss 
of SIRT3 results in aberrant mitochondrial metabolism and genomic instability, while 
its over-expression represses glycolysis and proliferation in breast cancer cells, 
providing a metabolic mechanism for tumor suppression (Kim et al., 2010, Finley et al., 
2011). Moreover, knocking down SIRT3 increases tumorigenesis in mouse xenograft 
models, and this is abolished by the antioxidant N-acetyl cysteine (NAC) (Bell et al., 
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Fig. 14. Regulation of HIF-1α stabilization by SIRT3. 
 
Activation of the PI3K pathway appears to be an important way to increase HIF-1 
transcription in cancer (DeBerardinis et al., 2008; Majumder and Sellers, 2005). In 
addition to increasing the expression of glycolytic enzymes, increased HIF-1 activity 
promotes aerobic glycolysis by upregulating the expression of pyruvate dehydrogenase 
kinase (PDK). HIF-1-induced PDK activity inhibits PDH, which converts pyruvate to 
acetyl-CoA (Kim et al., 2006; Papandreou et al., 2006). Inhibition of PDH activity 
decreases pyruvate flux into the TCA cycle, which promotes pyruvate conversion to 
lactate. Thus, activation of HIF resulting from hypoxia, PI3K activation, or other 
mechanisms can promote glucose metabolism by aerobic glycolysis. 
The transcription factor c-Myc promotes expression of glucose transporters and 
glycolytic enzymes (Ahuja et al., 2010; Osthus et al., 2000) (Fig. 13). c-Myc regulates 
the expression of LDHA (Shim et al. 1997), and c-Myc-dependent tumors cannot 
proliferate when LDHA expression is knocked down (Le et al., 2010). Furthermore, c-
Myc regulates enzymes in the nucleotide biosynthesis pathway, including thymidylate 
synthase, inosine monophosphate dehydrogenase 1 and 2, and phosphoribosyl 
pyrophosphate synthetase-2 (Tong et al., 2009b). Additional transcription factors related 
to c-Myc, ChREBP and MondoA, control glycolytic enzyme expression and can 
promote anabolic metabolism in some contexts (Sloan and Ayer, 2010; Tong et al., 
2009a). Ras, another oncogene widely implicated in human cancer, also promotes 
glucose metabolism by enhancing glucose uptake (Yun et al., 2009). Mutation of p53 is 
another common genetic event in human cancer, and the p53 protein prevents tumor 
growth by suppressing metabolic pathways conducive to proliferation of stressed or 
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damaged cells. p53 promotes mitochondrial respiration through expression of SCO2 
protein (Synthesis of Cytochrome c Oxidase), while inhibiting glycolysis by repressing 
glucose transporters, inhibiting the glycolytic enzyme phosphoglycerate mutase and 
decreasing the activity of PFK1 through TIGAR, that functions to lower fructose-2,6-
bisphosphate levels (Cheung and Vousden, 2010; Levine and Puzio-Kuter, 2010). Thus, 
glycolysis can be promote by loss of p53 function in cancer (Fig. 13). 
 
 
Regulation of cancer cell metabolism: the TCA cycle 
TCA cycle (also known as citric acid cycle or the Krebs cycle) (Fig. 15) is a series of 
chemical reactions used by all aerobic living organism to generate energy through the 
oxidization of pyruvate derived from carbohydrates, lipids and proteins into carbon 
dioxide and water. In addition, TCA cycle provides precursors for the biosynthesis of 
compounds including certain amino acids as well as the reducing agent NADH that is 
used in oxidative phosphorilation (Chen and Russo, 2012). 
It has been shown that a number mutations in genes that encode enzymes including 
aconitase, isocitrate dehydrogenase 1-2 (IDH1, IDH2), succinate dehydrogenase (SDH) 




Aconitase is a mitochondrial enzyme that catalyzes the stereospecific isomerization of 
citrate to isocitrate via cis-aconitate in the TCA cycle (Lauble et al., 1992; Lauble et al., 
1994). Aconitase is regarded as the key enzyme in citrate oxidation in human prostate 
epithelial cells, a unique organ that produces and releases large amounts of citrate. The 
abnormal expression and activity of aconitase have been implicated in tumorigenesis of 
the prostate (Mycielska et al., 2006). It has been observed that the mRNA levels of 
mitochondrial and cytosolic aconitases and aconitase activity, as well as fatty acid 
synthase, are significantly higher in metastatic PC3 cells than in normal human prostate 
cells (PNT2-C2) (Mycielska et al., 2006). Using immunohistochemical analysis of 
prostate cancer tissue sections and malignant prostate cell lines, Singh et al. (Singh et 
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al., 2006) detected the presence of mitochondrial-aconitase (m-aconitase) in the 
mitochondrial compartment in PC3, LNCaP, and DU-145 malignant prostate cell lines 
and prostate tissue sections from prostate cancer subjects where mitochondrial aconitase 
enzyme is present in the glandular epithelium of normal glands, hyperplastic glands, 
adenocarcinomatous glands, and prostatic intraepithelial neoplastic foci. Moreover, Tsui 
et al. (Tsui et al., 2011) observed that p53 down-regulated the gene expression of m-
aconitase in human prostate carcinoma cells (Fig. 15). 
 
ISOCITRATE DEHYDROGENASE 
IDH1 converts isocitrate to α-ketoglutarate with generation of NADH. Up to 12% of 
glioblastoma tumors have spontaneous point mutations in IDH1 genes (Parsons et al., 
2008). Mutations that affected IDH1 have also been identified in grades II and III 
astrocytomas, oligodendrogliomas and glioblastomas that developed from these lower-
grade lesions (Yan et al., 2009). Similar mutations in IDH2 at residue Arg172 in the 
active site have been identified in acute myeloid leukemia (Ward et al., 2010) and other 
diseases (Kranendijk et al., 2010). These mutations disable the enzyme's normal ability 
to convert isocitrate to α-ketoglutarate and confer on the enzymes a new function, i.e. 
the ability to convert α-ketoglutarate to d-2-hydroxyglutarate (D-2-HG) (Kranendijk et 
al., 2010; Dang et al., 2010). The elevated levels of 2HG in vivo are thought to 
contribute to the formation and malignant progression of gliomas (Dang et al., 2010). 
 
SUCCINATE DEHYDROGENASE 
SDH, an enzyme complex consisting of four subunits A, B, C and D, catalyzes the 
oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. SDH 
is bound to the inner membrane of mammalian mitochondria. It is the only enzyme that 
participates in both the TCA cycle and the electron transport chain (Oyedotun and 
Lemire, 2004). Inherited or somatic mutations in subunits B, C, or D of SDH have been 
associated with several types of cancers including pheochromocytoma, paraganglioma, 
renal cell carcinoma and papillary thyroid cancers (Baysal, 2003; Neumann et al., 2004; 
Pollard et al., 2003; Eng et al., 2003; Rustin and Rotig, 2002). Reduced expression and 
loss of heterozygosity of SDH gene are observed in gastric and colon carcinoma 
(Habano et al., 2003). The R22X mutation of SDH gene in hereditary paraganglioma 
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abolishes the enzymatic activity of complex II of mitochondrial respiratory chain and 
activates HIF-1α, leading to increased expression of HIF-1α-regulated genes (Gimenez-
Roqueplo et al., 2001, 2003, 2002). Selak et al. (Selak et al., 2005) have shown that 
succinate inhibits PHDs, leading to HIF-1α stabilization under normoxic conditions. 
Thus, succinate can increase expression of genes that facilitate angiogenesis, metastasis, 
and glycolysis, ultimately leading to tumor progression. 
 
FUMARATE HYDRATASE 
FH catalyzes the reversible hydration/dehydration of fumarate to malate. Mutations in 
the FH gene have been identified in chromosome 1q42.3-43 mapped to the genetic 
locus for multiple cutaneous and uterine leiomyoma syndrome (MCL), which is 
inherited in an autosomal dominant pattern (Tomlinson et al., 2002). Germline 
mutations in the FH gene predispose to multiple MCL and MCL-associated renal cell 
cancer. 
Reduced FH expression has been seen in clear cell renal cancer, the most common 
histologic variant of kidney cancer, leading to the accumulation of HIF-2α, which is 
known to promote renal carcinogenesis, migration and invasion whereas over-
expression of FH in renal cancer cells inhibits cellular migration and invasion 
(Sudarshan et al., 2011). These data provide novel insights into the tumor suppressor 
functions of FH in sporadic kidney cancer. 
FH-deficient cells and tissues accumulate high levels of fumarate, which may act as an 
oncometabolite and contribute to tumorigenesis. Fumarate has been proposed to have a 
role in the covalent modification of cysteine residues to S-(2-succinyl) cysteine (2SC) 
(termed protein succination). Bardella et al. (Bardella et al., 2005) assessed 2SC levels 
in the models of hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. 
They observed robust detection of 2SC in Fh1 (murine FH)-deficient renal cysts and in 
a retrospective series of HLRCC tumors with established FH mutations. Importantly, 
2SC was undetectable in normal tissues and tumor types not associated with HLRCC. In 
another study, Sullivan et al. showed that accumulated fumarate directly binds the 
antioxidant glutathione in vitro and in vivo to produce the metabolite succinated 
glutathione (GSF). GSF acts as an alternative substrate to glutathione reductase to 
decrease NADPH levels and enhance mitochondrial ROS and HIF-1 activation 
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(Sullivan et al., 2013). Increased ROS also correlates with hypermethylation of histones 
in these cells. Thus, fumarate serves as a proto-oncometabolite by binding to 
glutathione which results in the accumulation of ROS. 
 
 
Fig. 15. Regulation of TCA cycle and glutaminolysis by c-Myc and p53. 
 
 
Regulation of cancer cell metabolism: glutaminolysis 
Glutamine is the most abundant free amino acid in the circulation and in intracellular 
pools. It is not only a precursor for the synthesis of amino acids, proteins, nucleotides, 
and a number of biologically important molecules, but also play a regulatory role in 
several cell specific processes including metabolism (e.g. oxidative fuel, gluconeogenic 
precursor, and lipogenic precursor), cell integrity (apoptosis and cell proliferation), 
protein synthesis and degradation, redox potential, respiratory burst, insulin resistance, 
insulin secretion and extracellular matrix synthesis. Glutamine is also an essential 
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nutrient for cancer cell proliferation (Smith, 1990; Newsholme et al., 2003; Curi et al., 
2005; Cassago et al., 2012). 
Glutaminolysis (Fig. 15) is a series of biochemical reactions by which glutamine is 
degraded to glutamate, aspartate, CO2, pyruvate, lactate, alanine and citrate. Glutamine 
is imported into cells through high affinity surface glutamine importers such as ASCT2 
and SN2 (Wise et al., 2008). Once it enters the cells, the majority of glutamine either 
donates nitrogen to macromolecules or is deamidated by glutaminases (GLS), which 
converts glutamine to glutamate (Glu). Glu has several fates. It can be converted 
directly to glutathione (GSH) by glutathione cysteine ligase (GCL). The reduced GSH, 
one of the most abundant anti-oxidants present in mammalian cells, is vital to 
controlling the redox state of the subcellular compartments (Wu et al., 2004). Glu can 
also be catabolized through removal of α-nitrogen by aminotransferases or glutamate 
dehydrogenase (GDH) producing α-ketoglutarate. The latter can be oxidized through the 
TCA cycle for the production of ATP or serves as substrate for biosynthesis of the 
polyglutamated folic acid or processed further in mitochondria (Fig. 15). The 
cyclization of glutamate produces proline, an amino acid important for synthesis of 
collagen and connective tissue. Alternatively, some tissues e.g. rat liver and brown 
adipocyte cell lines can reductively carboxylate α-ketoglutarate to generate citrate (Des 
Rosiers et al., 1995; Yoo et al., 2008). There is evidence indicating that a fraction 
glutamine-derived carbon can exit the TCA cycle as malate and serve as substrate of 
malic enzymes 1, which produces NADPH (DeBerardinis et al., 2007). More recently, it 
has been demonstrated (Metallo et al., 2012) that human cells use reductive metabolism 
of α-ketogluatare to synthesize acetyl-CoA for lipid synthesis (Fig.15). This IDH1-
dependent pathway is active in most cell lines under normal culture conditions, but cells 
grown under hypoxia rely almost exclusively on the reductive carboxylation of 
glutamine-derived α-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines 
deficient in the von Hippel–Lindau tumor suppressor protein preferentially use 
reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. 
In order to compensate for Warburg effect and to help maintain a functioning TCA 
cycle, cancer cells often rely on elevated glutamine metabolism through a marked 
elevation of glutaminase activity (Erickson and Cerione, 2010). Several studies (Wise et 
al., 2008; Gao et al., 2009; Le et al., 2012) have revealed that c-Myc plays a major role 
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in regulating glutaminolysis. Le et al. (Le et al., 2012) investigated the metabolic 
responses of a c-Myc inducible human Burkitt lymphoma model P493 cell line to 
aerobic and hypoxic conditions, and to glucose deprivation, using radiolabeled glucose 
as the tracer isotope for resolving metabolomics. They observed that glutamine import 
and metabolism through the TCA cycle persisted under hypoxia and that glutamine 
contributed significantly to citrate carbons. Under glucose deprivation, glutamine-
derived fumarate, malate, and citrate were significantly increased, thus demonstrating 
an alternative energy-generating glutaminolysis pathway involving a glucose-
independent TCA cycle. 
There are three isoforms of glutaminases, GLS1, GLS2 and GLSC (a splice variant of 
GLS1) (Cassago et al., 2012). GLS1 is required for cell cycle progression through S 
phase (Colombo et al., 2011). GLS2 gene encodes a mitochondrial glutaminase, a key 
enzyme that catalyzes the hydrolysis of glutamine to glutamate and thereby a regulator 
of GSH synthesis and energy production (Perez-Gomez et al., 2003; Campos-Sandoval 
et al., 2007). It has been shown that glutamine importers and GLS1 expression are up-
regulated by c-Myc (Wise et al., 2008; Gao et al., 2009; Wise et al., 2010) and that 
GLS2 expression is up-regulated by p53 (Hu et al., 2010; Suzuki et al., 2010; 
Rajagopalan and DeBerardinis, 2011) (Fig. 15). 
Wise et al. (Wise et al., 2008) reported that c-Myc activates the transcription of 
glutamine importers ASCT2 and SN2 by selectively binding to the promoter regions of 
both genes that are required for glutamine uptake and metabolism (Fig. 15). A 
consequence of this c-Myc-dependent glutaminolysis is the reprogramming of 
mitochondrial metabolism to depend on glutamine catabolism to sustain cellular 
viability and TCA cycle anaplerosis. The ability of c-Myc-expressing cells to engage in 
glutaminolysis does not depend on concomitant activation of PI3K or AKT. The 
stimulation of mitochondrial glutamine metabolism resulted in reduced glucose carbon 
entering the TCA cycle and a decreased contribution of glucose to the mitochondrial-
dependent synthesis of phospholipids. Gao et al. (Gao et al., 2009) reported that the c-
Myc up-regulates the expression of mitochondrial GLS1 in human P-493 B lymphoma 
cells and PC3 prostate cancer cells through repressing microRNAs miR-23a and miR-
23b that target the GLS's 3′ untranslating regions and that glutamine and glutaminase 
are necessary for Myc-mediated cancer cell proliferation and survival. Together, these 
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studies suggest that oncogenic levels of c-Myc induce a transcriptional program that 
promotes glutaminolysis and triggers cellular addiction to glutamine as a bioenergetic 
substrate.  
On the other hand, we have to mention that GLS2 is a p53-target gene and contributes 
to its role in tumor suppression. GLS2 regulates cellular energy metabolism by 
increasing production of glutamate and α-ketoglutarate, which in turn results in 
enhanced mitochondrial respiration and ATP generation (Fig. 15). Furthermore, GLS2 
also regulates antioxidant defense function in cells by increasing GSH levels and 
decreasing ROS levels, which, in turn, protects cells from oxidative stress-induced 
apoptosis. It has been shown that GLS2 expression induced by p53 under both non-
stressed and stressed conditions leading to: 
 increased levels of glutamate and α-ketoglutarate, mitochondrial respiration rate, 
and GSH levels 
 decreased ROS levels in cells, resulting in an overall decrease in DNA oxidation 
(Hu et al., 2010; Suzuki et al., 2010; Eto et al., 1994).  
In agreement with this data, the expression of GLS2 is loss in human liver tumors 
whereas GLS2 over-expression reduces tumor cell colony formation abilities. 
Deregulated tumor cell metabolism provides an opportunity to selectively target this 
disease and to improve cancer therapy. Therefore, a number of small molecules 
targeting transporters, enzymes and proteins involved in metabolic deregulation of 
tumor cells have been developed and some of these are in pre-clinical or clinical studies 
(Zhao et al., 2013; Ramsay et al., 2011). 
 
 
Role of tumor microenvironment in regulation of 
cancer cell metabolism 
Several studies during the last years has demonstrated that tumor microenvironment 
modifies cancer cell metabolism. As previously reported, hypoxia induces a glycolytic 
switch in tumor metabolism as a result of HIF activation, in order to circumvent lack of 
oxygen. However, in solid tumors, tumor mass is composed by normoxic regions, 
closed to blood vessels, and hypoxic regions, as a results of disorganized vasculature. In 
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this regard, metabolic coupling was demonstrated between well-oxygenated and 
hypoxic cancer cells, whereby lactate produced by glycolysis of hypoxic tumor cells 
fuels mitochondrial oxidative phosphorylation in well-oxygenated tumor cells 
(Sonveaux et al., 2008). Thus, lactate produced by glycolytic tumor cells within hypoxic 
regions is used as an oxidative substrate by other tumor cells in which the oxygen 
supply is higher (Fig. 16). Moreover, in this way, normoxic subpopulation avoids 
extracellular glucose depletion, as glucose is metabolized through glycolysis by hypoxic 
cancer cells. 
Lactate used for mitochondrial metabolism gives several advantages to cancer cells: 
 pyruvate oxidation to lactate by LDH leads to production of reducing power 
that prevents harmful intracellular oxidative stress, thereby favouring cells 
survival (Lee et al., 2003; Pelicano et al., 2006); 
 lactate oxidation do not requires ATP consumption; 
 each molecule of lactate generates 18 ATP molecules, thereby allowing cells 
to save energy for glycolytic enzymes activity. 
In this model, lactate up-take in tumor cells is mediated by monocarboxylate 
transporter-1 (MCT1) (Fig. 16). In agreement, inhibition of MCT-1 with α-cyano-4-
hydroxycinnamate (CHC) or siRNA induces a switch from lactate-fueled respiration to 
glycolysis. A similar switch in oxygenated tumor cells in both a mouse model of lung 
carcinoma and xenotransplanted human colorectal adenocarcinoma cells is observed 
after administration of CHC. MCT1 inhibition delays tumor growth, induces tumor core 
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Fig. 16. Model of metabolic symbiosis between hypoxic and respiring cells. 
 
Besides hypoxia, stromal cells are emerging as important players in metabolic 
reprogramming of cancer cells (Koukourakis et al., 2006). In this regard, Lisanti and 
colleagues have developed a model of metabolic coupling between tumor stroma and 
cancer cells (Fig. 17). In this model, loss of caveolin-1 (Cav-1) causes the metabolic 
reprogramming of stromal cells to support the growth of adjacent epithelial tumor cells. 
Caveolins are a family of scaffolding proteins that function in endocytosis, signal 
transduction, and cholesterol transport (Okamoto et al., 1998). Interestingly, loss of 
Cav-1 in fibroblasts is sufficient to induce a CAF phenotype (upregulation of α-SMA, 
calponin, vimentin, increased deposition of MMP9 and ECM components, and 
hyperactivation of the TGF-β signaling pathway) (Sotgia et al., 2009; Martinez-
Outschoorn et al., 2010a; Martinez-Outschoorn et al., 2010b). Witkiewicz et al. have 
identified a loss of stromal Cav-1 as single independent predictor of clinical outcome in 
human breast cancer patients. More specifically, loss of stromal Cav-1 (in cancer 
associated fibroblasts) strictly correlates with early tumor recurrence, lymphonode 
metastasis, increased tumor stage, tamoxifen-resistance, and overall poor clinical 
outcome (Witkiewicz et al., 2009; Sloan et al., 2009). In agreement, loss of stromal 
Cav-1 in prostate cancer patients correlate with advanced prostate cancer and the 
presence of metastatic disease, as well as high Gleason score, another indicator of poor 
prognosis (Di Vizio et al., 2009). 
Introduction 
45 
Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 
Tesi di Dottorato in Scienze Biomolecolari e Biotecnologiche-Università degli Studi di Sassari 
 
 
Fig. 17. Model of metabolic symbiosis between cancer cells and CAFs. 
 
Lisanti's group performed unbiased proteomic analysis on mesenchymal stem cells 
derived from WT and Cav-1 (−/−) deficient mice, as CAFs are thought to originate from 
MSCs of the bone marrow. They showed that a loss of stromal Cav-1 expression up-
regulates the protein expression of: 8 myofibroblast markers (such as vimentin, 
calponin, and collagen), 8 glycolytic enzymes (LDHA and PKM2, as well as 
phosphoglycerate kinase-1 and triose-phosphate isomerase), 2 anti-oxidants which are 
markers of oxidative stress (catalase and peroxiredoxin-1) (Pavlides et al., 2009). Based 
on this and other unbiased transcriptional profiling studies, they proposed that a loss of 
stromal Cav-1 in CAFs is associated with ROS production and oxidative stress. This, in 
turn, is sufficient to activate HIF-1α and NF-kB, leading to the induction of aerobic 
glycolysis in CAFs under normoxic conditions (Martinez-Outschoorn et al., 2010). 
Lisanti and colleagues also proposed that the glycolytic metabolism in CAFs then drives 
the production of excess lactate and/or pyruvate; these high-energy metabolites could 
then be transferred to adjacent cancer cells where they enter the TCA cycle, resulting in 
increased oxidative phosphorylation and efficient ATP production (Fig. 17, Fig 18). 
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Secretion and re-uptake of lactate or pyruvate would be mediated by the 
monocarboxylate family of transporters, such as MCT1/4. This model was termed “The 
Reverse Warburg Effect”, which is just the opposite of the conventional Warburg effect, 
in which cancer cells are thought to undergo aerobic glycolysis. Importantly, fibroblast 
oxidative stress leads to up-regulation of the antiapoptotic protein TIGAR (TP53-
induced glycolysis and apoptosis regulator) in tumor cells (Martinez-Outschoorn et al., 
2010) (Fig. 18). TIGAR is a known inhibitor of both autophagy and apoptosis, and 
functionally shifts cancer cells away from aerobic glycolysis towards oxidative 
mitochondrial metabolism. (Bensaad et al., 2009; Li and Jogl, 2009; Bensaad et al., 
2006; Green et al., 2006). 
 
 
Fig. 18. The autophagic tumor-stroma model of cancer. In this model, cancer cells use oxidative stress as 
a “weapon” to extract recycled nutrients from cancer-associated fibroblasts, via the induction of 
autophagy. Stromal autophagy, in turn, provides energy-rich recycled nutrients (such as lacatate, ketones, 
and glutamine) to fuel oxidative mitochondrial metabolism in cancer cells. 
 
In addition, Cav-1-deficient CAFs undergo a catabolic process of autophagy/mitophagy 
(Fig. 18). Indeed, under conditions of oxidative stress, Cav-1 is target for 
autophagic/lysosomal degradation, which is efficiently blocked using either, anti-
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oxidants (N-acetyl cysteine, metformin, or quercetin) or lysosomal inhibitors 
(chloroquine) (Martinez-Outschoorn et al., 2010b). This process leads to generate 
chemical building blocks such as amino acids (glutamine), nucleotides, and lipids, that 
can sustain and support the mitochondria-dependent growth of tumor cells (Pavlides et 
al., 2009; Pavlides et al., 2010; Martinez-Outschoorn et al., 2010c; Martinez-
Outschoorn et al., 2011) (Fig. 18). In this regard, Lisanti's group proposed that 
autophagic fibroblasts may serve as a key source of energy-rich glutamine to fuel cancer 
cell mitochondrial activity, driving a vicious cycle of catabolism in the tumor stroma 
and anabolic tumor expansion (Fig. 19). Indeed, MCF7 cancer cells/fibroblasts co-
culture promotes glutamine catabolism and mitochondrial biogenesis, and decreases 
glutamine synthesis in MCF7 cancer cells. Furthermore, glutamine increases the 
expression of autophagy markers in fibroblasts, but decreases expression of autophagy 
markers in MCF7 cells, indicating that glutamine regulates the autophagy program in a 
compartment-specific manner. Functionally, glutamine protects MCF7 cells against 
apoptosis, via the upregulation of the anti-apoptotic and anti-autophagic protein 
TIGAR. Also, they show that glutamine cooperates with stromal fibroblasts to confer 
tamoxifen-resistance in MCF7 cancer cells (Ko et al., 2011). 
 
 
Fig. 19. Glutamine shuttle between CAFs and tumor cells. 
 
Further studies have also demonstrated that a highly catabolic tumor microenvironment 
supports tumor formation. Metabolomic analysis of colon and stomach cancer tissues, 
versus matched normal tissues, demonstrated the up-regulation of metabolites involved 
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in glycolysis, PPP, TCA and urea cycles, and the significant accumulation of amino 
acids and nucleotides in cancer tissues. These results indicate that cancer tissues rely 
upon glycolytic and mitochondrial metabolism for energy generation and display a 
highly catabolic microenvironment, which points to the augmented autophagic 
degradation of proteins (Hirayama et al., 2009). Consistent with the compartment-
specific effects of autophagy, clinical studies have indicated that the elevated expression 
of autophagy markers in cancer cells correlates with a favorable prognosis, whereas 
increased levels of autophagy markers in stromal cells predict poor clinical outcome 
(Futreal et al., 1992; Saito et al., 1993; Nicotra et al., 2010; Li et., al., 2009; Ding et al., 
2008; Tan et al., 2007). 
In agreement with Lisant's group results, other studies have similarly demonstrated the 
tumor-promoting effects of glycolytic enzymes in stromal cells. Laser capture 
microdissection and transcriptional profiling of human prostate cancer-associated 
stroma revealed the up-regulation of phosphoglycerate kinase-1, one of the two ATP-
generating enzymes of the glycolytic pathway. Phosphoglycerate kinase-1 
overexpression in normal primary human fibroblasts induces a CAF phenotype and, in a 
xenograft model, greatly supports the growth of coinjected prostate cancer cells via 
induction of CXCL12/SDF-1 (Wang et al., 2010). Conversely, overexpression of 
phosphoglycerate kinase-1 in lung tumor cells abrogates tumor growth and greatly 
prolongs survival in mice (Tang et al., 2008), which suggests that acute induction of 
glycolysis may differently affect tumor growth, depending on the cellular compartment. 
The model of coupling metabolism within tumor stroma, involving "direct" and "reverse 
Warburg" metabolism, could explain the controversial data concerning the role of 
mitochondria in cancer progression. Indeed, although the traditional view of cancer 
metabolism is that cells undergo aerobic glycolysis, it has been shown that cancer cells 
have a broad spectrum of bioenergetic states ranging from predominance of aerobic 
glycolysis to predominance of oxidative phosphorylation. Several data indicate a 
mandatory role of mitochondria in cancer cells, ranging from lactate respiration, to TCA 
cycle fueling with ketone bodies and glutamine, to citrate exportation to fuel fatty acids 
synthesis (Moreno-Sánchez et al., 2007). Thus, mitochondrial functional disruption may 
have positive effects on cancer progression and, to date, a number of mitochondrial 
metabolism inhibitors (e.g., oxidative phosphorilation inhibitors, mitochondrial ATP 
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transport inhibitors) are in pre-clinical or clinical development (Ramsay et al., 2011). In 
this regard, the "reverse Warburg model" could explain the antiproliferative effects of 
metformin. The latter is a widely used oral antidiabetic drug, endowed with promising 
effects for cancer prevention and treatment (Bost et al., 2012). Metformin is reported to 
inhibit mitochondrial complex I activity, thereby disrupting oxidative mitochondrial 
metabolism, mandatory for cancer "reverse Warburg" metabolism and granting survival 
and growth. Sanchez-Alvarez and colleagues (Sanchez-Alvarez et al., 2013) although 
not directly using metformin, reported that uncoupling protein-mediated mitochondrial 
dysfunction actually has compartment-specific effects. Indeed, mitochondrial 
dysfunction in stromal CAFs enhances their metabolic reprogramming to production of 
energy-rich metabolites, increasing tumor growth. On the contrary, disruption of 
mitochondrial function through mitochondrial uncoupling proteins (UCPs) 
overexpression in cancer cells leads to the opposite effect, restraining tumor growth. 
Finally, in contrast with the model of glycolytic and catabolic stroma, 
immunohistochemical data from evaluation of colorectal adenocarcinomas showed that 
cancer cells share common enzyme/transporter activities suggestive of an anaerobic 
metabolism (high HIF-1α and GLUT1 levels) with high ability for glucose absorption. 
The tumor-associated fibroblasts expressed proteins involved in lactate absorption (high 
MCT1/MCT2), lactate oxidation and reduced glucose absorption (low GLUT1 level). 
The expression profile of the tumor-associated endothelium indicated aerobic 
metabolism, and resistance to lactate intake (lack of MCT1). Thus, these results show 
that stroma express complementary metabolic pathways, buffering and recycling 




Tumor metabolism and chemoresistance 
Drug resistance of tumor cells is recognized as the primary cause of failure of 
chemotherapeutic treatment of most human tumors. Drug resistance can be described as 
a lack of meaningful response or a partial response to therapy, or regrowth of tumor 
after an initial response. Tumor cell population is characterized by subclones resistant to 
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anticancer drugs, which are responsible for the regrowth of the tumor mass after or 
during therapy. Although pharmacological factors including inadequate drug 
concentration at the tumor site can contribute to clinical resistance, cellular factors play 
a major role in intrinsic or acquired chemoresistance of several tumors (Zhao et al., 
2013). 
In general, anticancer agents work by interrupting critical events within the cellular 
lifecycle resulting in either irreversible damage to the cell or induction of apoptotic 
pathways. DNA replication is directly or indirectly a feature targeted by a wide variety 
of compounds. Both the cisplatin and temozolomide families of compounds modify the 
DNA, either by forming bulky adducts or by alkylating the bases, preying on the limited 
or compromised DNA repair ability that is common within many cancers. Similarly, 
nucleoside mimics such as gemcitabine and 5-FU (5-fluorouracil) disrupt replication by 
inhibiting the synthesis of deoxynucleotides through the inhibition of ribonucleotide 
reductase or thymidylate synthase, respectively. More indirect methods of disrupting 
DNA replication target the topoisomerases, using families of compounds such as 
adriamycin and doxorubicin. These intercalating drugs stop DNA replication by 
stabilizing topoisomerase II, which prevents progression of the replication fork and 
ultimately leads to cellular death. Similarly, taxol class drugs indirectly target 
replication by stabilizing tubulin. This blocks progression of the cellular cycle, as 
metaphase chromosomes can no longer achieve the correct configuration, ultimately 
resulting in cell checkpoint activation and/or stalling of the cell cycle. Although DNA 
replication is a common target for current clinical anticancer drugs, it is not the only 
clinically effective target. Other classes of drugs affect the deregulated signaling 
pathways within cancer. The unchecked activation of these signaling networks often 
results in increased angiogenesis and unregulated growth. Selective estrogen receptor 
modulators, such as tamoxifen and raloxifen, modulate signaling through the estrogen 
receptor-mediated pathways and have been particularly effective for patients with 
certain types of breast cancer. Similarly, the EGFR family has been effectively targeted 
using drugs such as lapatinib (tyrosine kinase inhibitor active against EGFR and HER2) 
and trastuzumab (a humanized antibody targeting the HER2 receptor). The EGFR 
family, and specifically HER2, are aberrantly active in many types of cancers and 
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initiate signaling pathways that lead the cells to grow aggressively and often results in a 
less positive outcome than seen in non-HER2 expressing tumors (Zhao et al., 2013). 
The relevant mechanisms that can contribute to chemoresistance in cancer include: 
increased expression of defense factors involved in reducing intracellular drug 
concentration; alterations in drug-target interaction; and changes in cellular response, in 
particular increased cell ability to repair DNA damage or tolerate oxidative stress 
conditions, and defects in apoptotic pathways. In most cases, such alterations promote 
the development of resistant cell clones that are associated with a trans-differentiation of 
cancer cell machinery that enables more aggressive and invasive phenotype, induces the 
activation of EMT programme, increases stemness-like features and proliferative rate 
(Gal et al., 2008; Iseri et al., 2011; Kajiyama et al., 2007; Wang et al., 2009; Yang et al., 
2006; Puhr et al., 2012). 
Increasing evidences support the idea that drug resistance in cancer therapy is link to 
adaptation of cancer cell to a deregulated cellular metabolism (Zhao et al., 2013) 
(Fig.20). Below, we will discuss the role of enzymes and metabolic pathways in 
resistance to anticancer drugs, as well as the mechanisms of some small molecules able 
to interfere with cell metabolism (Fig. 21). 
 
 
Fig. 20. Deregulated metabolism affects chemoresistance via multiple cellular pathways. 
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GLYCOLYSIS 
Inhibiting glucose uptake may potentiate cancer therapeutics or overcome 
hypoxia/drug-induced resistance. The GLUT family of proteins is responsible for the 
transport of glucose across the plasma membrane and are often found deregulated or 
overexpressed in malignant cells (Macheda et al., 2005) (Fig. 20). 
WZB117 is an inhibitor of GLUT1 that decreases glucose uptake, intracellular ATP 
levels and glycolytic enzymes leading to a lowered rate of glycolysis and cellular 
growth. The combination of WZB117 and cisplatin or paclitaxel displayed synergistic 
anticancer effects (Fig. 21) (Liu et al., 2012; Monti and Gariboldi, 2011). Under 
hypoxia, the GLUT1 inhibitor phloretin significantly enhances daunorubicin's 
anticancer effects (Fig. 21) and overcomes hypoxia-conferred drug resistance. 
Multiple myeloma (MM) cells are dependent on GLUT4 activity for basal glucose 
consumption, maintenance of anti-apoptotic Mcl-1 protein levels, growth and viability. 
Ritonavir displays off-target inhibitory effects on GLUT4 and inhibits glucose 
consumption and proliferation by reducing Mcl-1 expression to induce apoptosis. 
Ritonavir also inhibits viability of primary myeloma cells and increases the sensitivity 
to doxorubicin (Fig.21) (McBrayer et al., 2012). Temozolomide is used with radiation 
and chemotherapy to treat glioblastoma, yet nearly all glioblastoma patients develop 
resistance. Long-term treatment of glioblastoma cells with temozolomide in vitro 
induces partial resistance in vivo through up-regulation of GLUT3, suggesting 
involvement in temozolomide resistance and that selective targeting of GLUT3 could 
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Fig. 21. Targeting cellular metabolism improves therapy in several cancer types. 
 
HK has important roles in both glycolysis and apoptosis and inhibitors of HK, such as 
2-deoxyglucose (2-DG), 3-bromopyruvate (3-BrPA) and lonidamine (LND) are in pre-
clinical and early phase clinical trials. 
2-DG is a glucose analog that is phosphorylated by HK to 2-DG-phosphate, which 
cannot be further metabolized. Accumulation of 2-DG inhibits glycolysis causing ATP 
depletion, cell cycle inhibition and cell death (Maher et al., 2004; Pelicano et al., 
2006a). Combining 2-DG with radiation or chemotherapeutic treatments potentiates the 
tumor-destroying effects and enhances the clinical efficacy (Dwarakanath et al., 2009). 
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Trastuzumab is a humanized monoclonal antibody against ErbB2 and has shown 
efficacy treating ErbB2-positive breast cancer patients, yet acquired trastuzumab 
resistance occurs in most patients (Esteva et al., 2002; Lan et al., 2005; Hudis, 2007; 
Zhang et al., 2007; Slamon et al., 2001; Nagata et al., 2004; Nahta et al., 2006). Of note, 
overexpression of ErbB2 promotes glycolysis and increases their sensitivity to 
glycolytic inhibition (Zhao et al., 2009). Trastuzumab-resistant human cells also have 
increased glucose uptake and lactate production, indicative of increased glycolysis. 2-
DG/trastuzumab combination therapy synergistically inhibits growth of both 
trastuzumab-sensitive and trastuzumab-resistant human breast cancers in vitro and in 
vivo (Fig. 21), because of more efficient glycolysis inhibition (Zhao et al., 2011). These 
results suggest that 2-DG can effectively enhance efficacy of trastuzumab in treating 
ErbB2-positive human breast cancer cells and overcome trastuzumab resistance. 
3-BrPA is a glycolysis inhibitor that targets HKII and depletes cellular ATP reserves, a 
key determinant of chemoresistance in certain cancer types (Geschwind et al., 2004; Ko 
et al., 2001). In leukemia and MM cells increased glycolysis raises ATP levels, which 
activates ATP-binding cassette (ABC) transporters and confers drug resistance via 
enhanced drug efflux activity (Fig. 20). 3-BrPA causes ATP depletion, decreasing ABC 
transporter activity and drug efflux, therefore enhancing drug retention in cells 
producing preferential cell death in malignant cells. Glycolysis inhibition by 3-BrPA 
not only enhances the cytotoxic effects of daunorubicin and doxorubicin, but also 
markedly suppresses tumor growth when used with doxorubicin to treat MM-bearing 
mice (Fig. 21) (Nakano et al., 2011). In addition to activating ABC transporters, 
increased ATP levels from elevated glycolysis upregulate HIF-1α and enhance HIF-1α-
mediated signaling, which can confer chemoresistance (Fig. 20). ATP depletion by 3-
BrPA partially reversed the resistant phenotype and resensitized cells to 
chemotherapeutic agents such as oxaliplatin and 5-FU (Fig. 21) (Zhou et al., 2012). 
Most treatment failure in childhood acute lymphoblastic leukemia (ALL) is ascribed to 
glucocorticoid (e.g., prednisolone) resistance. Increased glycolysis is directly associated 
to glucocorticoid resistance and inhibition of glycolysis by 2-DG, 3-BrPA or LND 
increases prednisolone-induced toxicity in leukemia cells (Fig. 21) (Hulleman et al., 
2009). Importantly, 2-DG can reverse glucocorticoid resistance in primary leukemia 
cells isolated from pediatric ALL patients (Hulleman et al., 2009). 
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As previously reported, several data indicate that PKM2 is expressed predominantly in 
tumor cells (Hitosugi et al., 2009) and is important for cancer metabolism (Christofk et 
al., 2008). However, there are conflicting data in literature about the role of this enzyme 
in chemoresistance. A number of studies show a negative correlation between PKM2 
expression and drug resistance. (Li et al., 2010; Martinez-Balibrea et al., 2009; Yoo et 
al., 2004). Decreased PKM2 protein and activity is linked to cisplatin resistance while 
suppression of PKM2 expression by siRNA increased cisplatin resistance (Yoo et al., 
2004). Both PKM2 mRNA and protein levels are downregulated in oxaliplatin-resistant 
cells and PKM2 mRNA levels are inversely correlated with oxaliplatin resistance in a 
panel of eight colorectal cancer cell lines. Low PKM2 mRNA levels in patients are 
associated with high p53 protein levels and predict poor response to oxaliplatin 
(Martinez-Balibrea et al., 2009). In contrast, PKM2 levels are significantly up-regulated 
in secreted proteins of the 5-FU-resistant colon cancer cell line. Moreover, increased 
PKM2 is also observed in sera and tissues from colorectal cancer patients with poor 
response to 5-FU. 
Changes in PKM2 expression are associated with drug resistance in different tumors. 
This indicates that PKM2 is a potential target for adjuvant cancer therapy. For example, 
shRNA targeting PKM2 improves the therapeutic efficacy of cisplatin by increasing 
apoptosis and inhibiting proliferation (Fig. 21) (Guo et al., 2011). Silencing of PKM2 
enhances the efficacy of docetaxel because of increased inhibition of proliferation and 
apoptosis-inducing activity both in vitro and in vivo (Fig. 21) (Shi et al., 2010). A 
possible mechanism for the sensitization of lung cancer cells to docetaxel is that 
shPKM2 decreases ATP levels leading to intracellular accumulation of docetaxel (Shi et 
al., 2010). 
LDHA catalyzes the conversion of pyruvate and NADH to lactate and NAD
+
 and has a 
critical role in tumor maintenance. Knockdown of LDHA in tumor cells produces 
increased mitochondrial respiration, decreased cellular ability to proliferate under 
hypoxic conditions, and suppressed tumorigenicity (Fantin et al., 2006). LDHA-
knockdown in the fumarate hydratase-knockdown background results in increased 
apoptosis via ROS production, resulting in a reduction in tumor growth and indicating 
that LDHA might be a promising therapeutic target.  
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Paclitaxel (taxol) is a widely used chemotherapeutic agent in the treatment of a variety 
of human cancers (Fig. 21). LDHA expression and activity is higher in taxol-resistant 
breast cancer cells than in taxol-sensitive cells, and down-regulation of LDHA 
resensitizes taxol-resistant cells to taxol. Taxol-resistant cells are more sensitive to 
oxamate, a pyruvate analog that inhibits glycolysis by inhibiting the conversion of 
pyruvate to lactate. Moreover, combination of paclitaxel with oxamate shows 
synergistic inhibitory effect on taxol-resistant cells (Fig. 21) by promoting cellular 
apoptosis (Zhou et al., 2010). 
Heat shock factor-1 (HSF1) is the master regulator of the heat shock response in 
eukaryotes. HSF1 functions primarily to coordinate the response to heat shock, but 
recent studies demonstrate HSF1 exhibiting non-heat shock functions important for 
cancer development (Khaleque et al., 2008; Khaleque et al., 2005; Min et al., 2007). Dai 
et al (Dai et al., 2007) reported that HSF1 increases glucose uptake, lactate production 
and LDH activity. Of note, ErbB2 promotes glycolysis partially through up-regulation 
of HSF1 and LDHA (Fig. 20), whereas down-regulation of HSF1 leads to decreased 
glycolysis (Zhao et al., 2009). It has been reported that trastuzumab-resistant cells have 
significantly higher HSF1 protein levels than trastuzumab-sensitive cells. Thus, the 
inhibition of HSF1 sensitizes cells to trastuzumab and overexpression of HSF1 
increased trastuzumab resistance, demonstrating that HSF1 can have an important role 
in resistance to this drug (Zhao et al., 2011). Finally, the combination of trastuzumab 
and oxamate synergistically inhibits growth of both trastuzumab-sensitive and 
trastuzumab-resistant cancer both in vitro and in vivo (Fig. 21), because of more 
efficient glycolysis inhibition (Zhao et al., 2011) Overall, high-rate glycolysis confers 
chemoresistance and HSF1 and LDHA may potentially act as excellent targets for 
overcoming this resistance in cancer patients. 
 
PDK 
PDH is responsible for the rate-limiting conversion of pyruvate to acetyl-CoA, which 
enters the TCA cycle to generate ATP. PDK phosphorylates PDH and inhibits its 
enzymatic activity. Four isotypes of PDK (PDK1-4) have been identified with PDK3 
demonstrating the highest activity coupled with a lack of inhibition in response to high 
concentrations of pyruvate (Lu et al., 2008). Hypoxia induces PDK3 expression via up-
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regulation of HIF-1α, resulting in a switch from mitochondrial respiration to glycolysis 
for energy production. Hypoxia-mediated PDK3 induction or forced PDK3 
overexpression significantly inhibits cell apoptosis and increases resistance to cisplatin 
or paclitaxel (Fig. 20). Knockdown of PDK3 inhibits hypoxia-induced glycolysis and 
increases susceptibility of cancer cells to anticancer drugs such as cisplatin, paclitaxel or 
oxaliplatin (Fig. 21). Moreover, PDK3 levels are elevated and correlated with the HIF-
1α level in patient colon cancer tissues and strongly correlates with the severity of the 
cancer while predicting poor disease-free survival outcomes (Lu et al., 2011). These 
findings indicate that PDK3 is potentially a novel target for improving chemotherapy or 
overcoming drug resistance. 
Dichloroacetate (DCA) inactivates PDK leading to reactivation of PDH and a metabolic 
switch from glycolysis to mitochondrial respiration (Zhao et al., 2011; Kato et al., 
2007). Owing to its low price, low toxicity, oral administration, long history of clinical 
use and ability to overcome cancer cells apoptosis resistance, DCA serves as a potential 
metabolic-targeting molecule for sensitizing cancer cells to chemotherapy or 
radiotherapy (Michelakis et al., 2008). For example, co-treatment with DCA and 
omeprazole exhibits synergistic antitumor activity (Fig. 21) (Ishiguro et al., 2012). DCA 
potentiates the anticancer effects of 5-FU (Fig. 21) via inducing more mitochondrial-
mediated apoptosis. Moreover, Cao et al. (Cao et al., 2008) reported that DCA 
sensitizes both wild-type and Bcl-2-overexpressing cancer cells to radiation (Fig. 21) by 
potentiating the apoptotic machinery via interaction with Bcl-2.  
 
FATTY ACID BIOSYNTHESIS 
The fatty acid biosynthesis pathway catalyzes lipid synthesis from basic metabolites like 
acetyl- and malonyl-CoA. The fatty acid synthase (FASN) complex facilitates 
lipogenesis by synthesizing palmitate from its base components. FASN expression in 
normal adult tissues is generally very low or undetectable, and it is significantly up-
regulated and correlates with poor prognosis in many types of cancer. The metabolic 
products of the FASN complex are rapidly consumed by actively dividing cells and 
recent data demonstrates that FASN expression is important for tumor growth and 
survival, suggesting that FASN is a metabolic oncogene (Flavin et al., 2010). 
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To date, several FASN inhibitors have shown antitumor activity including cerulenin, 
C75, orlistat, C93, GSK 837149A and natural plant-derived polyphenols. Cerulenin 
enhances the efficacy of docetaxel and trastuzumab therapy and increases 5-FU-induced 
growth inhibition (Fig. 21) (Vazquez-Martin et al., 2007) Similarly, C75 and 
trastuzumab synergistically decrease ErbB2 expression and enhance apoptotic cell death 
(Fig. 21) (Vazquez-Martin et al., 2007a). 
FASN has an active role in ErbB2-induced breast cancer chemoresistance to docetaxel 
(Menendez et al., 2004) while trastuzumab-resistant breast cancer cells gain high 
sensitivity to FASN inhibition indicating that FASN is also important in ErbB2-induced 
resistance in breast cancers (Vazquez-Martin et al., 2007a). FASN is overexpressed and 
its activity is increased in the multidrug-resistant breast cancer cell line 
MCF7/AdVp3000 (Liu et al., 2008). In pancreatic cancer, there is also a positive 
correlation between FASN expression and resistance to chemo- or radiotherapy. FASN 
expression is significantly upregulated in pancreatic cancer and inhibition of FASN by 
siRNA or the FASN inhibitor orlistat reduces gemcitabine resistance, whereas ectopic 
overexpression of FASN contributes to intrinsic resistance to gemcitabine and radiation. 
FASN-induced radiation resistance may result from decrease in radiation-mediated 
ceramide production, leading to reduced caspase 8-induced apoptosis. However, the 




Metabolic flux experiments tracking 
13
C show that cancer cells exhibiting Warburg-like 
metabolism do not stop utilizing the TCA cycle. These cells come to rely on glutamine 
as the carbon source for the TCA cycle (DeBerardinis et al., 2007). This allows the 
intermediates generated by the TCA cycle to feed other biosynthetic pathways as 
precursors (DeBerardinis et al., 2008). Therefore, cancer cells are dependent on 
glutamine to maintain the TCA cycle. Glutaminolysis co-induced by glutamine and 
leucine activates mTOR signaling, which triggers cell growth and inhibits autophagy 
(Duran et al., 2012). The mTOR pathway is involved in cisplatin resistance in highly 
malignant AFP-producing gastric cancer (AFPGC) (Kamata et al., 2007). This indicates 
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that elevated glutaminolysis is linked to drug resistance. Interestingly, mTOR inhibitor 
rapamycin enhances the antitumor effect of cisplatin in this tumor (Kamata et al., 2007).  
Amino-oxyacetate is a transaminase inhibitor that targets glutamate-pyruvate 
transaminase, which converts glutamate to α-ketoglutarate. In melanoma cell lines, 
amino-oxyacetate sensitizes cells to TRAIL (tumor necrosis factor-related apoptosis 
inducing-ligand)-induced cell death. It inhibits proliferation of MDA-MB-231 breast 
cancer and SF188 glioblastoma cell lines and suppresses growth of MDA-MB-231 
xenograft tumors in mice (Ramsay et al., 2011). 
Bis-2-[5-phenylacetamido-1,2,4-thiadiazol-2-yl] ethyl sulfide (BPTES), an inhibitor of 
GLS, caused decreased aerobic cell proliferation and hypoxic cell death (Robinson et 
al., 2007). Inhibition of GLS by siRNA or BPTES slows the growth of glioblastoma 
cells with a IDH1 mutation. BPTES treatment inhibits GLS activity, lowers glutamate 
and α-KG levels and increases glycolytic intermediates, suggesting that simultaneous 
inhibition of GLS and glycolysis may be a more efficient strategy to treat mutant IDH1 
patients (Seltzer et al., 2010). 
 
ADAPTATIONS TO OXIDATIVE STRESS AND PPP 
Many anticancer drugs induce oxidative stress either as a direct mechanism of cell death 
or as an indirect effect of exposure (Tiligada et al., 2006). It has been suggested that 
pathways involved in the ROS-adaptive response play a critical role in protecting cells 
against the damaging and cytotoxic effects of anticancer agents (Pennington et al., 
2005) (Fig. 22). Thus, many redox-dependent mechanisms of adaptation to stress have 
been explored in terms of their potential for inducing drug resistance, with those 
proposed including the induction of DNA repair systems, the reprogramming of cell-
cycle-regulation systems, and the up-regulation of non-enzymatic and enzymatic 
antioxidant defenses, and also of molecular chaperones and of stress-responsive proteins 
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Fig. 22. Adaptation to oxidative stress and drug resistance. nDNA: nuclear DNA; mtDNA: mitochondrial 
DNA; SOD: superoxide dismutase. 
 
Several studies link the up-regulation of antioxidants systems involved in cellular 
response to oxidative stress, to the onset of drug resistance in human malignancies (Fig. 
22). Indeed, glutathione reductase/glutaredoxin (GR/GRX) system, 
thioredoxin/thioredoxin reductase (Trx/TrxR) system, manganese superoxide dismutase 
(MnSOD) and peroxiredoxins (PRXs) are associated both to resistance to 
chemotherapeutic drugs that induce oxidative stress and apoptosis and to high tumor 
grade (Landriscina et al., 2009). For example, the gene-expression profile of non-
responder breast carcinomas treated with docetaxel was characterized by elevated 
expression of genes controlling the cellular redox environment, such as Trx, glutathione 
S-transferase (GST), and PRX (Iwao-Koizumi et al., 2005). Furthermore, 
overexpression of antioxidant enzymes appears to be present in various human tumors, 
thus confirming the importance for cancer cells to maintain homeostasis of intracellular 
redox-state, in order to avoid damages in macromolecules and to preserve genome 
stability (Landriscina et al., 2009). 
An important redox-sensitive factor is NF-E2-related factor 2 (Nrf2) (Moi et al., 1994). 
In response to oxidative stress, Nrf2 controls the fate of cells through transcriptional up-
regulation of antioxidant response element (ARE)-bearing genes, including those 
encoding for antioxidants enzymes, phase II detoxifying enzymes, and transporters. 
Expression of the Nrf2-dependent proteins is critical to maintain cellular redox 
homeostasis through elimination of toxicants/carcinogens. Nrf2 activity is regulated in 
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part by the association with Keap1 protein: a disruption of this association in response 
to stress signals causes the release of Nrf2 and its translocation into the nucleus, to 
effect its transcriptional activity (Fig. 23) (Itoh et al., 1999). Recent data revealed that 
Nrf2 and its target genes are up-regulated in resistant cancer cells (Lau et al., 2008). For 
example, it has been reported that the pharmacologic activation of Nfr2 induces 
mechanisms of cell survival in response to doxorubicin, cisplatin, and etoposide (Wang 
et al., 2008), whereas the downregulation of Nfr2 expression by using Nfr2-siRNA 
restores sensitivity to several chemotherapeutic and biologic agents (Pi et al., 2008). 
 
 
Fig. 23. Activations of Nrf2 pathway in response to stress/pro-oxidant signals. 
 
NADPH produced from PPP is a critical antioxidant and high levels maintained through 
increased glycolysis in cancer cells may contribute to chemoresistance (Zhao et al., 
2013). The glutathione reductase system uses NADPH reducing oxidized glutathione 
(GSSG) to sulfhydryl form GSH (Fig. 24). GSH removes ROS directly acting as a 
substrate for several peroxidases (Dringen et al., 2000; Sims et al., 2004). This 
tripeptide is also involved in the conjugation of foreign molecules catalyzed by GST, a 
target gene of Nrf2. Interestingly, GSH-depleting strategies have clearly been shown to 
improve the capacity of antiblastic agents to induce apoptosis in cancer cells both in 
vitro and in murine models (Esposito et al., 2002). Furthermore, several studies link the 
pleiotropic effects of GSH in promoting cell growth and broad resistance to therapy 
with the up-regulation of Bcl-2, which inhibits the activation of apoptosis and 
contributes to the elevation of GSH (Friesen et al., 2004; Mena et al., 2007; Osbild et 
al., 2006). This issue was clearly demonstrated in highly metastatic murine B16 
melanoma cells that are characterized by elevated levels of both GSH and Bcl-2. 
Interestingly, the reduction of Bcl-2 and GSH -combined with treatment with paclitaxel, 
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radiation, and cytokines- eliminates melanoma cells from liver and all other systemic 
disease, leading to long-term survival without recurrence in melanoma-injected mice 
(Mena et al., 2007). 
 
 
Fig. 24. The glutathione reductase system. 
 
Finally, Polimeni et al. showed that doxorubicin-resistant human colon cancer cell line 
exhibites increased activity of PPP and glucose-6-phosphate dehydrogenase; these are 
important to keep high GSH content that, in turn, is necessary to extrude doxorubicin 




Tumor microenvironment and resistance to cancer 
therapy 
Besides its role as a key regulator of tumor progression, tumor microenvironment has 
been associated with drug delivery and drug efficacy, thus emerging as a form of de 
novo drug resistance that protects cancer cells from several therapies. 
 
CAFs 
Among the different constituents of the microenvironment, CAFs play a primary role in 
this phenomenon (Crawford and Ferrara, 2009; Meads et al., 2009; Roodhart et al., 
2011). For example, CAFs can mediate resistance to anti-angiogenic therapy (Crawford 
and Ferrara, 2009): it has been shown that tumors may overcome inhibition of VEGF-
mediated angiogenesis through up-regulation of PDGF-C mediated by CAFs (Crawford 
et al., 2009). Furthermore, pancreatic carcinoma cells co-cultured with stromal 
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fibroblasts become much less sensitive toward treatment with etoposide than cells 
cultured under standard conditions (Muerkoster et al., 2004). In keeping, in a mouse 
model of pancreatic adenocarcinoma, Olive et al. showed that a depletion in the stromal 
component leads to an in increase in chemosensitivity (Olive et al., 2009). 
In addition, the achievement of EMT correlates to an increase in chemoresistance (Gal 
et al., 2008). Indeed, the shift in gene expression during EMT is reminiscent of the gene 
expression pattern present in cancer stem-like cells (Iseri et al., 2011; Kajiyama et al., 
2007; Wang et al., 2009; Yang et al., 2006) and the ectopic expression of EMT genes 
such as Snail, ZEB1, Notch, Twist leads to a resistant phenotype in vitro (Cheng et al., 
2007). Moreover, stromal fibroblasts can influence chemosensitivity of tumor cells by 
producing and activating ECM molecules. This activated ECM confers chemoresistance 
by integrin-mediated adhesion to fibronectin (Miyamoto et al., 2004; Van der Kuip et 
al., 2001). Finally, co-culture experiments and xenograft models demonstrated that the 
efficacy of chemotherapy-induced cell cycle arrest or senescence in stromal fibroblasts 
is critical for the sensitivity of the tumor compartment (Lafkas et al., 2008). 
Recent data have shown that metabolic coupling between CAFs and tumor cells play an 
important role to confer chemoresistance. Indeed, co-culture experiments between 
MCF7 cells and immortalized human fibroblasts showed that tamoxifen-sensitive 
MCF7 become resistant by the matabolic shift from glycolytic to an oxidative state, 
which is dependent on mitochondrial biogenesis and oxidative phosphorilation in cancer 
cells. Interestingly, tamoxifen-resistance is impaired by disrupting metabolic coupling 
and shifting MCF7 cells back to the aerobic glycolysis (Warburg effect) (Martinez-
Outschoorn et al., 2011). In keeping, also glutamine -supplied from autophagic CAFs to 
tumor cells- cooperates with stromal fibroblasts to confer tamoxifen-resistance in MCF7 
cells, thus confirming the key role of tumor-stroma metabolic coupling and "reverse 
Warburg" metabolism in chemoresistance (Ko et al., 2011). 
All this evidences suggests CAFs as possible targets of anti-cancer therapies in order to 
improve tumor chemosensitivity. 
 
HYPOXIA 
Intratumoral hypoxia and resulting HIF activation enhance chemoresistance of cancer 
cells in various ways. Firstly, the delivery of drugs in hypoxic area and cellular uptake 
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of it are affected by hypoxia or associated acidity. In this context, glycolytic metabolism 
leads to production of lactate, whose export results in the acidification of the 
extracellular environment. The resulting extracellular acidification, coupled with HIF-
1α-induced expression of carbonic anhydrases (Fig. 20), causes a significant change in 
the pH ratio between the intracellular and extracellular environment (Ceradini et al., 
2004; Greijer et al., 2005; Wykoff et al., 2000). This pH shift decreases the passive 
absorption of many drugs that would otherwise accumulate at a greater concentration 
within the cell. Secondly, some chemotherapeutic drugs require oxygen to generate free 
radicals that contribute to cytotoxicity. Last, hypoxia induces cellular adaptations that 
compromise the effectiveness of chemotherapy. In response to nutrient deprivation due 
to hypoxia, the rate of proliferation of cancer cells decreases but chemotherapeutic 
drugs are more effective against proliferating cells. On the other hand, hypoxia and HIF 
induce adaptation by transcriptional changes that promote cell survival and resistance to 
chemotherapy. Through these changes, hypoxia promotes angiogenesis, shift to 
glycolytic metabolism and PPP, expression of ABC transporters, cell survival and 
protection from apoptotic inducers (Cosse and Michiels, 2008). 
A number of studies underline the relevant role of HIF-1α activation in drug resistance. 
For example, inhibitors of EGFR family signaling, such as gefitinib, show reduced 
effect under high HIF-1α expression because of an up-regulation of MET, which allows 
alternative signaling networks to produce similar phenotypic effects in the presence of 
reduced EGFR family signaling (Engelman et al., 2007; Pennacchietti et al, 2003). In 
addition, down-regulation of other drug targets, such as topoisomerase II or estrogen 
receptor α (ERα), can occur when HIF-1α expression is high and reduces the effect of 
drugs such as tamoxifen and etoposide (Kronblad et al., 2005; Sullivan and Graham, 
2009; Wen et al., 2010). Finally, HIF-1α induces expression of genes that promote 
survival through anti-apoptotic signaling (survivin, Bcl-XL, Mcl-1) or other survival 
mechanisms such as autophagy (BNIP3, BNIP3L).119–123. HIF-1α activation also 
decreases pro-apoptotic signaling by inducing the expression of decoy receptors (such 
as DcR2) that compete for pro-apoptotic signaling factors (Mayes et al., 2005; Pei et al., 
2010). Attenuation of pro-apoptotic signaling allows cells to tolerate a higher level of 
chemotherapeutic insult before inducing cellular death pathways. HIF-1α signaling also 
works with glycolytic metabolism to trigger a variety of anti-drug mechanisms that 
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generate in vitro and clinical resistance. We have previously reported examples of how 
disrupting the cancer metabolism can short circuit the processes that provide protection 
from anticancer agents. 
Furthermore, the adaptations elicited by hypoxia in cancer cells are likely responsible 
for the failure of anti-angiogenic therapy of metastatic tumors (De et al., 2011; Ebos and 
Kerbel, 2011). Recent papers have proved that anti-angiogenic drugs used in clinical 
settings, by reducing tumor tissue oxygenation and by activating the hypoxic 
transcriptional response, trigger molecular events that foster cell motility and resistance 
to chemotherapy (Loges et al., 2009; Paez-Ribes et al., 2009). To date, the most 
accepted hypotheses to explain these effects imply: 
 activation of EMT by hypoxia following anti-angiogenic therapy as an escaping 
strategy to drive successful metastases (De et al., 2011; Maione et al., 2012; 
Shojaei et al., 2012); 
 the metabolic shift towards PPP to fuel NADPH production and resistance to 
oxidative stress and to chemotherapy (De et al., 2011; Maione et al., 2012; 
Shojaei et al., 2012; Kruger et al., 2011; Anastasiou et al., 2011; Brahimi-Horn 
et al., 2011; Gruning and Ralser, 2011). 
Moreover, mounting evidence indicates that hypoxic cancer cells undergo exposure to 
oxidative stress, thereby developing adaptive strategies to survive to the hostile milieu 
(Pani et al., 2010; Pani et al., 2009). Of note, hypoxic cells can enhance their 
antioxidant capacity and hypoxia can behave as a promoting factor for this behavior, 
leading cancer cells to resist to apoptosis and ultimately to chemotherapy and radiation 









Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 




Our aim is to investigate the role of stromal fibroblasts and ROS in prostate carcinoma 
(PCa) progression. We focused on the metabolic reprogramming of cancer cells, 
clarifying the metabolic signature elicited by cancer associated fibroblasts (CAFs) in 
PCa cells and vice versa, and analyzing the role of reactive oxygen species (ROS) in 
this reciprocal interplay. Furthermore, we investigated how tumor metabolism changes 
in chemoresistant PCa cells, even upon contact with microenvironment, analyzing the 
regulation of the “Warburg effect”, pentose phosphate pathway (PPP), oxidative 
phosphorylation and antioxidant response. Finally, considering the importance of 
oxidative stress in tumor-stroma interplay, we aimed at identifying natural antioxidant 
molecules able to disrupt the diabolic liaison between CAFs and PCa cells and to 
ultimately reduce CAFs-induced carcinoma progression. 
As in vitro models, we used human prostate carcinoma cell line PC3 isolated from a 
bone metastasis of PCa, and human prostate fibroblasts isolated from healthy 
individuals affected by benign prostatic hyperplasia (HPFs, Human Prostate 
Fibroblasts) or from aggressive carcinoma-bearing patients (CAFs). Surgical explants 
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 Unless specified, all reagents used for cell cultures were purchased from 
Euroclone Group, except penicillin/streptomicin from Sigma-Aldrich. 
 The HIF-1 farmacological inhibitor topotecan, N-acetyl cystein (NAC), 
kaempferol, docetaxel and metformin were purchased from Sigma-Aldrich. 
 DASA-58 was kindly provided by Prof. Cristina Nativi, Department of 
Chemistry, University of Florence. 
 Transwells for invasion assays were from Costar (Euroclone Group). The Diff-
Quik staining kit was purchased from BIOMAP SNC. 
 Matrigel was purchased from BD Biosciences. 
 Proteases and phosphateses inhibitors were from Sigma-Aldrich. 
 Bradford reagent for protein dosage and all materials for SDS-PAGE were from 
Biorad. 
 PVDF membrane (Polyvinylidene fluoride) used for western blotting was from 
Millipore. 
 All the primary antibodies used were purchased from Santa Cruz Biotechnology 
except antibodies against HIF-1 (BD Biosciences), SIRT3 (Cell Signaling), 
SOD2 (Abcam), acetyl-lysine (Abcam), CA IX (Bioscience Slovakia), PKM2 
(Cell Signaling), hexokinase II (Millipore). The secondary antibodies enzyme 
horseradish peroxidase (HRP)–coniugated were from Santa Cruz Biotechnology. 
 Chemiluminescence revelation kit is from GE Health Care. 
 The photographic plates were from Kodak. 
 HIF-1α-siRNA (sc-35561), MCT1-siRNA (sc-37235), and SIRT3-siRNA (sc-
61555), CA IX-siRNA (sc-29869), MMP-9-siRNA (sc-29400) were from Santa 
Cruz Biotechnology. siRNA products from Santa Cruz generally consist of pools 
of three to five target-specific 19–25 nucleotide siRNAs designed to knockdown 
gene expression. Scramble shRNA plasmid (sc-108060) and CA IX shRNA 
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plasmid (sc-29869-SH) from Santa Cruz was used for in vivo studies .TaqMan 
Reverse Transcription Reagents Kit, Lipofectamine 2000 and GLUT1 primers 
were from Invitrogen.  
 Mitosox and 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) were from 
Molecular Probe (Invitrogen). 
 The cytofluorimetric apoptosis staining kit Annexin V-IP Fluos Staining Kit was 
from Roche. 
 The metalloproteinase catalytic activity evaluation kit AmpliteTM Universal 
Fluorimetric MMP Activity Assay Kit - Red Fluorescence was purchased from 
AAT Bioquest. 
 The CA IX inhibitors 4-(2,4,6-trimethylpyridinium)-ethyl-benzenesulfonamide, 
perchlorate salt (compound 1) (FC3-148B bis), benzothiophene-3-
ylmethylsulfamide (compound 2) (FC5-207A), the fluorescent CAI (compound 
3) and MMP-9 inhibitors GlcNAc-SLS-HA and Lac-SLS-HA were previously 
reported by Alterio et al., 2009 and Calderone et al., 2006. It should be 
mentioned that compound 3 is a potent CA IX inhibitor, with a KI of 24nM 
against this isoform. (Supuran et al. 2008). It has also been proven that it binds 
the enzyme only in hypoxia and not normoxia (Švastová et al., 2004).  





C]-glucose) were purchased from 
PerkinElmer. 
 
COMMON USE SOLUTIONS 
 SDS−PAGE 4X Sample Buffer: 40% Glycerol, 240 mM Tris/HCl pH 6.8, 8% 
SDS, 0.04% bromophenol blue, 5% β-mercaptoethanol. 
 SDS-PAGE 1X running buffer: 25 mM Tris, 192 mM glycin, 0.1% (W/V) SDS, 
pH 8.3. 
 SDS-PAGE 1X blotting buffer: 25 mM Tris, 192 mM glycin, 10% methanol, pH 
8.3,. 
 RIPA lysis buffer: (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 2 
mM EGTA, 1mM sodium ortovanadate, 100 mM NaF). 
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 Washing solution: tween 0.1 % in PBS. 
 Blocking solution: non-fat dry milk 2 %, tween 0.05 % in PBS. 
 PBS (Phosphate buffered saline). 0.27 g/L di KH2PO4, 0.2 g/L KCl, 8.01 g/L 





CELL CULTURES AND TREATMENTS 
All cell types were cultured in DMEM high glucose (4,5 g/L) (Dulbecco’s Modified 
Essential Medium), supplemented with 10% bovine fetal serum (FCS), 2mM 
glutammine, 100U/mL penicillin and 100 μg/mL streptomicin, at 37°C in a 5% CO2 
humidified atmosphere. 
Human PCa cells (PC3 cell line) were from the European Collection of Cell Culture, 
were authenticated by PCR/short tandem repeat (STR) analysis (European Collection of 
Animal Cell Cultures) and used within 6 months of resuscitation of original cultures. 
Healthy human prostate fibroblasts (HPFs) and prostate cancer associated fibroblasts 
(CAFs) were isolated from surgical explanation of patients who signed informed 
consent in accordance with the Ethics Committee of Azienda Ospedaliera Universitaria 
Careggi. Tissues from patients affected by benign prostatic hyperplasia or aggressive 
PCa were used for obtaining HPFs or CAFs respectively. HPFs and CAFs between 4 
and 10 passages were used and tested by mycoplasma presence. Activation state of 
CAFs was confirmed by morphology and fibroblast activation protein expression. 
CAFs/PCa co-culture was performed by plating HPFs and PCa cells in different 
proportions (2:1, 3:1, 5:1, 10:1). 
Docetaxel-resistant PCa cell line (DoceRes) was developed from PC3 sensitive cells by 
stepwise increased concentrations of docetaxel. As cells displayed resistance to 
treatments of docetaxel, the concentration was subsequently increased until the final 
treatment doses of 10 nM. Resistance was judged based on decreased cell death. 
Conditioned media (CM) from PCa cells, HPFs and CAFs were obtained by 48h serum-
starved cells (DMEM high glucose, 2mM glutammine, 100U/mL penicillin and 100 
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μg/mL streptomicin, at 37°C in a 5% CO2 humidified atmosphere), clarified by 
centrifugation and used freshly. 
Treatments: 20nM NAC, 250nM topotecan, 25-50μM kaempferol, 10nM doectaxel, 
5mM metformin, 40μM DASA-58, Ca IX inhibitors 1 and 2 (100 μM final 
concentration), MMP-9 inhibitors GlcNAc-SLS-HA and Lac-SLS-HA (54 and 76 nM 
final concentration, respectively) were added to cells at the beginning of experiments 
and maintained until the end. 
 
ISOLATION OF PROSTATE FIBROBLASTS 
HPFs and CAFs were isolated from surgical explantations. A small slice of the tissue 
piece was minced with sterile scalpels and pieces of <1 mm in size were plated in Petri 
plates and covered with covering glasses, favouring pieces compression and 
fragmentation. Complete DMEM supplemented with 20% FCS, 2 mM glutammine, 100 
U/ml penicillin, 100 μg/ml streptomicin, 100 mg/L Kanamicyn and AMFO 
(Amphotericyn B).  
After 3-4 days culture medium was removed and fresh medium was then added. Days 
required for fibroblast cells exit from bioptic fragments is highly variable and depends 
on the type of bioptic tissue and the number of fibroblasts composing it. Usually it takes 
20-30 days and, after this period, tissutal fragments were removed with steril tweezers 
and trypsinyzed, thereby promoting fibroblasts isolation, as epithelial cells are not able 
to re-adhere to plate surface. Obtained fibroblasts were then maintained in culture with 
complete DMEM supplemented with 10% FCS, 2mM glutammine, 100U/ml penicillin, 
100 μg/ml streptomicin. 
 
FIBROBLASTS AND PCa CELLS ACTIVATION 
HPFs were grown to subconfluence and treated for 24h with CM-PCa to obtain PCa-
activated fibroblasts (PCa-AFs). Fresh serum-free medium was added PCa-AFs for an 
additional 24h before collection of CM-PCa-AFs. Activation state of PCa-AFs was 
confirmed by morphology and fibroblast activation protein expression. Note that PCa-
AFs behave similarly to in vivo extracted CAFs (Giannoni et al., 2010). CM-HPFs, CM-
CAFs and CM-PCa-AFs were used to treat PCa cells for 48h. 
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CELL TRANSFECTION WITH LIPOFECTAMINE 
Silencing with siRNA or shRNA plasmid was performed with Lipofectamine 2000 
following manufacturer’s instructions (Invitrogen). Cells plated at a 90% confluence 
and before transfection, DMEM culture medium is removed and replaced with 
Optimem medium (Invitrogen), lacking serum and antibiotics that could interfere with 
liposomes formation. Solution containing siRNA/shRNA was added to solution with 
lipofectamine and incubated at room temperature for 20 minutes, in order to promote 
liposomes formation; then equal amounts of final solution were added to each plate. 
Optimem medium was removed after 4-6 h from transfection, as lipofectamine could be 
slightly toxic for cells. Finally, cells were maintained in complete medium for 48 h and 
transfection efficiency was evaluated through immunoblotting assays using specific 
antibodies for the silenced protein. 
 
PROLIFERATION ASSAYS 
PCa cell proliferation has been measured cytometrically by the use of 
carboxyfluorescein diacetate succinimidyl ester (CFSE). Cells were treated with 10 
mmol/L CSFE for 15 minutes at 37°C and then plated alone or in co-culture with CAFs 
and cultured for 48 hours. Cytofluorimetric analysis allows the determination of cell 
proliferation index (the average number of cell divisions that a cell in the original 
population has undergone) on the basis of progressive decreasing of cell fluorescence as 
a function of the number of cell divisions. Alternatively, CAFs+PCa coculture were 
grown for 5 or 7 days, in presence or absence of 1 mg/mL 2-DG, 0.5 mM DCA acid, 20 
nM Antimycin A, 25-50 μM kaempferol, and PCa clones were counted under an optical 
microscope. 
Crystal violet proliferation assay. Crystal violet (CV) is a triphenylmethane dye (4-
[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dimethyl-aniline) also known as 
Gentian violet (or hexamethyl pararosaniline chloride). 20 x 10
3
 PCa cells were plated 
in 24-well culture dishes and coltured in complete DMEM for 24h and 48h. Then cells 
was washed with PBS and incubate with crystal violet solution for 5 minutes at 37 C°. 
The crystal violet solution contains 0,5% crystal violet in deionized water and 20% 
methanol. After incubation crystal violet was removed through aspiration and three 
washings in PBS solution. Finally, crystal violet uptaken by cells was solubilized after 
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incubation in slow agitation for 1 h at 37 C° with a solution containing 0,1M sodium 
citrate (Sigma-Aldrich), pH 4,2. After incubation, solution containing solubilized crystal 
violet was collected and its absorbance was evaluated at a 595nm wavelenght. Each 
measurement was made in triplicate for each point of the curve of growth. Absorbance 
is positively correlated to crystal violet amount bound to cells. 
 
INVASION ASSAY 
Transwell system, equipped with 8μm pore polyvinylpirrolidone-free polycarbonate 
filters (6.5 mm diameter) were used. Cells were loaded into the upper compartment (1 × 
10
5
 PCa cells in 200μL of serum-free medium, CM-HPFs or CM-PCa-AFs). The upper 
sides of the porous polycarbonate filters were coated with 50 ug/cm
2
 of reconstituted 
Matrigel and placed into 24-well culture dishes containing 500μl of complete growth 
medium. After 18 h of incubation at 37°C, non-invading cells were removed 
mechanically using cotton swabs, and the micro porous membrane was stained with 
Diff-Quick solutions. Chemotaxis was evaluated by counting the cells migrated to the 
lower surface of the filters (six randomly chosen fields). 
 
PROSTASPHERE FORMATION 
PCa cells were detached using Accutase (Sigma-Aldrich). For prostasphere formation, 
single cells were plated at 150 cells/cm
2
 on low-attachment 100mm plate (Corning) in 
DMEM/F12 (Invitrogen) supplemented with B27 and N2 (Invitrogen), 5μg/mL insulin, 
20ng/mL basic fibroblast growth factor (FGF) and 20ng/mL epidermal growth factor. 
Cells were grown under these conditions for 7 to 21 days and formed nonadherent P0 
spheres termed prostaspheres. 
 
ISOLATION OF PCa CELLS FROM CO-CULTURE 
PCa cells were isolated from fibroblasts using MACS
®
 system (Miltenyi Biotec). First, 
cells were detached from plates with Accutase and fibroblasts were magnetically 
labeled with Anti-Fibroblast MicroBeads, which bind fibroblast-specific antigen. Then, 
the cell suspension was loaded onto a MACS
®
 Column, which was placed in the 
magnetic field of a MACS Separator. The magnetically labeled fibroblasts were retained 
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within the column. The unlabeled PCa cells run through; this cell fraction is thus 
depleted of fibroblasts. 
 
ANNEXIN V/IODIDIUM PROPIDE CYTOFLUORIMETRIC STAINING 
Cells were washed in PBS solution and detached from plates with Accutase solution. 
The advantages of Accutase over the traditional Trypsin/EDTA treatment are that it is 
less damaging to cells. In this case cells treatment with Accutase carries lower risk to 
disrupt Annexin V antigens, expressed on the outer side of cell membranes during 
apoptotic events. 
After cells removal from the plates, they were resuspended in PBS solution and 
centrifugated at 1000 rpm for 3 minutes. Finally, pelletted cells were resuspended in 
100µl containing 1µl of annexin V, 1µl of iodidium propide and 98µl of buffer solution, 
all provided by the kit. After 15 minutes of incubation at room temperature, cells were 
evaluated by flow citometry for Annexin V/iodidium propide staining. 
 
CELL LYSIS AND PROTEIN QUANTIFICATION 
In order to identify proteins of interest, cell lysates were separated through SDS-PAGE 
(polyacrylammide gel elettrophoresis) and revealed with Western Blotting analysis.  
Cells were washed once with PBS solution and then lysated with RIPA lysis buffer 
supplemented with proteases inhibitors. Obtained protein lysates were collected, always 
kept in ice and centrifugated at 13000rpm for 10 minutes. After centrifugation, 
supernatant was collected and total proteins were quantified with Bradford assay. 
Total protein quantification, espresse in μg/mL, is evaluated with Coomassie Brilliant 
Blue (Bradford protein assay), which binds to basics and aromatics aminoacidic 
residues (specially arginins), leading to maximum absorption at 595nm wavelegth. 
Thus, Coomassie Brilliant Blue intensity is positively correlated to protein 
concentration.  
For the standard curve bovine serum albumine was used (BSA), diluting BSA 2 mg/ml 
concentrated in deionized water and then obtaining rising BSA concentrations from 
2μg/mL to 15μg/mL.  
Then Bradford reagent is prepared diluting 1/5 of starting solution with Coomassie 
Brilliant Blue in 4/5 of deionized water. 
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To run the assay, 50 μL of each sample, opportunely diluted in water in labelled 
eppendorfs, must be added to 950 μl of the working solution for each sample, 
resuspending well. After a 5 minutes incubation, the absorbance of each sample is 
evaluated at a wavelength of 595nm, subtracting the blank value. From values obtained 
from the standard curve it is possible to create a curve of absorbance in function of its 
concentration, thus, interpolating absorbances values to the standard curve, it is possible 
to calculate final protein concentration. 
Correlation between absorbance and concentration is expressed by Lambert-Beer law: 
A=εdc, where ε represents the molar extinction coefficient, d the path length and c 
represents sample concentration. 
For each Western Blotting experiment usually 20-25 μg of total proteins are loaded on 
SDS-PAGE for each sample. 
 
NUCLEAR FRACTIONATION 
Cells were harvested by spinning at 1000rpm for 5 min at 4°C and then washed cells 
with cold PBS. After that, cells were resuspended in ice cold Buffer A (10 mM Hepes 
pH 7.9, 1.5mM MgCl2, 10mM KCl, 1mM DTT, plus protease and phosphatase 
inhibitors), washed again with Buffer A (spin at 1000rpm, 5 min at 4°C) and lysated 
with buffer A+0.1% NP-40 (5 min. on ice). Volume of Buffer A+NP=40 should be 2-
3X volume of cell pellet. You can also use a dounce homogeniser. Cell lysates were 
centrifuged at max speed in microcentrifuge for 10 min. at 4°C. Supernatant is 
cytoplasmic extract. Pellets were resuspended in Buffer C (20mM Hepes pH 7.9, 
420mM KCl, 1.5mM MgCl2, 1mM DTT, 25% Glycerol plus protease and phosphatase 
inhibitors, 1-2 volumes of pellet) and rocked for 15 min. at 4°C. After centrifugation at 
max speed for 15 min, supernatants (nuclear extracts) were collected and then diluted 
with Buffer D (20mM Hepes pH 7.9, 0.5mM DTT, 20% Glycerol plus protease and 
phosphatase inhibitors) to reduce the salt concentration. 
 
SDS-PAGE ANALYSIS 
Sodium dodecyl sulfate polyacrylammide gel electrophoresis (SDS-PAGE) is a 
technique for separating proteins based on their ability to move within an electrical 
current, which is a function of the length of their polypeptide chains or of their 
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molecular weight. This is achieved by adding SDS detergent to remove secondary and 
tertiary protein structures and to maintain the proteins as polypeptide chains. The 
anionic SDS coats the proteins (almost one SDS molecule binds every two aminoacidic 
residues of the polipeptidic chain), mostly proportional to their molecular weight, and 
confers the same negative electrical charge across all proteins in the sample.  
SDS-PAGE samples are boiled for 5 minutes in a sample buffer containing SDS and β-
mercaptoethanol, which leads to disolfuric bonds reduction and destabilization of 
eventual protein tertiary structure. In addition, sample buffer is supplemented with 
bromophenol blue, ionizing coloured-tracking solution for the electrophoretic run, and 
glycerol, which increases sample density and promotes its stratification ate the bottom 
of the loading well.  
Once finished samples loading in the stacking gel, an electric field is applied across the 
gel, causing the negatively-charged proteins to migrate across the gel towards the 
positive electrode (anode). Stacking gel, characterized by very low acrilamide 
concentration (4%), is required to better stratify the samples before entering the 
separating gel. Separation of SDS-proteins complexes is achieved according to 
separating gel acrylamide concentration. Lower percentage gels are better for resolving 
very high molecular weight proteins, while much higher percentages are needed to 
resolve smaller proteins, while bromophenol blue is a very small molecule which is not 
affected by frictional forces, thereby representing the migration front. Proteins relative 
molecular mass is evaluated by comparison with protein ladder standard molecular 
weights, separated in the same gel. Running is carried on at 200V for almost 1 h. 
 
WESTERN BLOTTING 
After run, polyacrylamide gel is maintained for 5 minutes at room temperature in slow 
agitatation in the transfer blot. In order to make the proteins accessible to antibody 
detection they are moved from within the gel onto a membrane made of polyvinylidene 
difluoride (PVDF). The method for transferring the proteins is called electroblotting and 
uses an electric current to pull proteins from the gel into the PVDF membrane. The 
proteins move from within the gel onto the membrane while maintaining the 
organization they had within the gel. Proteins transfer is carried out at 100V for 1 h. 
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PVDF membrane must be previously activated through treatment with methanol for 15 
seconds and left at drying for at least 15 minutes at room temperature.  
After electroblotting the PVDF membrane is incubated overnight in slow agitation at 
4°C with specific primary antibodies in a blocking solution containing non-fat dry milk 
2% and Tween 0.05%. After incubation, the membrane is washed three times with a 
washing solution containing PBS 1X and Tween 0.1% and, in order to reveal the 
specific protein, the membrane is incubated with horseradish peroxidase conjugated 
secondary antibody for 1h at room temperature and then washed again for three times. 
In the chemiluminescence reaction horseradish peroxidase catalyzes the oxidation of 
luminol into a reagent which emits light when it decays. Since the oxidation of luminol 
is catalyzed by horseradish peroxidase, and the HRP is complexed with the protein of 
interest on the membrane, the amount and location of light that HRP catalyzes the 
emission of, is directly correlated with the location and amount of protein on the 
membrane. Chemiluminescent protein revelation is carried out with ECL-Amersham 
Pharmacia kit reagents and developing of blots is carried out in the developing room 
placing imaging films on top of the membrane. Exposure is repeated, varying the time 
as needed for optimal detection. 
 
REAL-TIME PCR 
Total RNA was extracted from cells using the RNeasy Minikit kit (Qiagen). RNA (1 
μg) was reverse transcribed using TaqMan Reverse Transcription Reagents Kit 
following manufacturer’s instructions (Invitrogen). Measurement of gene expression 
was performed by quantitative real-time PCR (RT-PCR; ABI PRISM 7700 Sequence 
Detector, Applied Biosystems). The amount of target, normalized to an endogenous 






For the evaluation of intracellular ROS amount, staining with 2',7'-
dichlorodihydrofluorescein diacetate (H2DCF-DA) probe was performed. H2DCF-DA 
passively diffuses into cells, where its acetate groups are cleaved by intracellular 
esterases and its thiol-reactive chloromethyl group reacts with intracellular glutathione 
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and other thiols. H2DCF-DA is solubilized in DMSO at moment of usage and avoided 
from light exposure. 
H2DCF-DA (5μM) probe was added to cells and incubated for 3 minutes at 37°C. After 
the incubation time, cells are blocked through PBS washing, quickly lisated in RIPA 
lysis buffer supplemented with proteases inhibitors and kept for 1 minute at 4°C. 
Lysates were then collected and centrifugated for 1 minute at 13000rpm. For each 
sample 100µl were transferred on a 96 wells multiwell and analyzed by fluorimetric 
quantification (excitation wavelength of 488nm, emission wavelength of 510nm). 
Obtained values were finally normalized on protein content of each sample. 
Evaluation of mitochondrial ROS was performed adding 5μM Mitosox to the cells for 




Lactate was measured in the cultured media with Lactate Assay kit (Source Bioscience 
Life Sciences) according to the manufacturer's instruction. 
 
GLUCOSE AND LACTATE UPTAKE 
2-deoxy-glucose or lactate uptake was evaluated in a buffered solution (140mM NaCl, 
20mM Hepes/Na, 2.5mM MgSO4, 1mM CaCl2, and 5mM KCl, pH 7.4) containing 
0.5μCi/mL [3H]-deoxyglucose or 0.2μCi/mL D-[U-14C]-lactate for 15 minutes at 37°C. 
Cells were subsequently washed with cold PBS and lysed with 0.1M NaOH. 
Incorporated radioactive was assayed by liquid scintillation counting and normalized on 
protein content. PCa cells were treated with CM or co-cultured with HPFs for 72h 
(unless specified) before the analysis. 
 
INCORPORATION OF LACTATE INTO PROTEINS 
PCa cells were treated with CM or co-cultured with HPFs for 72h and then [U-
14
C]-
lactate was added for additional 24h. Cells were then resuspended in 20% 
trichloroacetic acid, placed on ice for 30 minutes and centrifuged. The resuspended 
pellet was assayed for [
14
C]-labeled proteins by scintillator. 
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DETECTION OF RELEASED CO2 BY RADIOACTIVE GLUCOSE AND 
LACTATE 
PCa cells were treated with CM or co-cultured with HPFs for 72h (unless specified) and 
then 0.2μCi/mL D-[U-14C]-lactate or 0.5μCi/mL [U-14C]-glucose were added for 15 
minutes. Each dish had a taped piece of Whatman paper facing the inside of the dish 
wetted with 100μL of phenyl-ethylamine-methanol (1:1) to trap the CO2. Then 200μL 
of 4M H2SO4 was added to cells. Each plate was incubated for 37°C, 5%CO2 for 1h to 
permit releasing of 
14
CO2. Finally, Whatman paper was removed and transferred to 
scintillation vials for counting. 
 
MEASUREMENT OF PPP ACTIVITY 









C]-glucose oxidation originates by the PPP or by the TCA cycle, 
whereas 
14
CO2 released from [6-
14
C]-glucose originates only by TCA cycle. 2μCi [1-
14
C]-glucose or 2μCi [6-14C]-glucose were added for 1h to cells, in two different plates 
of same sample. Each plate had a taped piece of Whatman paper facing the inside of the 
dish wetted with 100μL of phenyl-ethylamine-methanol (1:1) to trap the CO2. Then, 
200μL of 4M H2SO4 was added to cells. Each plate was incubated for 37°C, 5%CO2 for 
1h to permit releasing of 
14
CO2. Finally, Whatman paper was removed and transferred 
to scintillation vials for counting. The extent of PPP metabolic flux was obtained by 
subtracting the amount of CO2 developed from [6-
14





ANALYSIS OF CA IX ACTIVITY 
CA IX activity was analyzed either by confocal microscopy or fluorescence stop-flow. 
For confocal microscopy analysis, cells were cultured on glass coverslips and treated 
with appropriate medium depending on the experiments. After the treatment, cells were 
washed with PBS and the CA IX fluorescent probe FITC-labeled CAI#3 (1mM, final) 
(compound 3) (Supuran et al., 2008) was added to living cells for 1h. Cells were then 
washed extensively with PBS, mounted with glycerol plastine and observed with a 
fluorescence microscope (Leica TCS SP5) (Švastová E. et al., 2004). An Applied 
Photophysics stopped-flow instrument has been used for assaying the CA catalyzed CO2 
Materials and Methods 
79 
Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 
Tesi di Dottorato in Scienze Biomolecolari e Biotecnologiche-Università degli Studi di Sassari 
 
hydration activity. Phenol red (at a concentration of 0.2 mM) has been used as indicator, 
working at the absorbance maximum of 557nm, with 20mM Hepes (pH 7.4) as buffer, 
and 20mM Na2SO4 (for maintaining constant the ionic strength), following the initial 
rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 sec. The CO2 
concentrations ranged from 1.7 to 17mM for the determination of the kinetic parameters 
and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the 
reaction have been used for determining the initial velocity. The uncatalyzed rates were 
determined in the same manner and subtracted from the total observed rates. Stock 
solutions of inhibitor (10mM) were prepared in distilled-deionized water, and dilutions 
up to 0.001nM were done thereafter with the assay buffer. Inhibitor and enzyme 
solutions were pre-incubated together for 15 min at room temperature prior to assay, in 
order to allow for the formation of the E-I complex. The inhibition constants were 
obtained by nonlinear least-squares methods using PRISM 3, as reported earlier, and 
represent the mean from at least three different determinations. All CA isoforms were 




Zimography was performed using cultured media collected in our experimental 
conditions. Aliquots of cultured media were electrophoresed on 8% SDSPAGE co-
polymerized with 0.1% (w/v) type A gelatine. Gels were washed twice in 2.5% v/v 
Triton X-100 for 30 min and then incubated in 50mM TRIS-HCl, pH 7.4, 200mM NaCl 
and 5mM CaCl2 at 37°C for 24 h. After incubation, the gels were stained with 0.1% 
Coomassie brilliant blue in acetic acid, methanol and distilled water (1:2:3, 
respectively) for 60 min at room temperature. After destaining, the gels were immersed 
in distilled water and scanned immediately with Quantity-One Image Analysis software 
(Bio-Rad). Bands of gelatinase activity appeared as transparent areas against a blue 
background. Metalloproteinases activity was measured with Amplite™ Universal 
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ANALYSIS OF MMP-9 INHIBITORS BY FLUORIMETRIC ASSAYS 
The values of Ki for the compounds GlcNAc-SLS-HA and Lac-SLS-HA were 
determined by evaluating their ability to inhibit the hydrolysis of fluorescence-quenched 
peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Biomol, Inc). The analyses 
have been performed at 298K in 50mM HEPES buffer, containing 10mM CaCl2, 0.05% 
Brij-35, at pH 7, using 1nM of MMP catalytic domains and 1μM of peptide. The 
experiments were performed with peptide concentration much lower than Ki. The 
fluorescence (excitation max 328nm; emission max 393nm) was measured for 3 min 
after the addition of the substrate using a Varian Eclipse fluorimeter. Fitting of rates as a 
function of inhibitor concentration provided the Ki values (Calderone et al., 2006). 
 
XENOGRAFT EXPERIMENTS 
In vivo experiments were conducted in accordance with national guidelines and 
approved by the ethical committee of Animal Welfare Office of Italian Work Ministry 
and conform to the legal mandates and Italian guidelines for the care and maintenance 
of laboratory animals. Experiments were performed using 6–8-wk-old male severe 
combined immunodeficient (SCID)-bg/bg mice (Charles River Laboratories 
International). Animals (six per group) were monitored daily and tumor size was 
measured every 2–3 d by a caliper. Tumor volumes were determined by the length (L) 
and the width (W): V = (LW2)/2. 
Histology. Tissues were fixed in 4% (vol/vol) phosphatebuffered formalin and paraffin 
embedded. Consecutive sections with 5μm thick were mounted on positively charged 
slides. Tissue sections were de-paraffinazed, re-hydrated and stained with hematoxylin-
eosin or Azan-Mallory trichromic stainings. Metastases were counted using NIS 
ELEMENTS_F-2.20 software combined with a microscope Nikon Eclipse 50i. 
 
STATISTICAL ANALYSIS 
Data are presented as means ± SD from at least three independent experiments. 
Statistical analysis of the data was performed by Student’s t-test. p values of ≤ 0.05 
were considered statistically significant. 
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EXPERIMENTAL PART I 
 
Aim of study 
It is now well established that cancer cells undergo profound changes in their 
metabolism (Hanahan and Weinberg, 2011). Several studies showed that tumor cells 
typically use glucose by aerobic glycolysis, producing lactate and undergoing the so 
called Warburg effect, thereby facilitating anabolism of macromolecules needed to 
construct a new cell from glycolytic intermediates (Vander Heiden et al., 2009). 
Deregulation of oncogenes/tumor suppressor genes molecular pathways is involved in 
metabolic changes in cancer cells, leading to expression or down-regulation of protein 
and enzyme of cell metabolism (Chen and Russo, 2012). 
In the last years, tumor stroma, and in particular CAFs, are emerging as key players in 
metabolic reprogramming of tumor mass, thus sustaining cancer cell growth and 
affecting tumor progression. A number of studies demonstrated the existence of 
metabolic coupling between stroma and tumor, but controversial results have been 
obtained. Indeed, colorectal carcinoma histological analyses suggest that the stroma 
infiltrating this cancer buffers and recycles products of anaerobic metabolism of cancer 
cells, in order to sustain invasive cancer growth (Koukourakis et al., 2006). On the 
contrary, fibroblasts undergoing activation due to deletion of Cav-1 experience 
oxidative stress and a HIF-1-mediated shift toward aerobic glycolysis, which is 
associated with elimination of mitochondrial activity through autophagy/mitophagy 
process (Pavlides et al., 2009; Lisanti et al., 2010). As a consequence of these profound 
metabolic alterations, CAFs secrete energy-rich metabolites (such as lactate, ketones, 
and pyruvate, derived from glycolysis) and chemical building blocks (such as amino 
acids nucleotides, and lipids, derived from autophagy) that can sustain and support the 
mitochondria-dependent growth of tumor cells (Sotgia et al., 2012). In agreement, in 
breast cancers, PKM2 and lactate dehydrogenase, two enzymes associated with aerobic 
glycolysis, are highly expressed in stromal CAFs (Pavlides et al., 2009). 
In this controversial context, we analyzed if prostate fibroblasts undergo a glycolytic 
shift in response to PCa contact, thereby engaging a metabolic interplay with PCa cells. 
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Furthermore, given that CAFs have been associated by our research group to a pro-
oxidant environment, deeply affecting tumor progression and metastatic spread 
(Giannoni et al., 2010; Giannoni et al., 2011), we also investigated the role of ROS in 
metabolic reprogramming of CAFs and PCa cells. We demonstrated that, following 
activation, CAFs shift their metabolism toward a more glycolytic one, through a HIF-1- 
and oxidative stress-dependent extrusion of lactate. This catabolite shuttles back to 
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ANALYSIS OF HPFs AND CAFs FROM HUMAN PATIENTS 
In order to investigate the metabolic interplay between PCa and prostatic fibroblasts, we 
first analyzed the metabolic signature of CAFs. We have already demonstrated that 
CAFs from aggressive prostate carcinoma undergo in vivo activation in response to 
factors secreted by cancer cells, achieving a "reactive" state characterized by expression 
of typical myfibroblasts markers, such as α-SMA and FAP (Giannoni et al., 2010). 
Human prostate CAFs were isolated from prostate biopsies from nine patients with PCa, 
whose pathological values are reported in Tab. 1. Our choice has been driven by cancer 
aggressiveness and PSA (Prostate-Specific Antigen) values. As healthy counterparts, we 
used HPFs isolated from four men with benign prostatic hyperplasia. Of note, HPFs do 
not express markers of activated fibroblasts (Giannoni et al., 2010). HPFs and CAFs 
were then used to perform ex vivo cultures. 
 
 
Table 1. Pathological parameters of individuals from which CAFs have isolated; CAFs have been 
isolated from surgical biopsy from nine individuals with prostate carcinoma. Table reports the 
pathological parameters of the patients before surgery (PSA and Biopsy Gleason Score) and after surgery 
(Anatomy Pathologic Gleason Score and Pathological Stage). 
 
We firstly observed that CAFs show increased basal glucose uptake compared to HPFs, 
consistent with increased glycolytic pathway (Fig. 1A). In keeping, the analysis of gene 
pathways revealed up-regulation of glycolytic enzymes in CAFs respect to HPFs, such 
as PKM2, ALDO-A/B/C (aldolase), ENO-1/2 (enolase), TPI-1(triose-phosphate 
isomerase), further confirming activation of glycolysis (Fig. 2A, 2B). We also observed 
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that CAFs show increased expression of monocarboxylate transporter MCT4 (Fig. 1B). 
MCT4 has low affinity for lactate and is consequently expressed by glycolitic cells in 
order to release the metabolite in extracellular compartment, thereby validating the idea 
that prostate CAFs increase their lactate production with respect to healthy HPFs. 
Finally, we observed that both cytoplasmic and mitochondrial ROS are greater in CAFs 
compared to HPFs, thus demonstrating that CAFs experience a state of oxidative stress 
compared to HPFs (Fig. 1C and 1D). This last findings are in agreement with other data 
in literature reporting that ROS are important players for fibroblast activation (Toullec 
et al., 2010). Taken together, these results indicate that prostate CAFs, under normoxic 
conditions, undergo a Warburg metabolism due to their activation in response to cross-
talk with cancer cells. 
 
 
Fig. 1. Analysis of human ex vivo HPFs and CAFs. A) analysis of [3H]-glucose uptake in HPFs and 
CAFs. B) MCT4 immunoblot in HPFs and CAFs. Normalization was done by actin immunoblot. The plot 
below reports densitometric quantitation (ratio MCT4:actin). Oxidative stress in CAFs and HPFs 
evaluated as level of total ROS released, analyzed using H2DCF-DA (C) or using the Mitosox probe for 
the detection of mitochondrial ROS (D). Values of plots C and D were normalized on sample protein 
content. *, p < 0.001 versus HPFs; #, p < 0.01 versus HPFs. a.u., arbitrary units. 
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Fig. 2 (See previous page). Enrichment of glycolitic enzymes among genes up-regulated in prostatic 
CAFs. Gene expression profiles were analyzed using an Illumina microarray platform on paired CAFs 
and HPFs isolated respectively from the tumor and the adjacent normal tissue from three prostate cancer 
patients subjected to radical prostatectomy. Gene Set Enrichment Analysis (GSEA) (ref1, ref2 
http://broadinstitute.org/gsea) was conducted between CAFs and HPFs, and revealed, among the others, a 
significant enrichment for gene sets related to carbohydrate catabolism among the genes that were up-
regulated in CAFs. Specifically, when the analysis was carried out searching among gene ontology gene 
sets (C5), enrichment was found for Carbohydrate_Catabolic_Process set, whereas and ever higher 
enrichment was found for a set of glycolytic enzymes (referred to as Mootha_Glycolysis) when the 
analysis was performed on literature based gene sets (C2). A) Table showing normalized enrichment 
scores and significance for enriched gene set. B) Enrichment plot (left) and heatmaps of gene intensities 
(left) for the gene set emerged from GEMSA. In the heatmaps, gene intensities are colored from blue (low 
expression) to red (high expression). (ref1) Subramanian, Tamayo et al. (2005) PNAS 102, 15545-15550 
(ref2) Mootha, Lindgren et al. (2003) Nat Genet 34, 267-273. 
 
 
PROSTATE HPFs UNDERGO WARBURG EFFECT IN RESPONSE TO 
ACTIVATION 
To investigate the activation of Warburg metabolism due to CAFs differentiation, we 
used HPFs activated in vitro using conditioned medium (CM) from PCa cells. Indeed, 
we have already reported that PCa cells secrete soluble factors (such as IL-6) able to 
elicit a mesenchymal-mesenchymal transition in HPFs, leading them to an activation 
state similar to myofibroblasts (Giannoni et al., 2010) with expression of specific 
markers (e.g., FAP). We termed these in vitro activated HPFs as PCa-activated 
fibroblasts (PCa-AFs). As CAFs, PCa-AFs show a clear increase in lactate secretion 
compared to HPFs (Fig. 3A), likely due to up-regulation of MCT4 transporter (Fig. 3B). 
Activation of fibroblasts does not affect their utilization of lactate, as revealed by 
immunoblot analysis of MCT1 expression level (Fig. 3B). The latter has high affinity 
for lactate, thereby promoting its uptake in cells (Halestrap et al. 1999; Dubouchaud et 
al. 2000; Ullah et al. 2006). As a consequence, we found no difference in lactate up-load 
between HPFs and CAFs (Fig. 3B). Finally, PCa-AFs increase both expression of 
GLUT1 glucose transporter and glucose uptake (Fig. 3C, 3D). These data confirm that 
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Fig. 3. Analysis of Warburg metabolism in HPFs activated in vitro. HPFs were treated with CM-PCa 
for 24 hours obtaining PCa-AFs, then serum-free medium was added for an additional 48 hours. A) 
Lactate assay in culture medium. B) Upper panel: MCT4 and MCT1 immunoblots in HPFs and PCa-AFs. 
Normalization was done by actin immunoblot. Lower panel: lactate up-load by HPFs and PCa-AFs. C) 
RT-PCR analysis for GLUT1 mRNA in HPFs and PCa-AFs. D) [
3
H]-glucose uptake in HPFs and PCa-
AFs. *, p < 0.001 versus HPFs. 
 
 
THE WARBURG METABOLIC SHIFT IN CAFs IS REDOX- AND HIF-1-
DEPENDENT 
It has been reported that differentiation of CAFs toward a myofibroblast phenotype is a 
redox dependent event (Toullec et al., 2012; Cat et al., 2006). HIF-1 transcription factor 
promotes expression of many glycolytic enzymes, thus driving anaerobic metabolism 
during exposure to hypoxia. Of note, even under normoxic conditions, HIF-1 can be 
induced by several factors, such as ROS, TCA cycle metabolites and oncogene gain of 
functions or tumor suppressor gene loss of function, thereby promoting glucose 
metabolism by aerobic glycolysis (McFate et al., 2008; Semenza, 2010b; Semenza, 
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2010a). We hypothesized that the conversion to a Warburg phenotype of HPFs in 
normoxia could be dependent on oxidative stress, which in turn could drive HIF-1 
stabilization and consequent activation of its transcriptional program. To confirm this 
hypothesis, we firstly analyzed the intracellular ROS in HPFs and PCa-AFs. As 
previously reported for CAFs (Fig.1), PCa-AFs have a higher basal level of ROS with 
respect to HPFs (Fig. 4A). In agreement with ROS content, PCa-AFs show a clear 
stabilization of HIF-1 under normoxic conditions (Fig. 4C). Treatment of PCa-AFs with 
the ROS scavenger N-acetyl cysteine (NAC) leads to down-regulation of HIF-1 (Fig. 
4C), thus confirming the ROS-mediated stabilization of this transcription factor in 
activated fibroblasts. Finally, the inhibition of HIF-1 either by RNA interference, by 
topotecan (a known HIF-1 pharmacological inhibitor; Rapisarda et al., 2004) or by 
NAC decreases both expression of MCT4 transporter (a target gene of HIF-1) and 
lactate extrusion in PCa-AFs (Fig. 4B, 4C and 4D). Taken together, these data confirm 
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Fig. 4 (See previous page). Warburg metabolism of PCa-AFs is ROS- and HIF1-dependent. HPFs 
were treated with CM-PCa for 24 hours obtaining PCa-AFs, then serum-free medium was added for an 
additional 48 hours. A) analysis of total ROS content in HPFs and PCa-AFs. B) Assay of lactate extruded 
by HPFs and PCa-AFs. A total of 20mM NAC was added to serum-free medium for 24 hours. C) 
Immunoblot analysis of redox- and HIF-1-dependence of MCT4 expression. HIF-1 was silenced in HPFs 
by RNA interference for 48 hours before adding CM-PCa. 20mM/L NAC and 250nM topotecan were 
added for 24 hours. HIF-1 silencing, topotecan, or NAC treatments are indicated on the left. Actin 
immunoblot was used for normalization. D) Assay of lactate in HPFs and PCa-AFs medium after 
treatment with topotecan or HIF-1 silencing as in C. *, p < 0.001 versus HPFs; #, p < 0.001 versus 
control; §, p < 0.01 versus HPFs. 
 
 
SIRT3 IS INVOLVED IN ROS PRODUCTION AND HIF-1 STABILIZATION IN 
PCa-AFs 
It has recently been demonstrated that the mitochondrial deacetylase SIRT3 (sirtuin-3) 
is involved in the control of HIF-1 expression, and redox signaling has been implicated 
in such control (Finley et al., 2011). Superoxide dismutase 2 (SOD2 or MnSOD) is 
involved to maintain ROS homeostasis in mitochondria and is a target enzyme of 
SIRT3. Deacetylation of SOD2 by SIRT3 induces its activations; a decrease in SIRT3 
expression leads to increased SOD2 acetylation/inhibition, thereby causing ROS 
increase and HIF-1 stabilization (Bell et al., 2011; Chen et al., 2011). In turn, HIF-1 
activation following SIRT3-loss is able to induce metabolic reprogramming toward 
aerobic glycolysis in cancer cells (Finley et al., 2011). 
To address the possibility that the conversion to a Warburg phenotype of HPFs as a 
consequence of activation could be dependent on SIRT3-mediated ROS production, we 
firstly analyzed the expression of SIRT3 in both HPFs and PCa-AFs. Immunoblot 
analysis revealed a down-regulation of SIRT3 and an increase in SOD2 acetylation in 
PCa-AFs (Fig. 5A). As a result of SOD2 inhibition, mitochondrial ROS are strongly 
increased upon HPFs activation (Fig. 5B). Finally, in agreement with the idea of a 
redox-mediated activation of HIF-1 via SIRT3 down-regulation, we observed a clear 
stabilization of HIF-1 in PCa-AFs under normoxic conditions (Fig. 5A). To further 
confirm the role of SIRT3 in HIF-1 stabilization, we silenced SIRT3 by RNA 
interfering in HPFs before activation with CM-PCa. The abolish of SIRT3 expression 
leads to a strong overproduction of intracellular ROS associated to a dramatic increase 
of HIF-1 accumulation (Fig. 5C). These data demonstrate that SIRT3 acts as a key 
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upstream regulator of ROS production during HPFs activation, leading to HIF-1 
stabilization and, ultimately, to the Warburg metabolism. 
 
 
Fig. 5. HIF-1 accumulation is regulated by SIRT3 in PCa-AFs. HPFs were treated with CM-PCa for 
24 hours obtaining PCa-AFs, then serum-free medium was added for an additional 48 hours. A) 
Immunoblot analysis of HIF-1, SIRT3, SOD2, and acetyl-SOD2. Actin immunoblot was used for 
normalization. B) Cytofluorimetric analysis of mitochondrial ROS using Mitosox probe. C) SIRT3 was 
silenced in HPFs by RNA interference for 48 hours before adding CM-PCa. HIF-1 and SIRT3 
immunoblots are shown and total ROS production of the same samples is reported in the plot below. *, p 
< 0.001 versus HPFs; #, p < 0.001 versus control. 
 
 
PCa CELLS UP-LOAD LACTATE PRODUCED BY CAFs 
Several evidences in literature suggest that the glycolytic metabolism in CAFs leads to 
production of lactate and/or pyruvate which could be transferred to adjacent cancer cells 
where they enter the TCA cycle, resulting in increased oxidative phosphorylation and 
efficient ATP production (Pavlides et al., 2009). Since HPFs undergo Warburg effect 
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upon their activation in response to PCa interplay, extruding lactate in the extracellular 
compartment, we speculate that PCa cells can upload such lactate generated by stromal 
fibroblasts, using it for different purposes. To address this point, PCa cells were treated 
with CM from HPFs or CAFs (ex vivo cultures), or co-cultured with HPFs (obtaining 
PCa-AFs by direct contact with PCa cells). On the basis of data obtained by our analysis 
of ex vivo fibroblasts (Fig. 1), we used for further studies HPFs 1, 3 and 4 or CAFs 1, 4 
and 9 to obtain CM. The results show that lactate produced by CAFs is strongly 
decreased where PCa are present (both treatment with CM-CAFs or co-culture), thus 
suggesting that lactate has been consumed by PCa cells (Fig. 6A). Since activated 
fibroblasts showed unchanged MCT1 expression and unaffected lactate up-load 
compared to HPFs (Fig. 3B), we speculated that PCa cells in contact with CAFs are also 
metabolically reprogrammed to upload lactate. In keeping, we found that the MCT1 
transporter is up-regulated in PCa cells treated with CM from CAFs or in co-culture 
with CAFs (Fig. 6B), thereby allowing lactate up-load. In agreement, CM-CAFs or co-
culture with fibroblasts do not induce MCT4 expression in PCa cells (Fig. 6B, bottom). 
In addition, we observed a clear up-regulation of HIF-1 under normoxic conditions 
when PCa cells are in contact with CAFs (both CM-CAFs and co-culture with CAFs) 
(Fig. 6B). Treatments with ROS scavenger NAC or topotecan lead to down-regulation 
both of HIF-1 and MCT1, thereby confirming that ROS-dependent stabilization of HIF-
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Fig. 6. PCa cells upload and use lactate produced by CAFs. PCa cells were cultured with serum-free 
medium (st) or with CM-HPF, CM-CAF, or co-cultured with CAFs (proportion CAFs:PCa 3:1). A) Assay 
for lactate extrusion in culture media. B) MCT1, MCT4 or HIF-1 immunoblots of the same samples. 
Actin immunoblot was used for normalization. *, p< 0.001 versus HPFs. 
 
 
To analyze the fate of lactate extruded by CAFs, we treated PCa cells with [
14
C]-lactate 
and analyzed its upload by PCa cells after treatment with CM or co-culture with CAFs 
(Fig. 6C, upper panel). In the same experimental setting, we also evaluated respiration 
of lactate by PCa, through analysis of released [
14
C]-CO2, and lactate reconversion 
toward anabolic pathways, through analysis of its incorporation in [
14
C]-proteins (Fig. 
6C, middle and lower panels). We found that both CM or direct contact with CAFs, 
drive a metabolic reprogramming of PCa cells, leading them to upload lactate and to use 
it both in mitochondrial respiration and in anabolic reactions. Furthermore, we observed 
a decrease in GLUT1 expression and [
3
H]-glucose uptake (Fig 6D). This results suggest 
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that PCa cells become glucose-independent and lactate-dependent upon contact with 




Fig. 6. PCa cells upload and use lactate produced by CAFs. PCa cells were cultured with serum-free 
medium (st) or with CM-HPF, CM-CAF, or co-cultured with CAFs (proportion CAFs:PCa 3:1). C) [
14
C]-
lactate upload (top), respiration of [
14
C]-lactate, evaluated as [
14
C]-CO2 released (middle) and 
incorporation of [
14
C] into proteins (bottom). D) Analysis of [
3
H]-glucose uptake (top) and GLUT1 
expression by RT-PCR (bottom). #, p < 0.001 versus st; §, p < 0.01 versus st. 
 
 
NATURAL ANTIOXIDANT KAEMPFEROL IMPAIRS HIF-1 
STABILIZATION IN CAFs/PCa CO-CULTURE 
Several studies on a wide spectrum of phenolic compounds extract from vegetables and 
fruits showed that these natural products can act as potent antioxidant or anticancer 
agents (Aravindaram et al, 2010), behaving as chemopreventive molecules (Singh et al. 
2006). Kaempferol (3,4',5,7-tetrahydroxyflavone) is a flavonoid with pro- and anti-
oxidant activity present in various natural sources (Marfe et al., 2009). It has been 
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reported that kaempferol, as well as resveratrol, is able to activate sirtuins, such as 
SIRT1 and SIRT3, increasing mitochondrial biogenesis and function (Rasbach et al., 
2008). Furthermore, in human leukemia cell lines, kaempferol induces expression of 
SIRT3 and SOD2, showing anti-proliferative properties (Marfe et al., 2009). 
Given the importance of ROS- and SIRT3-dependent stabilization of HIF-1 for 
metabolic reprogramming in our model, we analyzed the effect of kaempferol in 
CAFs+PCa co-culture. Treatment with kaempferol leads to a up-regulation of SIRT3, 
accompanied by a remarkable decrease of ROS production and a down-regulation of 
HIF-1 (Fig. 7). Inhibition of HIF-1 transcriptional activity was confirmed by reduced 
expression of its target gene carbonic anhydrase IX (CA IX) (Fig. 7). These data further 
confirm the mandatory role of SIRT3 and ROS in HIF-1-mediated metabolic 
reprogramming and represent an important example of how natural antioxidant can 
inhibit ROS-dependent mechanism involved in cancer progression. 
 
Fig. 7. Kaempferol impairs HIF-1 stabilization in CAFs+PCa co-culture. Immunoblots for SIRT3, 
HIF-1, and CA IX (a common target of HIF-1) were done on CAFs+PCa coculture (proportion CAFs:PCa 
5:1). Note that 25μM and 50μM kaempferol was added to serum-free medium for 24 hours. Actin 
immunoblot was used for normalization. Total ROS production of the same samples is reported in the 
plot below. 
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LACTATE SHUTTLE IS FUNCTIONAL FOR PCa CELL GROWTH 
With the aim to investigate which is the benefit for PCa cells to upload lactate produced 
by surrounding CAFs, we firstly analyzed cell proliferation. PCa cells were labeled with 
the fluorochrome CSFE (carboxyfluorescein succinimidyl ester), cultured alone or co-
cultured with CAFs and then assayed for proliferation by flow cytometry. CFSE binds 
intracellular proteins and its fluorescence is halved progressively within each cell 
division. The results indicate that the proliferation index of PCa cells (the average 
number of cell divisions that a cell in the original population has undergone) increases 
by 30% when are in contact with CAFs, suggesting an active role of fibroblasts in 
sustaining PCa cells proliferation (Fig. 8A). The relevance of lactate up-load for PCa 
cell growth was confirmed using α-cyano-4-hydroxycinnamate (CHC), a specific MCT1 
inhibitor (Sonveaux et al., 2008; Colen et al., 2011), which abolishes the trophic effect 
of CAFs (Fig. 8A). 
 
 
Fig. 8. Lactate produced by CAFs is useful for PCa growth. A) Analysis of PCa growth in co-culture 
with CAFs. PCa cells were first labeled with CFSE and then cocultured with CAFs for 48 hours, in the 
presence or not of 2,5mM CHC, before cytofluorimetric analysis of cell proliferation. Proliferation index 
has been reported in the bar graph (fold increase respect to PCa cells alone). *,p < 0.001 versus (−). 
 
 
Furthermore, PCa cell growth was assayed in a time course co-culture experiment, in 
which cancer cells were seeded with increasing number of CAFs (1:3; 1:5; 1:10) and 
number of PCa clones were counted. PCa islets developed after some days and we 
observed a clear trophic effect of CAFs for PCa cell proliferation (Fig. 8B). Again, the 
advantage given by co-culture with CAFs for PCa cell growth was reverted by blocking 
the function of MCT1 transporter with CHC (Fig. 8B). The effect of CHC is highly 
specific for PCa cells, which are actively up-loading lactate, since it impairs the 
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viability of PCa cells without significantly affecting CAFs viability (Fig. 8C). Similar 
results were observed after silencing of MCT1 by RNA interference (Fig. 8B) or by the 
use of different metabolism inhibitors (Fig. 8D). Indeed, the block of the metabolic 
circuitry established between co-cultured PCa cells and CAFs, by treatment with 2-
deoxyglucose (2-DG), dichloroacetate (DCA) or Antimycin A, as well as forced re-
expression of SIRT3 by kaempferol, leads to a remarkable decrease of PCa cell growth 
(Fig. 8D). Each of these molecules block the metabolic loop at different points and in 
different cell types. 2-DG (Fig. 8C) and DCA target glycolytic CAFs, being respectively 
an inhibitor of hexokinase and an inhibitor of pyruvate dehydrogenase kinase (PDK). 
Conversely, Antimycin A inhibits cytochrome c reductase, targeting PCa respiring cells. 
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Fig. 8. Lactate produced by CAFs is useful for PCa growth. B) Number of PCa cell clones in co-
culture with CAFs. A total of 3 × 10
3
 PCa cells were seeded with increasing number of CAFs (proportion 
CAFs:PCa cells 3:1, 5:1, 10:1) for 5/7 days and PCa cells clones were counted under an optic microscope 
(top). Note that 2,5mM CHC was added to co-culture for the whole period (bottom, left panel). MCT1 
silencing was obtained by RNA interference in PCa cells. 48 hours after silencing, PCa cells were used to 
seed a co-colture with CAFs (proportion CAFs:PCa cells 5:1). PCa clones are counted after five, six and 
seven days and the mean are shown in the bar graph (bottom, right panel). C) Representative images of 
PCa clones obtained in co-colture with CAFs for 7 days in the presence of 2,5 mM CHC, 1 mg/mL 2-
deoxyglucose (2-DG). D) Increase in PCa cell clone number (% fold increase respect to PCa cells alone), 
in coculture with CAFs (5:1 ratio), for 7 days with 1 mg/mL 2-DG, 0.5mM DCA acid, 20nM Antimycin 
(Ant. A), 25 and 50 μM kaempferol. *, p < 0.001 versus t0; #, p < 0.01 versus t0; §, p < 0.001 versus C. 
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We finally validated in vivo the idea that CAFs induce a metabolic shift in neighboring 
PCa cells, leading them to become MCT1-dependent for their growth. Wild type or 
MCT1 silenced PCa were subcutaneously injected in immunodeficient SCID bg/bg 
mice together with CAFs. As we already reported, co-injection of CAFs with PCa cells 
strongly enhances the tumor growth rate (Giannoni et al., 2010), while we observed that 
silencing of MCT1 reduces this ability by 50%, thereby underscoring the significance of 
lactate shuttle between CAFs and PCa cells during tumor growth (Fig. 8E). 
 
 
Fig. 8. Lactate produced by CAFs is useful for PCa growth. E) Xenograft growth in SCID-bg/bg mice 
of wild-type or MCT1-silenced PCa cells injected subcutaneously. PCa cells were injected alone or with 
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EXPERIMENTAL PART II 
 
Aim of study 
Metastatic process is an hallmark of tumor malignancy and the most common cause of 
death for cancer patients. The key events in such metastatic pathway is EMT, an 
epigenetic program that leads epithelial cells to lose their cell–cell and cell-ECM 
interactions to undergo cytoskeleton reorganization and to gain morphological and 
functional characteristics of mesenchymal cells, thus generating an invasive cell able to 
secrete proteases to deeply change the surrounding ECM and to move away from the 
site of the primary tumor. Both hypoxia and CAFs have been described to elicit EMT in 
cancer cells. In particular, our research group demonstrated that CAFs promote EMT in 
PCa cells, as well as increase of stem cell markers development and spontaneous 
metastases (Giannoni et al., 2010). The ability of CAFs to elicit EMT and stem-like 
traits is due to activation of a pro-inflammatory signature involving cycloxygenase-2, 
NF-kB and HIF-1 which is responsible for a motogen transcriptional program (Giannoni 
et al., 2011). 
Acidic extracellular pH has been associated with tumor progression via multiple effects 
including up-regulation of angiogenic factors and proteases, increased invasion and 
impaired immune functions. In addition, it can influence the uptake of anticancer drugs 
and modulate the response of tumor cells to conventional therapy. Among proteins that 
regulate intracellular and extracellular pH, an important role is played by carbonic 
anhydrases (CAs). CAs are a family of zinc metalloenzymes that rapidly catalyze the 




.There are at least 13 human active CA 
isoforms expressed in different tissue and/or subcellular compartments. CA I, II, III, VII 
and XIII are expressed in cytosol; CA VA and VB are expressed in mitochondria; CA 
IV, IX, XII and XIV are expressed in plasma membrane. An hallmark feature of solid 
tumors is the high expression of CA IX. The latter is an hypoxia-induced enzyme that is 
controlled by the transcription factor HIF-1 (Parks et al., 2011). Located at the cell 
surface with an extracellular catalytic domain, CA IX activity contributes to 
acidification of tumor environment, which has been associated with acquisition of 
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metastatic phenotypes and chemoresistance (Kim et al., 2006; Lee et al., 2007; 
Robertson et al,. 2004). 
The aim of this study is to address the role of CA IX in EMT regulation of PCa cells in 
response to CAFs. We found that CA IX is dramatically up-regulated in CAFs upon 
contact with cancer cells, thereby enhancing extracellular acidification and activation of 
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CA IX IS EXPRESSED IN BOTH PCa CELLS AND CAFs 
We have recently demonstrated that both prostate CAFs isolated from aggressive PCa 
and PCa-AFs (PCa-activeted fibroblasts) are able to elicit EMT program in PCa cells 
(Giannoni et al., 2010). Here, we used HPFs and PCa-AFs obtained by in vitro 
activation (here termed as CAFs) to analyze their role in extracellular acidification 
during the EMT process induced in PCa cells. Immunoblot analysis on HPFs and CAFs 
revealed that only CAFs express CA IX, while HPFs do not express the enzyme (Fig. 
1A). We also confirmed that CAFs isolated from patients bearing aggressive prostate 
carcinoma express CA IX at similar levels with respect to in vitro activated CAFs (Fig. 
1A). Furthermore, PCa cells express CA IX and exposure to the conditioned medium 
(CM) from CAFs elicits an increase of expression of the enzyme (Fig. 1B). 
 
 
Fig. 1. CAFs show high expression of CA IX. A) Immunoblot analysis of CA IX expression in HPFs, in 
vitro activated CAFs and in CAFs isolated from human prostate carcinoma biopsy (in vivo activated 
CAFs). In vitro activated CAFs were obtained culturing HPFs with CM from PCa cells for 24 hours. B) 
Immunoblot analysis of CA IX expression in PCa cells. Prostate cells were treated with CM from HPFs 
or CAFs for 24h. Actin immunoblot was used for normalization. 
 
 
The expression of CA IX in both CAFs and PCa cells upon exposure to CM-CAFs is 
also correlated with increase in enzymatic activity of CA IX, as revealed by 
fluorescence analysis after the treatment of cells with the fluorescent probe FITC-
labeled CAI#3, which targets the activated state of the extracellular catalytic domain of 
the enzyme (Fig. 1C), as well as by stop-flow analysis (Fig. 1D). Of note, in both 
analyses we observed that maximum activity is reached by CA IX expressed by CAFs. 
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Fig. 1. CA XI activity in CAFs and PCa cells. C) Analysis of CA IX activity by fluorescence 




HIF-1 ACTIVATION IS MANDATORY FOR CA IX EXPRESSION IN BOTH 
CAFs AND PCa CELLS 
We previously demonstrated that redox-dependent stabilization of HIF-1 drive the 
metabolic reprogramming of CAFs toward Warburg metabolism. Furthermore, HIF-1 
has already been reported as a master transcription factor involved in CA IX expression 
(Brahimi-Horn and Pouyssegur, 2009), although data on its involvement in the stromal 
counterpart are still at their infancy. We therefore analyzed CA IX expression in CAFs 
and PCa cells in normoxia during HIF-1 inhibition following treatment with topotecan 
or N-acetyl cysteine (NAC). Both treatments lead to the almost complete abolishment of 
CA IX expression in both cell types (Fig. 2A, 2C). In addition, silencing of HIF-1 by 
RNA interference in fibroblasts leads to down-regulation of CA IX, thereby confirming 
its mandatory role in CA IX expression in prostate carcinoma stroma (Fig. 2B). 
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Fig. 2. CA IX expression is HIF 1-dependent both in CAFs and PCa cells. A) Immunoblot analysis of 
ROS- and HIF-1-dependance of CA IX expression in HPFs and CAFs. HPFs were cultured in serum-free 
medium or treated with CM-PCa for 24h in the presence of 20mM NAC or 250nM topotecan. B) HIF-1 
silencing was performed in HPFs and after 48h serum-free medium (for HPFs) or CM-PCa (for CAFs) 
were added to the cells for 24h. C) Immunoblot analysis of ROS- and HIF-1-dependance of CA IX 
expression in PCa cells. 20mM NAC or 250nM topotecan were added to CM from HPFs or CM from 
CAFs and maintained throughout the experiment. In each immunoblot, actin was used for normalization. 
 
 
CA IX EXPRESSION LEADS TO ACIDIFICATION OF CANCER-STROMAL 
ENVIRONMENT 
To investigate in our model the role of CA IX in extracellular acidification, we analyze 
the pH of culture media of HPFs, CAFs and PCa cells after the treatment with CM from 
HPFs or CAFs in normoxic conditions. We observed that the activation of fibroblasts 
upon CM-PCa contact gives rise to an increase in extracellular acidity, thereby 
suggesting that the mutual interactions among stromal and cancer cells also embraces 
acidification of tumor microenvironment (Fig. 3A). The use of two selective inhibitors 
of CA IX, namely compounds 1 and 2, lead to alcalinization of extracellular milieu, 
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Fig. 3. CA IX induces the acidification of extracellular medium. A) Measure of extracellular pH in 
HPFs, CAFs and in PCa cells after treatment with different CM. B) Measure of extracellular pH in HPFs, 
CAFs and PCa cells after the treatment with CA IX inhibitors 1 (FC3-148 bis) and 2 (FC5–207A) for 
48h. *,p < 0.001 versus HPFs; #,p < 0.01 versus control; §,p < 0.001 versus control. 
 
 
CA IX ACTIVITY OF CAFs ENHANCES MMP-2 AND MMP-9 SECRETION 
The ability of prostate CAFs to elicit a pro-invasive behavior in PCa cells is mainly due 
to a secretion of MMPs (MMP-2 and MMP-9), which drive activation of a Rac1-
dependent EMT program (Giannoni et al, 2011). Owing to the acknowledged sensitivity 
of MMPs to acidity, we investigated if acidic environment due to CA IX expression is 
involved in MMPs expression and activation. Metalloproteinase analysis with 
zimography of fibroblasts' culture media reveal that the ability of CAFs to secrete 
MMP-2 and MMP-9 is severely impaired during administration of CA IX inhibitors 1 
and 2 (Fig. 4A), as well as following down-regulation of CA IX by RNA interfering 
(Fig. 4B). Indeed, the activity of MMP‑9, and to a smaller extent of MMP-2, is 
significantly decreased in media collected from CA IX-silenced HPFs or CAFs, thereby 
confirming a key role played by CA IX in MMP-2 and MMP-9 secretion by CAFs (Fig. 
4C). 
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Fig. 4. Silencing of CA IX in CAFs decreases MMP-9 secretion. A) Metalloproteinase analysis with 
zimography of MMP-9 and MMP-2 in media of HPFs and CAFs after the treatment with the CA IX 
inhibitor 1 (FC3–148 bis) and 2 (FC5–207A) Bar graphs show the level of MMP-2 and MMP-9 in HPFs 
and CAFs after the treatment with CA IX inhibitors. B) CA IX silencing was performed in HPFs and 
CAFs, and then MMP-9 and MMP-2 were analyzed by zymography. C) Assay of MMP-2 and MMP-9 




CA IX ACTIVITY OF CAFs IS MANDATORY TO DRIVE ACTIVATION OF 
EMT IN PCa CELLS 
We already demonstrated that CM collected from prostate CAFs are able to elicit 
invasive features and EMT in PCa cells (Giannoni et al., 2010). We observed that 
acidification of extracellular milieu of CAFs+PCa cells co-cultures obtained omitting 
buffering of culture media, thereby allowing rapid acidification, greatly increased the 
ability of CAFs to drive the EMT program in PCa cells, as revealed by E-cadherin 
decrease and morphological analysis (Fig. 5A, 5B). To investigate the role of CA IX-
mediated acidification and MMPs secretion, we analyzed the sensitivity of CAFs-
mediated EMT to silencing of CA IX. To do that, we collected CM from HPFs and 
CAFs, silenced or not for CA IX, and we used them to treat PCa cells. We observed that 
CA IX silencing in CAFs impairs their ability to induce EMT in cancer cells, as we can 
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see by stable maintenance of E-cadherin expression, inhibition of invasiveness and 
prevention of elongation of the cells (Fig. 5D, 5E, 5C). These data suggest that, within 
the tumor-stroma interplay, acidification due to CA IX expression in CAFs plays a key 
role for activation of EMT in PCa cells. 
 
 
Fig. 5. Modulation of CA IX expression affects EMT in PCa cells. A) E-cadherin expression in HPFs, 
PCa cells and in PCa cells+CAFs co-colture cultured in DMEM buffered at pH 7 and in unbuffered 
medium (placed at 37°C without CO2) for 48h. E-cadherin expression was shown in bar graph. B) 
Representative image of PCa cells treated as described in (A). C) CA IX was silenced in HPFs and CAFs 
and CM were harvested. PCa cells were then treated with serum-free medium (st) or different CM for 
72h, and then cells were photographed. D) Evaluation of E-cadherin expression in the same experimental 
setting described in (C). In each analysis, actin immunoblot was used for normalization. a.u., arbitrary 
units. E) Boyden invasion assay of PCa cells after treatment for 18h with different CM obtained from 
HPFs or CAFs (control or silenced for CA IX). Bar graph represents the mean of invaded PCa cell (six 
fields for sample). *,p < 0.001 versus. buffered medium; #,p < 0.001 versus control CAFs; §,p < 0.001 
versus control CAFs. 
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MMP-9 FROM CAFs IS A KEY PLAYER TO DRIVE ACTIVATION OF EMT 
IN PCa CELLS 
To confirm that MMP-2 and MMP-9 are mandatory factors in EMT of PCa cells, we 
used nanomolar competitive inhibitors of these two matrix proteases, namely GlcNAc-
SLS-HA and Lac-SLS-HA. These inhibitors belong to an unprecedented family of 
atoxic, water-soluble arylsulfonamides characterized by a saccharidic residue (Glc, 
GlcNAc or Lactose) linked, through a spacer, to the sulfonamidic nitrogen. Except for 
MMP-1 and -7, all compounds showed low nanomolar Ki values for the MMPs tested 
(MMP-2, -8, -9, -12 and -13). Peculiarly, the inhibitors here tested present a hydrophilic 
chain that protrudes out of the protein toward the solvent region, allowing a complete 
water solubility without affecting the affinity for the enzymes. GlcNAc-SLS-HA and 
Lac-SLS-HA inhibitors was added to CM collected from HPFs and CAFs, and we 
observed that inhibition of MMP-2 and MMP9 is extremely active in impairing EMT 
due to CAFs contact, preventing the elongation of the cells (Fig. 6A), the E-cadherin 
decrease (Fig. 6B) and, finally, PCa cell invasiveness (Fig. 6C). 
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Fig. 6 (See previous page). The modulation of MMP-9 expression prevents EMT in PCa cells. A) 
Representative images of PCa cells treated for 72h with CM from HPFs and CAFs containing MMP-9 
inhibitors GlcNAc-SLS-HA or Lac-SLS-HA. B) Immunoblot of E-cadherin expression in the same 
experimental setting described in (A). C) Invasion analysis of PCa cells in the presence of MMP-9 
inhibitor GlcNAc-SLS-HA or Lac-SLS-HA. Bar graph represents the mean of invaded PCa cells (six 
fields for sample randomly chosen). *,p < 0.001 versus control CAFs. 
 
On the basis of the acknowledged hierarchy between MMP-2 and MMP-9, we also 
silenced MMP-9 in CAFs by RNA interference and observed abolishment of EMT, as 
suggested by cell morphology (Fig. 6D), stable maintenance of E-cadherin expression 
(Fig. 6E) and decreased invasiveness (Fig. 6F), thereby confirming the key role played 
by this protease in eliciting EMT and motility in PCa cells. Furthermore, the addition of 
recombinant MMP-9 to CM collected from CA IX-silenced CAFs rescues the ability of 
PCa cells to undergo EMT, thereby confirming the hierarchy between CA IX and 
MMP-9 in EMT activation (Fig. 7). 
 
 
Fig. 6D, E, F. For figure legend, see next page. 
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Fig. 6 (See previous page). The modulation of MMP-9 expression prevents EMT in PCa cells. D) 
MMP-9 was silenced in HPFs and CAFs. Silencing was confirmed performing zimography of CM (upper 
panel). Then, CM from HPFs or from CAFs (both control and MMP-9 silenced) were added to PCa cells 
for 72h, and cells were photographed (lower panel). E) Immunoblot analysis of E-cadherin in PCa cells in 
the same experimental setting described in (D). Actin immunoblot is used for normalization (a.u., 
arbitrary units). F) Invasion assay of PCa cells treated with CM from control HPFs or CAFs or with CM 




Fig.7. The addition of recombinant MMP-9 rescue EMT in PCa cells. CA IX was silenced in HPFs 
and CAFs. Then, CM from HPFs or from CAFs (both control and CA IX-silenced) were collected. 100μg 
of recombinant MMP-9 (200U/μg) were added to CM of CA IX-silenced CAFs. PCa cells were cultured 
for 72h with different CM and morphological analysis of EMT was performed under optical microscope. 
 
 
Finally, we used a spontaneous metastasis assay in immunodeficient SCID mice to 
assess the role of CA IX expressed by stromal CAFs for tumor outgrowth and lung 
metastatic dissemination of cancer cells. We co-injected in the lateral flanks of mice 
PCa cells and CAFs (1:5 ratio). We already reported that in the absence of CAFs, PCa 
cells are unable to elicit tumors upon heterotopic injection, and that CAFs behave as 
synergistic bystanders eliciting survival and growth of cancer cells, allowing their 
escaping from primary tumors by EMT. We observed that CAFs silenced for CA IX 
elicit a delayed tumor onset and growth (Fig. 8A), and, more strikingly, that they are 
mostly unable to induce metastatic dissemination of PCa cells to lungs (Fig. 8B), likely 
due to their inability to drive EMT. 
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Fig. 8. CA IX silencing in CAFs decreases tumor growth and lung micrometastasis formation. A) 
Xenograft growth in SCID bg/bg mice of wild-type (control) or CA IX-silenced CAFs injected s.c. with 
PCa cells (CAFs:PCa cells ratio 1:5). B) Bar graph shows the mean of lung micrometastasis. C) 
Representative images of lung micrometastasis (arrows) in control and CA IX silenced treated mice. D) 
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EXPERIMENTAL PART III 
 
Aim of study 
Drug resistance of cancer cells is recognized as the primary cause of failure of 
chemotherapeutic treatment in most human tumors. The ability to reduce 
chemoresistance would be a significant benefit for cancer patients, demonstrating the 
importance of research into mechanism underlying how chemoresistance arise. In this 
regard, mounting evidences supports the idea that deregulated cellular metabolism is 
linked to drug resistance in cancer therapy (Zhao et al., 2013). For example, several 
components of the glycolytic pathways and associated with Warburg effect, such as 
GLUTs transporters, HK, PKM2 and LDHA, contribute to chemoresistance in many 
cancer models. However, a number of data indicate that even mitochondria are involved 
in altered metabolism of cancer cells, and targeting mitochondrial metabolism has 
potential for the treatment of this disease (Ramsay et al., 2011). In cancer cells, 
mitochondria play a key roles, ranging from lactate respiration (Sotgia et al., 2012), to 
TCA cycle fueling with ketone bodies and glutamine, to citrate exportation to fuel fatty 
acids synthesis; of note, a few of these metabolic pathways are associated with drug 
resistance (Zhao et al., 2013). In this context, tumor stroma is emerging as a key player 
to modulate drug sensitivity in cancer cells, fueling oxidative mitochondrial metabolism 
with energy rich metabolites (e.g., lactate, glutamine). Indeed, MCF7 breast cancer cells 
become resistant to tamoxifen after co-culturing with human immortalized fibroblasts, 
shifting their metabolism from glycolysis to mitochondrial oxidative phosphorilation 
(Martinez-Outschoorn et al., 2011). Considering all of these findings, targeting cellular 
metabolism with small molecules interfering with protein/enzymes of metabolic 
pathways, can improve cancer therapy and overcome certain types of drug resistances 
(Zhao et al., 2013). 
Here, we characterized a PCa cell line resistant to docetaxel, a promising drug for 
treatment of metastatic PCa. Firstly, we evaluated the phenotypic features of the 
resistant cells, such as proliferation, invasive properties, expression of apoptotic 
markers, and ability to growth in suspension. We then focused on the metabolic 
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adaptations induced by drug in these cells and on their role to confer advantages respect 
to sensitive cell line. Finally, we analyzed the role of CAFs to modulate the sensitivity 
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PHENOTYPIC CHARACTERIZATION OF DOCETAXEL-RESISTANT PCa 
CELLS 
Docetaxel is a taxane used mainly for the treatment of breast, ovarian, prostate, and 
non-small cell lung cancer. Taxanes is a class of anti-mitotic drugs produced by the 
plants of the genus Taxus, which disrupt microtubule function stabilizing GDP-bound 
tubulin and thus inhibiting the process of cell division. 
In our laboratory, we developed a PCa-resistant cell line (DoceRes) by treating sensitive 
PCa cells (Control) with increased doses of docetaxel, up to a final concentration of 10 
nM. Boyden chamber assay and immunoblot analysis of sensitive and resistant cells 
(Fig, 1A, 1B), showed pro-invasive behavior and down-regulation of E-cadherin in 
DoceRes, consistent with an EMT program and a pro-metastatic phenotype. 
Furthermore, resistant cells show a reduced expression of the pro-apoptotic proteins 
Bim and Bax (Fig. 1B), and produce larger prostasphere in suspension than sensitive 
cells, in agreement with a decreased susceptibility to apoptosis and anoikis (Fig. 1C). 
Finally, DoceRes showed reduced cell growth rate compared to sensitive cells (Fig. 1D, 
blue and green lines). These data demonstrate that DoceRes cell line developed a more 
aggressive phenotype during the acquisition of chemoresistance. 
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Fig.1. Docetaxel resistant PCa cells show a more aggressive phenotype compared to sensitive PCa 
cells. A) Boyden invasion assay of Control and DoceRes cell lines.  Bar graph represents the mean of 
invaded cells (six fields for sample). *,p<0,01 versus Control. B) Immunoblot analysis of E-cadherin, 
Bim and Bax in Control and DoceRes. Actin immunoblot was used for normalization. C) Nonadheretnt 
P0 prostaspheres. Cells were plated in low attachement plate and grown for 7 and 21 days. Then, 
prostaspheres were photographed with optical microscopy. D) Evaluation of cell growth in complete 
medium by crystal violet assay. 20 x 10
3
 cells were plated at the start of experiment. Cell growth was 
followed until 48h. 
 
 
EVALUATION OF ANTIOXIDANT RESPONSE IN DoceRes CELL LINE 
Anticancer drugs are able to induce oxidative stress either as a direct mechanism of cell 
death or as an indirect effect of exposure. For example, it has been reported that 
docetaxel induce ROS production through NADPH oxidase activation (Cao et al., 
2005). Furthermore, it has been suggested that pathways involved in the ROS-adaptive 
response play a critical role in protecting cells against the damaging and cytotoxic 
effects of anticancer agents, thus highlighting their importance in chemoresistance 
(Landriscina et al., 2009). In this regard, it has been reported that Nrf2/Keap1 pathway 
induces mechanisms of cell survival in response to many anticancer drugs. Indeed, Nrf2 
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transcription factor regulates the expression of several antioxidant enzymes (such as 
peroxiredoxin 1, glutathione peroxidase, thioredoxin reductase), phase II detoxifying 
enzymes (glutathione S-transferase) and transporters in cell membrane (ABC 
transporters), thereby maintaining cellular redox homeostasis. 
We investigated the role of Nrf2/Keap1 pathway in docetaxel resistance. Immunoblot 
analysis of whole cell lysate and nuclear fractions of DoceRes and Control cell lines, 
showed increased expression and nuclear translocation of Nrf2 transcription factor in 
resistant cells compared to sensitive cells, associated with a down-regulation of its 
repressor Keap1 and consistent with an activation of Nrf2-mediated anti-oxidant 
response (Fig. 2A, 2B). In agreement with these findings, we observed that resistant 
cells show decreased ROS production when treated with 10nM docetaxel respect to 
sensitive cells (Fig. 2C). These results suggest that DoceRes cell line is able to manage 
drug-induced oxidative stress better than sensitive cells, therefore reducing oxidative 




Fig. 2. For figure legend, see next page. 
Experimental Part III 
116 
Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 
Tesi di Dottorato in Scienze Biomolecolari e Biotecnologiche-Università degli Studi di Sassari 
 
Fig. 2. (See previous page). Resistant cells show a reduced ROS production. A) Immunoblot analysis 
of Nrf2 and Keap1 in sensitive and resistant cells in cellular fractions. Cells were cultured in serum-free 
medium for 48h before nuclear extraction. Actin and nuclear lamin immunoblot were used for 
normalization. B) Immunoblot analysis of Nrf2 and Keap1 in whole cell lysate. Cells were cultured as in 
(A). Where indicated, 10nM docetaxel was added to medium. C) Evaluation of intracellular ROS with 
H2DCF-DA. Cells were cultured as in (A) Where indicated, 10nM docetaxel was added to medium. 
Sample protein content was used for normalization. *,p<0,05 versus Control without docetaxel. 
 
 
ANTIOXIDANT RESPONSE IN DoceRes IS NOT ASSOCIATED WITH 
INCREASED PPP ACTIVITY 
NADPH is a critical source of electrons to fuel antioxidant systems in cells and PPP is 
an important oxidative pathway to generate this coenzyme. NADPH keeps the pool of 
intracellular GSH and both GSH and PPP has been associated with resistance to 
anticancer therapy (Zhao et al., 2013; Landriscina et al., 2009; Polimeni et al., 2011). 
In order to investigate the role of PPP to fuel antioxidant response in docetaxel-resistant 
PCa cells, we evaluated the expression of glucose-6-phosphate dehydrogenase 
(G6PDH), the rate limiting enzyme of PPP, and we analyzed the metabolic flux through 





We found reduced expression of G6PDH and reduced activity of PPP in resistant cells 
compared to control (Fig. 3A, 3B). Furthermore, even the treatment of DoceRes with 
10nM docetaxel, which elicited an increased Nrf2 expression, it is associated with 
reduced G6PDH levels and metabolic flux through PPP (Fig. 3A, 3B). Interestingly, 
even docetaxel treatment of sensitive cells causes a down-regulation of G6PDH 
expression and activity (Fig. 3C, 3D). These results confirm that PPP is not involved in 
counteracting oxidative stress induced by drug. 
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Fig. 3. No evidence of PPP engagement in docetaxel resistance. A) Immunoblot analysis of G6PDH 
expression in Control and DoceRes cell lines. Cells were cultured in serum-free medium for 48h before 
cell lysis. Where indicated, 10nM docetaxel was added to medium. Actin immunoblot was used for 
normalization. B) Analysis of PPP activity (fold change respect to Control). Cells were cultured as in (A). 
Where indicated, 10nM docetaxel was added to medium. The PPP metabolic flux was obtained  by 
substracting the amount of CO2 developed from [6-
14
C]-glucose from the CO2 released from [1-
14
C]-
glucose. The extent of [6-
14
C]-glucose metabolism is an index of TCA cycle alone. *,p<0,01 vs. Control. 
C) Immunoblot analysis of G6PDH in sensitive cells. Cells were cultured in serum-free medium for 24h, 
48h and 72h before cell lysis. Where indicated, 10nM docetaxel was added to medium. D) G6PDH 
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METABOLIC CHARACTERIZATION OF DoceRes CELL LINE 
Both aerobic glycolysis and mitochondrial respiration have been associated with 
increased resistance to anticancer drugs (Zhao et al., 2013; Martinez-Outschoorn et al., 
2011). To investigate the metabolic signature of DoceRes cell line, we analyzed both 
the expression of protein/enzyme involved in glycolytic pathway and the respiration of 
radiolabelled glucose through the release of [
14
C]-CO2. To better understand the 
metabolic adaptations of resistant cells in presence of drug, we performed these analysis 
even after treatment of DoceRes with 10 nM docetaxel. We firstly observed that, 
compared to DoceRes, Control cell line expresses basal level of HIF-1, a master 
regulator of glycolytic metabolism (Fig. 4A). In keeping, sensitive cells show increased 
expression of hexokinase II (a common target of HIF-1) and produce more lactate than 
resistant cells (Fig. 4A, 4D). These data suggest that Control cell line exploits a typical 
Warburg metabolism. Conversely, DoceRes show down-regulation of HIF-1 and 
hexokinase II, both in presence and in absence of drug. Moreover, docetaxel treatment 
leads to down-regulation of PKM2, the PK isoform involved in aerobic glycolysis (Fig. 
4A). In addition, treatment with drug induces [
14
C]-glucose oxidation to CO2 in 
DoceRes cell line through mitochondrial respiration (Fig. 4B). Taken together, these 
results suggest that resistance to docetaxel leads to an escape from Warburg metabolism 
with a potential role of oxidative mitochondrial metabolism to ensure metabolic 
advantages during acquisition of resistant phenotype. 
In order to confirm this hypothesis, we treated sensitive and resistant cells with DASA-
58, which activates PKM2 inducing tetramer formation and production of pyruvate 
(Anastasiou et al., 2012). Sensitive and DoceRes cell lines use this metabolite 
differently, producing, more lactate and more CO2 from glucose respectively (Fig. 4C, 
4D). Therefore, whereas sensitive cells show a typical Warburg effect in response to 
DASA-58, resistant cells show an inhibition of aerobic glycolysis, consuming pyruvate 
in TCA cycle to oxidize it to CO2. 
In addition, compared to sensitive cells, DoceRes cell line is able to metabolize through 
TCA cycle other carbon source, such as lactate, further confirming an involvement of 
mitochondrial respiration in docetaxel resistance (Fig. 4E) 
To test the importance of oxidative mitochondrial metabolism during acquisition of 
resistant phenotype, we used metformin, a widely used antidiabetic drug, endowed with 
Experimental Part III 
119 
Dott. Alberto Marini 
"Role of stromal fibroblasts in prostate carcinoma progression and metabolic reprogramming of cancer cells" 
Tesi di Dottorato in Scienze Biomolecolari e Biotecnologiche-Università degli Studi di Sassari 
 
promising effects for cancer prevention and treatment (Sotgia et al., 2012). Metformin is 
reported to inhibit mitochondrial complex I activity, thereby disrupting oxidative 
phosphorilation (Fendt et al., 2013). We firstly observed that metformin up-regulates 
HIF-1 and hexokinase II both in sensitive and resistance cells, thereby confirming its 
ability to shift cell metabolism toward a more glycolytic one (Fig. 4F, bottom). To 
analyze the effect of metformin on cell growth of sensitive and resistant cells, we 
performed a crystal violet assay. We observed that metformin is able to inhibit cell 
growth selectively in DoceRes (Fig. 4F, top) and such effect is enhanced in presence of 
docetaxel. These data further confirm the dependence on mitochondrial metabolism of 
resistant cells. 
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Fig. 4. (See previous page). Metabolic characterization of DoceRes cell line. Control and DoceRes cell 
lines were cultured in serum-free medium for 48h before analysis. Complete medium was used only for 
crystal violet assay. Where indicated, 10nM docetaxel, 40μM DASA-58, or 5mM metformin were added 
to medium. A) Immunoblot analysis of PKM2, HKII and HIF-1 in sensitive and resistant cells. Actin 
immunoblot was used for normalization. B), C) Evaluation of [
14
C]-glucose respiration by [
14
C]-CO2 
release (fold change respect to Control in B; fold change respect to Control without DASA-58 in C. 
*,p<0,05 versus Control; §,p<0,05 versus Control without DASA-58. D) Lactate assay in culture medium. 
Sample protein content was used for normalization. *,p<0,01 versus Control without DASA-58; #, p<0,01 
versus Control without DASA-58. E) Evaluation of [
14
C]-lactate respiration by [
14
C]-CO2 release (fold 
change respect to Control). *,p<0,01 versus Control. F) Upper panel: evaluation of living cells after 48h 
in complete medium by crystal violet assay. 20 x 10
3
 cells were plated at the start of experiment. 
Absorbance of Control (-/-) and DoceRes (-/-) was used for normalization. *,p<0,001 versus Control (-/-); 
**, p<0,01 versus DoceRes (-/-); §,p<0,01 versus DoceRes (-/-); #,p<0,01 versus DoceRes with 
metformin. Lower panel: immunoblot analysis of HKII and HIF-1 in sensitive and resistant cells. HK II 
expression in the same samples was shown in bar graph. Actin immunoblot was used for normalization. 
a.u.; arbitrary unit: *,p<0,05 versus Control (-/-); #, p<0,01 versus DoceRes (-/-); §,p<0,01 versus 
DoceRes with docetaxel/without metformin. 
 
 
METFORMIN IMPAIRS INVASIVENESS OF RESISTANT CELLS 
Recently, it has been observed that metformin reversed EMT phenotype and decreased 
the invasive capacity of multidrug-resistant breast cancer cells derived from MCF7 and 
MDA-MB-231 cell lines (Qu et al., 2013). 
To test the effect of metformin on pro-invasive phenotype of DoceRes, we evaluated the 
invasiveness of these cells by Boyden invasion assay. We found that metformin inhibits 
invasiveness only in resistant cells, with no effect in sensitive cell line (Fig. 5). These 
findings show that inhibition of oxidative mitochondrial metabolism in DoceRes cell 
line is able to revert its invasive properties, further confirming the important role of 
mitochondria to ensure drug resistance advantages. 
 
 
Fig. 5. Metformin impairs invasiveness of resistant cells. Boyden invasion assay of Control and 
DoceRes cell lines. Bar graph represents the mean of invaded cells (six fields for sample). Number of 
invaded cells was expressed as fold change respect to Control cells without metformin. §,p<0,05 versus 
Control without metformin; #,p<0,05 versus DoceRes without metformin. 
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CAFs REDUCE SENSITIVITY TO DOCETAXEL 
CAFs have been associated with reduced chemosensitivity in a number of cancer 
models. Some of these studies have highlighted the importance of tumor-stroma 
metabolic coupling in this process. In particular, the metabolic shift from glycolysis to 
an oxidative mitochondrial metabolism upon contact with stromal fibroblasts (the so 
called "reverse Warburg" effect) plays a key role to induce tamoxifen-resistance in a 
breast cancer model (Martinez-Outschoorn et al., 2011). 
We have previously reported that PCa cells undergo a "reverse Warburg" metabolism 
upon contact with CAFs. To test if CAFs are able to confer protection against 
docetaxel-induced apoptosis, we carried out co-cultures of sensitive PCa cells and 
CAFs, treating them with 10nM docetaxel. We found that CAFs are able to protect PCa 
cells to docetaxel toxicity, reducing the number of apoptotic cells (Fig. 6A). Same 
results were obtained for DoceRes+CAFs co-cultures, increasing docetaxel dose up to 
20nM (Fig. 6B). Of note, lactate produced by PCa-activated fibroblasts (PCa-AFs) is 
uploaded by both sensitive and DoceRes cell lines, as confirmed by lactate in medium 
(Fig. 6C) and uptake of radioactive lactate (Fig. 6D). These findings are consistent with 
a “reverse Warburg” phenotype, which may be important to counteract the toxic effect 
of docetaxel. 
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Fig. 6. CAFs reduce sensitivity to docetaxel-induced apoptosis. A), B) Analysis of docetaxel-induced 
apoptosis with Annexin V/Iodidium Propide cytofluorimetric staining. Control and DoceRes were 
cultured alone or co-cultured with CAFs (proportion CAFs:PCa 2:1) for 48h; then, docetaxel was added 
for 72h. After that, cells were detached from plates with Accutase. For co-culture, PCa cells were isolated 
using immunomagnetic beads targeting fibroblasts. Then, PCa cells were stained with Annexin V and 
Iodidium Propide and apoptosis was evaluated by flow citometry.*,p<0,01 versus Control cells alone 
treated with docetaxel; §,p<0,01 versus DoceRes cells alone treated with docetaxel. C) Lactate assay in 
culture medium. CM-HPFs and CM-PCa-AFs were obtained as previously described. Sensitive and 
resistant cells were treated with serum free medium (Control and DoceRes) or CM-HPFs or CM-PCa-AFs 
for 48h. Then, lactate in media was evaluated. *,p<0,01 versus CM-PCa-AFs. D) Analysis of [
14
C]-lactate 
upload in Control and DoceRes cell lines after treatments described in (C). *,p<0,01 versus Control+CM-
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Deregulation of tumor metabolism has been recently included in the so called 
"Hallmarks of cancers" (Hanahan and Weinberg, 2011). Several studies report the 
importance of metabolic reprogramming of cancer cells, which involves a number of 
metabolic pathway such as glycolysis, TCA cycle, glutaminolysis and fatty acids 
metabolism (Lunt and Vander Heiden, 2011, Chen and Russo, 2012, Cairns et al., 
2011). Metabolic changes in tumor cells often result from deregulation of 
oncogenes/tumor suppressor genes molecular pathways, but also microenvironmental 
factors (e.g. hypoxia, CAFs) and mutations in metabolic enzymes affect tumor 
metabolism (Chen et al. 2012, Israelsen et al. 2013). These adaptations are able to 
provide metabolic advantages to cancer cells, from growth and survival in hostile 
environments to chemoresistance. A typical event associated with metabolic 
reprogramming of cancer cells is the so called Warburg effect (aerobic glycolysis), by 
which non-hypoxic tumor cells entirely rely on glycolysis in order to support the high 
biosynthetic and energy demands of actively proliferating cells. Interestingly, Warburg 
metabolism is not exclusively of tumors, as many non-transformed cells also exhibit 
high aerobic glycolysis during rapid proliferation (Lunt and Vander Heiden, 2011). To 
date, a number of studies identified molecular pathways and metabolic enzymes 
involved in Warburg effect in cancer cells. For example, the M2 isoform of PK is 
preferentially expressed in cancer, where complex regulation of its activity is important 
for control of aerobic glycolysis and cell metabolism (Christofk et al, 2008, Anastasiou 
et al., 2011). 
Recently, several findings highlighted the important role of stromal fibroblast to 
establish a metabolic coupling with cancer cells, thus influencing their metabolic 
reprogramming. CAFs are a relevant component of tumor microenvironment, being the 
most represented cells in tumor masses. They can either be fibroblasts resident in the 
target organ or recruited and differentiated by circulating MSCs of bone marrow origin 
(Taddei et al. 2013). In any case, they respond to cancer-delivered factors able to 
enhance their reactivity towards a myofibroblas-like state; in turn, CAFs affect tumor 
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progression promoting invasive and metastatic phenotype and, ultimately, cancer 
malignancy. 
To date, it has been reported several models of metabolic coupling between stromal and 
cancer cells. However, controversial data are emerged from these studies. Lisanti's 
group proposes that, in response to oxidative stress induced by contact with cancer cells, 
stromal fibroblast undergo activation due to Cav-1 down-regulation, showing a 
stabilization of HIF-1, a key regulator of glycolytic enzymes; the latter drives a 
metabolic shift towards aerobic glycolysis, which is associated with elimination of 
mitochondrial activity through autophagy/mitophagy process (Pavlides et al., 2009, 
Sotgia et al. 2012, Martinez-Outschoorn et al. 2011, Ko et al., 2011). In turn, energy-
rich metabolites secreted by stromal fibroblasts (e.g. lactate/pyruvate and amino acids) 
can support the mitochondria-dependent growth of tumor cells, fueling oxidative 
mitochondrial metabolism. In agreement, immuno-histochemical analysis of sections 
from human breast cancer tissues reveal that PKM2 and lactate dehydrogenase, two 
enzymes associated with Warburg metabolism, are highly expressed in the stromal 
compartment (Pavlides et al., 2009). Interestingly, in this model, aerobic glycolysis is 
considered as a "stromal event" induced by cancer cells in order to sustain their own 
growth. On the contrary, histological analyses of colorectal carcinoma suggest that the 
stroma infiltrating these tumors expresses aerobic metabolism enzymes that are 
involved in recycling products of anaerobic metabolism of cancer cells to sustain 
invasive cancer growth. In keeping, another study report that hypoxic breast cancer cells 
recruit mesenchymal stem cells through their secretion of lactate due to glycolytic 
Warburg metabolism, allowing stromal cells to use lactate produced by tumor cells 
(Rattigan et al., 2012). 
On the basis of these controversial studies, we investigated the metabolic signature of 
activated CAFs obtained by patients bearing aggressive prostate carcinoma. We also 
used healthy HPFs activated in vitro upon contact with PCa cells (co-culture or CM). 
Our in vitro and in vivo analysis revealed that CAFs and PCa cells undergo a mutual 
metabolic reprogramming. In particular, PCa cells induce in CAFs a Warburg-like 
glycolytic metabolism, thus increasing glucose uptake and its conversion into lactate. 
Conversely, PCa cells undergo a "reverse Warburg" phenotype, by which lactate 
extruded by CAFs by MCT4 transporter is uploaded by PCa cells, through their MCT1 
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transporter and used for fueling TCA cycle, as well as anabolic processes and cell 
proliferation. PCa cells gradually become glucose consumption-independent and 
develop a dependence on lactate upload; indeed, MCT1 expression in cancer cells is 
mandatory for tumor growth, as indicated by the efficiency of in vitro and in vivo 
targeting of MCT1 with CHC or RNA interference. In agreement with our results, it has 
been reported that expression of MCT4 is increased in CAFs extracted by human PCa, 
and such expression is correlated with poor clinical outcome both in prostate and breast 
cancer (Witkiewicz et al., 2012). In addition, the expression of MCT1 in cancer cells is 
also associated with poor prognosis (Boidot et al, 2012). 
Previous studies conducted in our laboratory demonstrated that CAFs induce in PCa 
cells stem-like features and mesenchymal motility through EMT (Giannoni et al., 2010). 
These events are driven by HIF-1 and NF-kB dependent pro-inflammatory signature 
(Giannoni et al., 2011). In particular, we showed that CAFs are able to mimic a hypoxic 
environment, eliciting ROS production in PCa cells and thereby inducing HIF-1 
stabilization under normoxic conditions. Here, we demonstrate that even PCa cells can 
elicit oxidative stress in stromal fibroblasts, as demonstrated by increased ROS 
production in in vivo and in vitro activated CAFs. ROS-mediated stabilization of HIF-1 
drives metabolic reprogramming both in CAFs and tumor cells, leading to glycolytic 
metabolism in CAFs and "reverse Warburg" phenotype in PCa cells. The importance of 
oxidative stress and ROS-mediated activation of HIF-1 in reciprocal interplay between 
tumor and stomal cells, it has been demonstrated by other research group. In particular, 
Toullec et al. and Lisanti's group reported that ROS are key regulators during activation 
of fibroblasts in response to tumor, leading to stabilization of HIF-1 (Toullec et al. 
2010; Sotgia et al. 2012; Lisanti et al. 2011; Pavlides et al, 2012). In addition, Toullec et 
al. showed that HER2-human breast adenocarcinoma exhibit a high proportion of 
myofibroblasts, which was significantly correlated to nodal metastases. Interestingly, 
this subset of tumors display a molecular signature characteristic of oxidative stress–
response. 
In our model, redox-dependent activation of HIF-1 in CAFs results from down-
regulation of mitochondrial deacetylase SIRT3. Sirtuins are a conserved family of 
NAD-dependent ADP-ribosyltransferases and/or protein deaceytlases involved in 
metabolism, stress response and longevity. Mammals express seven sirtuins (SIRT1-7), 
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three of which (SIRT3-5) are localized to the mitochondrion. SIRT3 is a major 
mitochondrial deacetylase that targets many enzymes involved in central metabolism, 
resulting in the activation of many oxidative pathways. For example, SIRT3 
deacetylates complex I and complex II to activate electron transport. Interestingly, 
SIRT3 opposes to Warburg phenotype of cancer cells, mainly acting via destabilization 
of HIF-1, leading to inhibition of glycolysis and activation of oxidative metabolism. As 
a consequence, the genetic loss of the SIRT3 in breast cancers favors aerobic glycolysis, 
causing oxidative stress that culminates in HIF-1 up-regulation (Finley et al., 2011). Our 
data show that, in activated fibroblasts, SOD2 acetylation/inactivation due to SIRT3 
down-regulation causes an increase of ROS production and consequent HIF-1 
stabilization, leading to glycolytic switch. Therefore, we can include CAFs as cells 
undergoing a SIRT3-mediated activation of HIF-1 and Warburg metabolism, enlarging 
the role played by SIRT3-loss to stromal cells. 
Given the importance of ROS in metabolic reprogramming of CAFs and PCa cells, we 
aimed at identifying natural antioxidant molecules able to disrupt the diabolic liaison 
between tumor and stroma. To date, several studies on a wide spectrum of phenolic 
compounds extract from vegetables and fruits showed that these natural products can act 
as potent antioxidant or anticancer agents (Aravindaram et al, 2010), behaving as 
chemopreventive molecules (Singh et al. 2006). The molecular targets of these agents 
include cell signaling, cell-cycle regulators, survival/apoptotic molecules and 
antioxidant enzyme systems, but can also act directly as ROS scavenger (Singh et al. 
2006, Aravindaram et al, 2010). For example, curcumin and green tea catechins (GTCs) 
show chemopreventive effect in prostate carcinoma (Singh et al. 2006). In particular, 
GTCs prevent PCa onset in transgenic adenocarcinoma mouse prostate (TRAMP) mice 
that spontaneously develop prostate cancer (Caporali et al., 2004). In addition, a 
randomized controlled trial showed that daily administration of GTCs in volunteers with 
high-grade prostate intraepithelial neoplasia prevent aggressive PCa development 
(Bettuzzi et al., 2006). In our study, considering the key role played by SIRT3 down-
regulation and ROS in metabolic reprogramming of CAFs, we used the flavonoid 
kaempferol, a known SIRT3-activator, in order to inhibit such process. Kaempferol is 
able to increase SIRT3 expression, thus reducing ROS production and HIF-1 
stabilization. As a consequence, kaempferol block the metabolic loop between CAFs 
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and PCa cells, leading to decrease of PCa cell growth. These results clearly demonstrate 
that kaempferol could be a useful molecule in the management of PCa and represents an 
important example of how natural antioxidant can inhibit ROS-dependent mechanism 
involved in cancer progression, thereby reducing tumor aggressiveness. 
Our model of metabolic coupling between stroma and tumor highlight the important 
role of mitochondrial respiration in cancer metabolism and tumor progression, and it is 
in agreement with other models described in literature where energy rich metabolites 
derived from corrupted stoma fuel TCA cycle. The ability of tumor cells to exploit 
oxidative phosphorylation indicates that the traditional view of cancer metabolism 
requires careful revision. In particular, recent data highlight the inconsistencies of the 
Warburg effect in tumor cells. First of all, not all tumors are glycolytic. A systematic 
review of the literature in which the relative contributions to ATP production were 
measured from both glycolysis and oxidative metabolism indicates that cancer cells 
display a wide range of metabolism and that only ~30% of the tumors are glycolytic 
(Sotgia et al., 2012). Some tumors (for example, glioma), show an increase in both 
glycolysis and oxidative phosphorylation, thus displaying metabolic heterogeneity. 
Furthermore, some oncogenes commonly associated to aerobic glycolysis, such as c-
Myc and Ras, also stimulate mitochondrial biogenesis and function. For example, c-
myc induces cancer cells to utilize both oxidative phosphorylation and glycolysis and 
promotes glutamine oxidation by TCA cycle. In addition, several studies indicate that 
mitochondrial respiration is necessary to sustain aggressive tumor growth. For example, 
the mitochondrial protein p32 was recently shown to promote oxidative phosphorylation 
and to sustain tumor growth and increased levels of respiratory electron transport chain 
subunits predict poor clinical outcome in human breast cancer (Sotgia et al., 2012). 
Finally, drugs targeting mitochondrial respiration are being evaluated as anti-neoplastic 
agents in clinical trials (Sotgia et al., 2012; Ramsay et al., 2011). In particular, 
metformin, a widely used oral anti-diabetic drug, exhibits a strong anti-proliferative 
action in numerous cancer cell lines in vitro and in vivo. Metformin is reported to inhibit 
mitochondrial complex I activity, thereby disrupting oxidative mitochondrial 
metabolism and promoting glycolysis and lactate accumulation. Diabetic patients 
treated with metformin experience a lower risk of pancreatic cancer compared with 
those who had not taken metformin. In addition, in a large retrospective study with 
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more than 2,500 breast cancer patients, metformin treatment increased the complete 
pathological response rates following neoadjuvant chemotherapy, which points to its 
potential role as a new anticancer drug (Sotgia et al., 2012).  
 
Mounting evidence supports the idea that deregulated cellular metabolism is linked to 
drug resistance in cancer therapy. To address this point, we developed a PCa cell line 
resistant to docetaxel, a promising drug for treatment of metastatic PCa and we 
evaluated phenotypic and metabolic features of these cells. 
Resistance to docetaxel confers to PCa cells a pro-invasive behavior and a down-
regulation of E-cadherin, consistent with an EMT program and a pro-metastatic 
phenotype. The acquisition of EMT in docetaxel-resistant PCa cells it has been reported 
also by Puhr and colleagues (Puhr et al., 2012), who demonstrated that EMT results 
from down-regulation of miR-205 and is at least in part responsible for chemotherapy 
failure. Moreover, we found that resistant cells show up-regulation of Nrf2, a master 
regulator of antioxidant response, able to maintain cellular redox homeostasis through 
elimination of toxicants/carcinogens. Interestingly, a link between Nrf2 and EMT it has 
been demonstrated, implying that chemoresistance of cancer cells upon the loss of E-
cadherin might be associated with Nrf2 (Kim et al., 2012). In particular, the authors 
report that E-cadherin recruits Nrf2 through β-catenin, and assists the function of Keap1 
for the inhibition of nuclear localization and transcriptional activity of Nrf2. In our 
model, up-regulation and nuclear localization of Nrf2 is associated with down-
regulation both of E-cadherin and Keap1. In agreement, we observed that resistant cells 
show decreased ROS production when treated with docetaxel respect to sensitive cells. 
Given that docetaxel induce cell death in a ROS-dependent manner (Cao et al., 2005), 
we speculate that activation of Nrf2 transcriptional program play a key role in 
management of drug-induced oxidative stress in resistant cells, resulting, together with 
reduced expression of pro-apoptotic proteins, in cell survival. Interestingly, the 
docetaxel transporter MDR1 (multidrug transporter proteins-1 or P-glycoprotein), which 
regulates its efflux from cell, is included among Nrf2 target gene (Klaassen and 
Aleksunes, 2010; Hardwick et al, 2011; Ehrlichova et al., 2005), further demonstrating 
the important role of Nrf2 in docetaxel resistance. 
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Antioxidant response requires NADPH in order to fuel antioxidant systems. PPP is an 
important pathway to generate this coenzyme and it has been already associated with 
chemoresistance (Polimeni et al, 2011). The analysis of PPP in docetaxel resistant cells 
revealed that such pathway is down-regulated compared to sensitive cells and it is not 
involved in counteracting oxidative stress induced by drug. However, other metabolic 
enzymes produce NADPH in cells, such as malic enzyme and cytosolic IDH1; hence, 
further analyses are needed in order to identify a source of NADPH that sustains 
antioxidant response in resistant cells. 
Metabolic analysis of resistant and sensitive cells suggest that chemoresistance to 
docetaxel induces an escape from Warburg metabolism with a potential involvement of 
mitochondrial respiration to confer a metabolic advantage to these cells. Indeed, 
docetaxel-resistant cell line shows a grater utilization of glucose by mitochondrial 
respiration, a down-regulation of HIF-1 actvity and PKM2 and a decreased lactate 
production compared to sensitive cell line. Reduced cell growth rate and down-
regulation of PPP, the latter commonly associated with Warburg effect and cell growth, 
being a source of NADPH and nucleotides, further confirm the metabolic shift from 
aerobic glycolysis to oxidative mitochondrial metabolism in resistant cells. In addition, 
the PKM2-activator DASA-58, a well known molecule that allows the escape from 
Warburg metabolism (Anastasiou et al., 2011, 2012), is able to induce glucose oxidation 
to CO2 only in resistant cells, whereas sensitive counterpart produce lactate. A possible 
explanation of this result is that down-regulation of HIF-1 in resistant cells leads to 
decreased expression of its target gene PDK. Therefore, the re-activation of PDH could 
be responsible of pyruvate oxidation in TCA cycle. Finally, resistance to docetaxel 
confers the ability to metabolize extracellular lactate by mitochondrial respiration. This 
feature could be considered as a further advantage for resistant cells, which could 
exploit energy rich metabolites in microenvironment derived from corrupted stroma. 
Taken together, these findings suggest that the shift towards oxidative mitochondrial 
metabolism could be an important feature useful to overcome docetaxel toxicity. In 
particular, we hypothesize that the recovery of mitochondrial respiration could subtract 
glycolytic intermediates from anabolic processes and from PPP, to drive ATP 
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Given the importance of oxidative mitochondrial metabolism in resistant cells, we used 
the mitochondrial complex I inhibitor metformin in order to impairs metabolic 
advantages of these cells. In agreement with other studies (Fendt et al. 2013, Sotgia et 
al, 2012), we found that metformin causes a shift towards glycolytic metabolism (up-
regulation of HIF-1 and hexokinase II); however, such drug inhibits cell growth 
selectively in resistant cells, further confirming their dependence on mitochondrial 
respiration. Interestingly, metformin is able also to impair invasiveness of resistant 
cells. This result is in agreement with data obtained by Qu and colleagues (Qu et al., 
2013), who demonstrated that metformin reverses EMT phenotype and decreases the 
invasive capacity of multidrug-resistant breast cancer cells.  
Finally, our data demonstrate the protective effect of CAFs against docetaxel toxicity, 
both in sensitive and resistant cells, likely by inducing the "reverse Warburg" phenotype 
in cancer cells. These results are in agreement with Lisanti and colleagues (Martinez-
Outshoorn et al., 2011), who proposes that the metabolic shift from glycolysis to an 
oxidative mitochondrial metabolism, upon contact with stromal fibroblasts, plays a key 
role during acquisition of chemoresistance in breast cancer. However, further 
experiments will be necessary to elucidate the role of prostate fibroblasts and lactate 
shuttle in resistance to docetaxel. In conclusion, our results are consistent with the idea 
that chemoresistance may be both a metabolic and stromal phenomenon, that can be 
overcome by reducing mitochondrial function. 
 
Besides the role in metabolic reprogramming, we report that redox-based HIF-1 
activation is involved in CA IX de novo expression in CAFs upon contact with PCa 
cells. In particular, we observed that CA IX up-regulation in activated fibroblasts is 
mandatory to elicit the secretion of MMP-2 and MMP-9 through acidification of 
extracellular milieu, thus driving EMT program in PCa cells. 
CA IX is a common target gene of HIF-1 and it has been widely correlated to 
intratumoral hypoxia. Indeed, CA IX over-expression has been demonstrated in several 
cancer models as a master regulator of pH homeostasis, which is crucial for cancer cells 
in order to avoid potentially harmful effects of an highly glycolytic and therefore pro-
acidic metabolism (Robertson et al., 2004; Neri and Supuran 2011). However, CA IX 
participation in the generation of an increasingly acidic extracellular environment and 
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the consequential promotion of tumor cells invasiveness, is still poorly understood. In 
literature, few data indicate a CA IX contribution in motility of cancer cells. Svastova et 
collegues pointed out the ability of CA IX to modulate E-cadherin-dependent cell 
adhesion through direct co-localization with β-catenin and to promote loss of cell-cell 
contact, the key initial step of cancer invasion (Svastova et al., 2003). Furthermore, in 
colorectal cancer cells it has been proved that COX-2-dependent expression of CA IX 
correlates with tumor stage and increases cancer cells invasiveness (Sansone et al., 
2009). Finally, in cervical carcinoma cells, the over-expression of exogenous human 
CA IX leads to weakened cytoskeletal remodeling, disassembled focal adhesion, cell-
cell adhesion and increased cell motility, mainly acting through inactivation of Rho 
small GTPase (Shin et al., 2011). 
Unlike these data, we report that stromal fibroblasts infiltrating prostate carcinoma 
concur to extracellular acidification through CA IX over-expression, which are essential 
to drive MMP-2 and -9 secretion, rapidly leading to PCa cells EMT and metastatic 
dissemination in SCID mice. Interestingly, in our model, Warburg metabolism and 
acidification of extracellular environment due to lactate production, features commonly 
associated to cancer cells, are exploited by stromal compartment corrupted by tumor. 
However, although CAFs can be viewed as acidifying cells, due to their dramatic 
production of lactate, extruded together with H
+
 using their over-expressed MCT-4, 
lactate and H
+
 are both rapidly removed from tumor microenvironment by metabolically 
reprogrammed cancer cells, expressing MCT-1 and uploading lactate to sustain cell 
growth. In this context, extracellular acidification due to H
+
 produced by CA IX of 
CAFs plays a key role in activation of MMPs, due to their well known sensitivity to 
acidity. In turn, MMPs drive EMT in PCa cells, by promoting the pro-oxidant/pro-
inflammatory pathway previously described (Giannoni et al., 2011). 
 
Taken together, our data highlight the plasticity of cancer cells, which engage adaptive 
strategies corrupting their stroma and reprogramming their metabolism to satisfy their 
requirements. Tumor cells rely on stromal fibroblasts both for a metabolic support and 
to engage invasive program in order to survive and escape from hostile environments. 
In our model, malignant cells are able to exploit byproducts of stromal cells in catabolic 
and anabolic processes, reprogramming their metabolism towards mitochondrial 
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respiration (the so called "reverse Warburg" phenotype) and becoming progressively 
independent from Warburg metabolism. This strategy could be important when 
conditions of nutrient starvation occur inside the tumor mass. Furthermore, 
metabolically reprogrammed fibroblasts are able to engage pro-invasive and pro-
metastatic properties in cancer cells, by CA IX-mediated acidification of extracellular 
milieu. Finally, we demonstrated the key role played by ROS in the reciprocal interplay 
between tumor and stromal cells. In this context, we showed that antioxidant molecules 
could represent an effective strategy to target oxidative stress and reduce, ultimately, the 
aggressiveness of tumor. 
The adaptations in the metabolism of cancer cells play an important role even during 
acquisition of chemoresistance, providing metabolic advantages useful to overcome the 
toxic effect of anticancer drugs. To date, both aerobic glycolysis and mitochondrial 
respiration have been associated with increased resistance to anticancer drugs (Zhao et 
al., 2013; Martinez-Outshoorn et al., 2011). Our model suggests that the shift from 
Warburg metabolism to mitochondrial respiration is an important mechanism to confer 
these advantages to resistant cancer cells. Furthermore, we include CAFs as active 
bystanders during the phenomenon of chemoresistance.  
Our results highlight the importance to understand the metabolic reprogramming and 
the adaptive strategies of cancer cells in order to identify new therapeutic targets which 
can be used in combination with conventional chemotherapy. To date, several 
molecules targeting cellular metabolism are able to improve cancer therapeutics and 
overcome drug resistance (Zhao et al., 2013). Here, we point out the important role of 
mitochondrial respiration in cancer progression and chemoresistance and we propose 
the disruption of mitochondrial function as attractive therapy. Furthermore, our data 
include stromal fibroblasts as key regulators of adaptation strategies used by tumors, 
adding a further level of complexity to the system. Indeed, CAFs, as they are non-
transformed genetically stable cells, could be ideal pharmacological targets with respect 
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